var title_f40_15_41200="Ciprofloxacin: Patient drug information";
var content_f40_15_41200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/39/36468?source=see_link\">",
"       Ciprofloxacin (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/21/15700?source=see_link\">",
"       Ciprofloxacin (otic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/11/17590?source=see_link\">",
"       Ciprofloxacin (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12188 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41200=[""].join("\n");
var outline_f40_15_41200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/39/36468?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/21/15700?source=related_link\">",
"      Ciprofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/11/17590?source=related_link\">",
"      Ciprofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_15_41201="Treatment overweight and obesity";
var content_f40_15_41201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Treatment overweight and obesity algorithm*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 626px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * This algorithm applies only to the assessment for overweight and obesity and subsequent decisions based on that assessment. It does not include any initial overall assessment for cardiovascular risk factors or diseases that are indicated.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res 1998; 6:51S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41201=[""].join("\n");
var outline_f40_15_41201=null;
var title_f40_15_41202="Patient information: Hemorrhoids (The Basics)";
var content_f40_15_41202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15404\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/33/44575\">",
"         Hemorrhoids",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/59/21426\">",
"         Patient information: Constipation in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/51/35634\">",
"         Patient information: High-fiber diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/55/23411\">",
"         Patient information: Pregnancy symptoms (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/47/40689\">",
"         Patient information: Hemorrhoids (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hemorrhoids (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hemorrhoids-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H33215967\">",
"      <span class=\"h1\">",
"       What are hemorrhoids?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hemorrhoids are swollen veins in the rectum. They can cause itching and pain. Sometimes they can also make you bleed during a bowel movement.",
"     </p>",
"     <p>",
"      In some cases, you can see or feel hemorrhoids around the outside of the rectum. In other cases, you cannot see them because they are hidden inside the rectum (",
"      <a class=\"graphic graphic_figure graphicRef73076 \" href=\"mobipreview.htm?43/33/44575\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33215974\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should see a doctor or nurse if you have any bleeding or if your bowel movements look like tar. Bleeding could be caused by something other than hemorrhoids, so you should have it checked out.",
"     </p>",
"     <p>",
"      If you do have hemorrhoids, your doctor or nurse can suggest treatments. But there some steps you can try on you your own first.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33215981\">",
"      <span class=\"h1\">",
"       What can I do to keep from getting more hemorrhoids?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most important thing you can do is to keep from getting constipated. You should have a bowel movement at least a few times a week. When you have a bowel movement, you also should not have to push too much. Plus, your bowel movements should not be too hard.",
"     </p>",
"     <p>",
"      Being constipated and having hard bowel movements can make hemorrhoids worse. Here are some steps you can take to avoid getting constipated or having hard stools:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eat lots of fruits and vegetables. They have fiber, which helps to increase bowel movements.",
"       </li>",
"       <li>",
"        Take fiber powders, wafers, or pills. You should get 20 to 35 grams of fiber a day.",
"       </li>",
"       <li>",
"        Take medicines called stool softeners such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/14/8420?source=see_link\">",
"         docusate",
"        </a>",
"        &nbsp;sodium (sample brand names: Colace&reg;, Dulcolax&reg;) or bulk forming laxatives. Bulk forming laxatives include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/23/21876?source=see_link\">",
"         psyllium",
"        </a>",
"        &nbsp;seed (sample brand names: Metamucil&reg;, Konsyl&reg;),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/14/14564?source=see_link\">",
"         methylcellulose",
"        </a>",
"        &nbsp;(brand name: Citrucel&reg;), calcium",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/36/11844?source=see_link\">",
"         polycarbophil",
"        </a>",
"        &nbsp;(sample brand name: FiberCon&reg;), and wheat",
"        <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"         dextran",
"        </a>",
"        &nbsp;(brand name: Benefiber&reg;).These medicines increase the number of bowel movements you have. They are safe to take and they can prevent problems later.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33215988\">",
"      <span class=\"h1\">",
"       What can I do to reduce my symptoms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people feel better if they soak their buttocks in 2 or 3 inches of warm water. You can do this up to 2 to 3 times a day for 10 to 15 minutes. Do not add soap, bubble bath, or anything to the water.",
"     </p>",
"     <p>",
"      There are also medicines that you can get without a prescription. They are usually creams or ointments that you rub on your anus to relieve pain, itching, and swelling. Some hemorrhoid medicines come in a capsule (called a suppository) that you put inside your rectum. Others come in a cream that comes in a bottle with a nozzle that you put inside your rectum. It is OK to try these medicines. But do not use medicines that have",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/9/39056?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (a steroid medicine) for more than a week, unless your doctor or nurse approves.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33215995\">",
"      <span class=\"h1\">",
"       What if the self-care steps do not work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you still have symptoms after trying the steps listed above, you may need treatments to destroy or remove the hemorrhoids.",
"     </p>",
"     <p>",
"      One popular treatment is called &ldquo;rubber band ligation.&rdquo; For this treatment, the doctor ties tiny rubber bands around the hemorrhoids. A few days later the hemorrhoids shrink and fall off. The doctor can also use lasers, heat, or chemicals to destroy hemorrhoids. But if none of these options works, there is always surgery to remove the hemorrhoids.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33216002\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/59/21426?source=see_link\">",
"       Patient information: Constipation in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/51/35634?source=see_link\">",
"       Patient information: High-fiber diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/55/23411?source=see_link\">",
"       Patient information: Pregnancy symptoms (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/47/40689?source=see_link\">",
"       Patient information: Hemorrhoids (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/15/41202?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15404 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41202=[""].join("\n");
var outline_f40_15_41202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33215967\">",
"      What are hemorrhoids?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33215974\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33215981\">",
"      What can I do to keep from getting more hemorrhoids?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33215988\">",
"      What can I do to reduce my symptoms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33215995\">",
"      What if the self-care steps do not work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33216002\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15404\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/33/44575\">",
"      Hemorrhoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/59/21426?source=related_link\">",
"      Patient information: Constipation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/47/40689?source=related_link\">",
"      Patient information: Hemorrhoids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/51/35634?source=related_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/55/23411?source=related_link\">",
"      Patient information: Pregnancy symptoms (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_15_41203="Very large septated fetal cystic hygroma";
var content_f40_15_41203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axial image of the fetal head of an early second trimester fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posterior and lateral to the cranium is a large septated cystic hygroma. Very little amniotic fluid is present in this image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41203=[""].join("\n");
var outline_f40_15_41203=null;
var title_f40_15_41204="Gold sodium thiomalate: Drug information";
var content_f40_15_41204=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gold sodium thiomalate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/11/34996?source=see_link\">",
"    see \"Gold sodium thiomalate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/59/35763?source=see_link\">",
"    see \"Gold sodium thiomalate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Myochrysine&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F176985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Myochrysine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gold Compound",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     I.M.: 10 mg first week; 25 mg second week; then 25-50 mg/week until development of toxicity or 1 g cumulative dose has been given; if improvement occurs without adverse reactions, the dose may be decreased or the dosing interval increased; Maintenance: 25-50 mg every other week for 2-20 weeks, then every 3-4 weeks indefinitely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Failure to improve during initial therapy may warrant continuation of 25-50 mg for additional 10 weeks or a dose increase in increments of 10 mg every 1-4 weeks (maximum: 100 mg/injection). Discontinue therapy if no improvement or toxicity develops.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F176994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/59/35763?source=see_link\">",
"      see \"Gold sodium thiomalate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     I.M.: Initial: Test dose of 10 mg is recommended, followed by 1 mg/kg/week (maximum: 50 mg/injection); maintenance: 1 mg/kg/dose (maximum: 50 mg/injection) at every-other-week intervals for 2-20 weeks, then every 3-4 weeks. Early improvement may be observed after 6-8 weeks of therapy; months of therapy may be required before clinical improvement is observed.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F176989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aronoff, 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myochrysine&reg;: 50 mg/mL (1 mL [DSC], 10 mL [DSC]) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Deep I.M. injection into the upper outer quadrant of the gluteal region; addition of 0.1 mL of 1% lidocaine to each injection may reduce the discomfort associated with I.M. administration. Patient should remain in recumbent position for approximately 10 minutes following administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of active rheumatoid arthritis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, fever, Guillain-Barr&eacute; syndrome, hallucinations, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, dermatitis, nail shedding, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, abdominal cramps, diarrhea, dysphagia, enterocolitis (ulcerative), gingivitis, glossitis, nausea, stomatitis, taste disturbance (metallic), thick tongue, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, leukopenia, purpura, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestasis, hepatitis, hepatotoxicity, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis, corneal ulcers, gold deposits in ocular tissues, iritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, gold bronchitis, interstitial pneumonitis, pulmonary fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glomerulitis, hematuria, nephrotic syndrome, proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction, anaphylaxis, nitritoid reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F176975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gold compounds or any component of the formulation; history of severe toxicity to gold compounds or heavy metals; systemic lupus erythematosus; severe debilitation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Dermatitis and lesions of the mucous membranes are common and may be serious; pruritus may precede the early development of a skin reaction. Consider alternative therapy in patients with dermatitis (urticaria or eczema; relative contraindication); may increase risk and/or symptoms of gold toxicity may be more difficult to detect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: Signs of toxicity include persistent diarrhea, stomatitis, and enterocolitis; avoid use in patients with prior inflammatory bowel disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Signs of toxicity include hematologic depression (depressed hemoglobin, eosinophilia &gt;5%, leukocytes, granulocytes, or platelets). Avoid use in patients with a history of blood dyscrasias (anemia, agranulocytosis), hemorrhagic diathesis, or drug induced granulocytopenia. Symptoms of gold toxicity may be difficult to detect in patients with prior abnormalities; consider alternative therapy. Therapy should be discontinued if platelet count falls to &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , WBC &lt;4000, granulocytes &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: May be associated with the development of cholestatic jaundice. Consider alternative therapy in patients with hepatic impairment (relative contraindication); may increase risk and/or symptoms of gold toxicity may be more difficult to detect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Rare hypersensitivity reactions, including anaphylactic shock, syncope, bradycardia, thickening of the tongue, difficulty in swallowing and breathing, and angioedema have been reported in association with injections of sodium aurothiomalate; treatment should be discontinued if occur. In addition, a vasomotor (nitritoid) reaction characterized by acute flushing and tachycardia may occur within minutes of injection; this reaction should be differentiated from anaphylaxis and therapy may be continued, but a careful evaluation of risk vs benefit should be undertaken and extreme caution should be exercised before resuming therapy, particularly in patient with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: May be associated with interstitial fibrosis; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal effects: Renal toxicity ranges from mild proteinuria to nephrotic syndrome. Consider alternative therapy in patients with renal impairment; may increase risk and/or symptoms of gold toxicity may be more difficult to detect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use caution in patients with HF, hypertension, or cerebrovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Consider alternative therapy is patients with SLE (relative contraindication); may increase risk and/or symptoms of gold toxicity may be more difficult to detect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ACE inhibitors: Concurrent use with ACE inhibitors may increase the risk of nitritoid reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corticosteroids: In general, corticosteroids may be discontinued after initiation of therapy (corticosteroid tapering may be required).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NSAIDs: May be discontinued after initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Injection contains benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Must not be injected I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Frequent monitoring of patients for signs and symptoms of toxicity will prevent serious adverse reactions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13293360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F176990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13293361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injectable gold salts have been detected in breast milk and the serum of nursing infants",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F176967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients should have a CBC with differential, platelet count, hemoglobin determination and urinalysis for protein, white cells, red cells and casts; at baseline and prior to each injection. Skin and oral mucosa should be inspected for skin rash, bruising or oral ulceration/stomatitis. Specific questioning for symptoms such as pruritus, rash, stomatitis or metallic taste should be included. Dosing should be withheld in patients with significant gastrointestinal, renal, dermatologic, or hematologic effects (platelet count falls to &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , WBC &lt;4000, granulocytes &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F176970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gold: Normal: 0-0.1 mcg/mL (SI: 0-0.0064 micromole/L); Therapeutic: 1-3 mcg/mL (SI: 0.06-0.18 micromole/L); Urine: &lt;0.1 mcg/24 hour",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Allochrysine (BE);",
"     </li>",
"     <li>",
"      Auromyose (NL);",
"     </li>",
"     <li>",
"      Aurothio (KP);",
"     </li>",
"     <li>",
"      Miocrin (CO, SG);",
"     </li>",
"     <li>",
"      Myocrisin (AE, AU, BB, BH, BM, BS, BZ, CY, DK, EG, FI, GB, GY, HK, HN, IE, IL, IQ, IR, JM, JO, KW, LB, LY, NO, NZ, OM, PR, QA, SA, SE, SR, SY, TH, TT, YE);",
"     </li>",
"     <li>",
"      Tauredon (AT, CH, CZ, HN, PL, PT, RU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unknown, may decrease prostaglandin synthesis or may alter cellular mechanisms by inhibiting sulfhydryl systems",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Delayed; may require up to 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5 days; may be prolonged with multiple doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% to 90%); feces (10% to 40%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8497 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41204=[""].join("\n");
var outline_f40_15_41204=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708895\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176984\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176985\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176998\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176987\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176994\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176988\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176989\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896380\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176969\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176954\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176972\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176971\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176996\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176975\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176958\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299416\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176963\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176965\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13293360\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176990\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13293361\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176967\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176970\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038648\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176957\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176974\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8497\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8497|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/11/34996?source=related_link\">",
"      Gold sodium thiomalate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/59/35763?source=related_link\">",
"      Gold sodium thiomalate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_15_41205="Overview of the development of the gastrointestinal tract";
var content_f40_15_41205=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the development of the gastrointestinal tract",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41205/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41205/contributors\">",
"     Ian Sanderson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41205/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41205/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41205/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41205/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41205/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/15/41205/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic formation of the esophagus, stomach, intestine, liver, and pancreas are achieved in the fourth fetal week through a series of evaginations, elongations, and dilatations. Anatomic development progresses through cell proliferation, growth, and morphogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CEPHALOCAUDAD DIFFERENTIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three distinct regions of the intestine give rise to specific portions of the gastrointestinal tract:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The foregut is the precursor of the pharynx, esophagus, stomach, liver, gall bladder, pancreas, and the cranial portion of the duodenum (",
"      <a class=\"graphic graphic_figure graphicRef60244 \" href=\"mobipreview.htm?23/24/23941\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The midgut gives rise to the caudal portion of the duodenum, the jejunum, ileum, the ascending colon, and two-thirds of the transverse colon (",
"      <a class=\"graphic graphic_figure graphicRef63200 \" href=\"mobipreview.htm?10/58/11176\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The hindgut is the precursor of the distal one-third of the transverse colon, the descending colon, the rectum, and the urogenital sinus (",
"      <a class=\"graphic graphic_figure graphicRef81367 \" href=\"mobipreview.htm?24/42/25251\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the process of maturation proceeds, the mucosal surface of the intestine rapidly increases and folds to form villi. Each step of development can be influenced by a variety of processes, including genetic endowment; the biologic clock; cellular, neural, and hormonal regulatory mechanisms; and the environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On a cellular level, these mechanisms most likely are regulated by the homeobox (Hox) genes, cell-to-cell interactions, epithelial-mesenchymal interactions, and transcription factors. As a general rule, maturation tends to occur along craniocaudal and proximodistal axes (",
"    <a class=\"graphic graphic_table graphicRef65282 \" href=\"mobipreview.htm?28/13/28892\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Determination of the specific program of an intestinal region (ie, anterior, mid, or posterior) occurs first, followed by detailed differentiation within that region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/2\">",
"     2",
"    </a>",
"    ]. The signal pathways for mid-gut development may be a default pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/3\">",
"     3",
"    </a>",
"    ], with plasticity imposed on the anterior or posterior regions by Hox genes. It is in these areas that more specialized organs develop (eg, stomach and distal colon, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LEFT-RIGHT ASYMMETRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The asymmetry of the contents of the abdomen is more obvious than in any other part of the body. Only in congenital disorders of the heart are the clinical consequences of deranged asymmetry greater than in the GI tract (",
"    <a class=\"graphic graphic_figure graphicRef66413 \" href=\"mobipreview.htm?40/63/41977\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63200 \" href=\"mobipreview.htm?10/58/11176\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Examples of disorders that may be caused by disturbances of lateral development include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Situs inversus abdominus",
"     </li>",
"     <li>",
"      Polysplenia or asplenia",
"     </li>",
"     <li>",
"      Pancreas divisum or annular pancreas (",
"      <a class=\"graphic graphic_figure graphicRef78995 \" href=\"mobipreview.htm?18/24/18822\">",
"       figure 5",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3431?source=see_link\">",
"       \"Anatomy and clinical significance of pancreas divisum\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Malrotation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20232?source=see_link\">",
"       \"Intestinal malrotation\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A series of genes (Left, nodal and Pitx2) regulate lateral development. They, in turn, are controlled by Gaf-1, a member of the transforming growth factor beta (TGFB) gene family. Pitx2 (and its partner Isl1) has been identified in the dorsal mesentery, which anchors the gut to the embryo. It is in this area that extracellular matrix proteins first show asymmetry, tilting the gut to the left [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/4\">",
"     4",
"    </a>",
"    ]. The intracellular events are not fully elucidated, but involve hedgehog proteins and retinoic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/5\">",
"     5",
"    </a>",
"    ]. Primary ciliary dyskinesia also is associated with situs inversus but through different mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/37/9817?source=see_link\">",
"     \"Primary ciliary dyskinesia (immotile-cilia syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIGESTION AND ABSORPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both absorptive and digestive functions of the intestine are present at term in the human neonate. Disaccharidases expressed in the brush border become active in mid-gestation, and are all active during infancy in healthy children. Because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    activity in the fetus increases late in gestation, premature infants born at 28 to 32 weeks of gestation have reduced lactase activity. After about five years, lactase activity declines in many racial groups as part of a normal process of gene inactivation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=see_link&amp;anchor=H7#H7\">",
"     \"Lactose intolerance\", section on 'Developmental lactase deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=see_link&amp;anchor=H6#H6\">",
"     \"Lactose intolerance\", section on 'Racial or ethnic lactose malabsorption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Active electrogenic transport of glucose is present in the human fetal small intestine due to the high-affinity sodium-dependent system (SGLT1 co-transporter) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/6\">",
"     6",
"    </a>",
"    ]. The duodenum-to-ileum gradient of glucose absorption is established between the 17th and 30th weeks of gestation. The developmental expression of facilitated glucose transporter isoform GLUT2, which is responsible for exit of glucose across the basolateral membrane, follows that of SGLT1. Amino acid transporters follow a similar developmental trajectory and are fully active at birth.",
"   </p>",
"   <p>",
"    Prenatal expression of genes that code for nutrient transporters and disaccharidases occurs in both colon and small intestine, but the expression disappears from the colon during the third trimester, when the villous structure of the colon turns into a flat mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     VASCULARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The supportive elements that will provide the vascular supply, the neural and hormonal regulation, and the host defenses of the gastrointestinal tract evolve concurrently with its anatomic development. The arterial bed develops as three ventral outbuddings from the aorta to form the celiac axis, and the superior and inferior mesenteric arteries (",
"    <a class=\"graphic graphic_figure graphicRef80755 \" href=\"mobipreview.htm?26/58/27556\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Mesenteric blood flow is regulated at two points (the arteriole and the precapillary sphincter) and controlled at two levels (intrinsic and extrinsic). Intrinsic control by local factors regulates blood flow in response to changes in arterial pressure and tissue oxygenation, such as those caused by occlusion or feeding. Extrinsic regulation is mediated by sympathetic input from the splanchnic nerves.",
"   </p>",
"   <p>",
"    Several other factors are important. Circulating endogenous and exogenous factors (eg, hormones) may modulate vascular tone. The mesenteric blood flow also exhibits \"autoregulatory escape\", which refers to the restoration of gut blood flow in the face of extrinsic regulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/7\">",
"     7",
"    </a>",
"    ]. When gut blood flow is decreased artificially by stimulating periarterial mesenteric nerves (ie, the extrinsic system of control) or by infusing norepinephrine, blood flow is restored within minutes by the intrinsic system of control, which is triggered by local changes (eg, tissue hypoxia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NEURAL AND MOTOR FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neural structures of the alimentary tract are formed when neural crest cells migrate into the rapidly growing gut. Precursors migrate from the embryonic central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/8\">",
"     8",
"    </a>",
"    ]. The neural crest cells and muscle cells differentiate to form the three layers of muscle that surround the mucosa and the neural network that regulates its function.",
"   </p>",
"   <p>",
"    Control of motor function is provided primarily by the enteric nervous system (a subsystem of the autonomic nervous system), which is composed of a variety of plexuses of nerve cell bodies and interneuronal circuits. Immunohistochemical staining demonstrates the presence of neurotransmitters by 24 weeks gestation, but the adult distribution may not be achieved until near term. Abnormalities in the migration and differentiation of neural crest cells result in an array of gastrointestinal problems, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hirschsprung disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link\">",
"       \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Waardenburg-Shah syndrome (pigmentary abnormalities in association with aganglionic megacolon; this condition is also called Waardenburg syndrome type IV and Waardenburg-Hirschsprung disease) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=see_link&amp;anchor=H24#H24\">",
"       \"The genodermatoses\", section on 'Waardenburg syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Haddad syndrome (with central hypoventilation; this condition is also called Ondine-Hirschsprung syndrome) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22520?source=see_link&amp;anchor=H5#H5\">",
"       \"Disorders of ventilatory control\", section on 'Congenital central hypoventilation syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intestinal neuronal dysplasias (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=see_link&amp;anchor=H15#H15\">",
"       \"Constipation in children: Etiology and diagnosis\", section on 'Other causes'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Motor activity is immature in the preterm infant. The sucking mechanism does not appear until 32 to 34 weeks gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/11\">",
"     11",
"    </a>",
"    ]. Regulation of lower esophageal sphincter tone and small intestinal motor contractions are also immature, and continue to develop into adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Gastric contents are emptied more slowly in preterm infants than in term infants, and small intestinal transit is slower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HORMONAL REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids and thyroid hormone interact with cellular signals in the maturation of the intestinal epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/15\">",
"     15",
"    </a>",
"    ]. Numerous regulatory gut peptides are also produced in the developing gastrointestinal tract. Some of these peptides function as true hormones (eg, gastrin, cholecystokinin, motilin, pancreatic polypeptide, and somatostatin), whereas others have paracrine or neurocrine function (eg, gastric inhibitory peptide, bombesin, vasoactive intestinal polypeptide, neurotensin, enteroglucagon, and peptide YY). All of these peptides are present by the end of the first trimester in the fetus, but adult distribution may not be established until term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/16\">",
"     16",
"    </a>",
"    ]. Many of these hormones are released in response to feeding. The release of some of these is limited in the newborn compared to the adult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HOST DEFENSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many aspects of host defense are mechanical in nature and appear early in gestation. Mucus production, for example, is present in the very preterm infant. Transcription factors involved in early ontogeny, such as FOXQ, regulate genes that control mucin expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/18\">",
"     18",
"    </a>",
"    ]. On the other hand, gastric emptying and peristalsis, which prevent stasis of intestinal contents, appear later and may not be fully functional in the preterm infant.",
"   </p>",
"   <p>",
"    T cells and B cells are produced as early as 12 weeks gestation. However, antigenic stimulation of the lymphoid tissues cannot be demonstrated until 46 weeks gestation. Secretory immunoglobulin A (IgA) is present by 22 weeks gestation in very low concentrations, as the newborn intestine has few IgA-producing plasma cells. Therefore, preterm infants are unable to form antibodies to exogenous protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the production and release of cytokines are brisk.",
"   </p>",
"   <p>",
"    The gut is sterile in utero, and bacterial colonization begins at birth. A variety of factors influence colonization, including mode of delivery, type of feeding, and use of antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/20\">",
"     20",
"    </a>",
"    ]. In healthy infants, aerobic organisms are present within a few hours, and anaerobic organisms by 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/21\">",
"     21",
"    </a>",
"    ]. These organisms are capable of metabolizing bile acids, nonabsorbed proteins, lipids, and carbohydrates. Thus, they potentially may play an important role in the processing of nutrients in preterm infants.",
"   </p>",
"   <p>",
"    In addition, the microbial flora directs the maturation of the host immune system, including direct interaction with dendritic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/22\">",
"     22",
"    </a>",
"    ] and the regulation of T cell maturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41205/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first steps in gastrointestinal development involve the formation of the foregut, midgut, and hindgut from the embryonic gut tube. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cephalocaudad differentiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lateralization occurs in the developing embryo to form distinct left-right asymmetry. Some of the genetic and cellular mediators involved in lateralization have been identified. Disorders of lateralization include situs inversus abdominus, malrotation of the gut, and some congenital malformations of the pancreas and spleen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Left-right asymmetry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The arterial supply to the gut develops as three ventral outbuddings from the aorta to form the celiac axis, and the superior and inferior mesenteric arteries. Mesenteric blood flow is subject to extrinsic and intrinsic regulation; intrinsic regulation may compensate for extrinsic disturbances in a process termed \"autoregulatory escape\". (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Vascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Control of motor function is provided primarily by the enteric nervous system (a subsystem of the autonomic nervous system). Abnormalities in the migration and differentiation of neural crest cells result in an array of gastrointestinal problems, including Hirschsprung disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Neural and motor function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regulatory gut peptides that are produced in the developing gastrointestinal tract include gastrin, cholecystokinin, motilin, pancreatic polypeptide, and somatostatin, as well as some paracrine or neurocrine mediators. All of these peptides are present by the end of the first trimester in the fetus, but adult distribution may not be established until term. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hormonal regulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of immune defenses in the gut is distributed across embryonal maturation, and continues to develop after birth. Preterm infants have immature gut defenses because of decreased motility and reduced secretion of immunoglobulin A. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Host defense'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/1\">",
"      Lebenthal E, Lee PC. Review article. Interactions of determinants in the ontogeny of the gastrointestinal tract: a unified concept. Pediatr Res 1983; 17:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/2\">",
"      Horb ME, Slack JM. Endoderm specification and differentiation in Xenopus embryos. Dev Biol 2001; 236:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/3\">",
"      McLin VA, Henning SJ, Jamrich M. The role of the visceral mesoderm in the development of the gastrointestinal tract. Gastroenterology 2009; 136:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/4\">",
"      Davis NM, Kurpios NA, Sun X, et al. The chirality of gut rotation derives from left-right asymmetric changes in the architecture of the dorsal mesentery. Dev Cell 2008; 15:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/5\">",
"      Lipscomb K, Schmitt C, Sablyak A, et al. Role for retinoid signaling in left-right asymmetric digestive organ morphogenesis. Dev Dyn 2006; 235:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/6\">",
"      P&aacute;cha J. Development of intestinal transport function in mammals. Physiol Rev 2000; 80:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/7\">",
"      Shepherd AP, Granger HJ. Autoregulatory escape in the gut: a systems analysis. Gastroenterology 1973; 65:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/8\">",
"      Burns AJ, Thapar N. Advances in ontogeny of the enteric nervous system. Neurogastroenterol Motil 2006; 18:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/9\">",
"      Newgreen D, Young HM. Enteric nervous system: development and developmental disturbances--part 1. Pediatr Dev Pathol 2002; 5:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/10\">",
"      Newgreen D, Young HM. Enteric nervous system: development and developmental disturbances--part 2. Pediatr Dev Pathol 2002; 5:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/11\">",
"      Herbst JJ. Development of suck and swallow. J Pediatr Gastroenterol Nutr 1983; 2 Suppl 1:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/12\">",
"      Omari TI, Miki K, Davidson G, et al. Characterisation of relaxation of the lower oesophageal sphincter in healthy premature infants. Gut 1997; 40:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/13\">",
"      Amarnath RP, Berseth CL, Malagelada JR, et al. Postnatal maturation of small intestinal motility in preterm neonates. J Gastrointest Motil 1989; 1:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/14\">",
"      Berseth CL, Bisquera JA, Paje VU. Prolonging small feeding volumes early in life decreases the incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2003; 111:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/15\">",
"      Simo P, Simon-Assmann P, Arnold C, Kedinger M. Mesenchyme-mediated effect of dexamethasone on laminin in cocultures of embryonic gut epithelial cells and mesenchyme-derived cells. J Cell Sci 1992; 101 ( Pt 1):161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/16\">",
"      Lucas A, Bloom SR, Aynsley-Green A. Development of gut hormone responses to feeding in neonates. Arch Dis Child 1980; 55:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/17\">",
"      Berseth CL, Nordyke CK, Valdes MG, et al. Responses of gastrointestinal peptides and motor activity to milk and water feedings in preterm and term infants. Pediatr Res 1992; 31:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/18\">",
"      Penders J, Thijs C, Vink C, et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006; 118:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/19\">",
"      Rieger CH, Rothberg RM. Development of the capacity to produce specific antibody to an ingested food antigen in the premature infant. J Pediatr 1975; 87:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/20\">",
"      Verzi MP, Khan AH, Ito S, Shivdasani RA. Transcription factor foxq1 controls mucin gene expression and granule content in mouse stomach surface mucous cells. Gastroenterology 2008; 135:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/21\">",
"      Agostoni C, Axelsson I, Goulet O, et al. Prebiotic oligosaccharides in dietetic products for infants: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/22\">",
"      Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004; 303:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/23\">",
"      Williams AM, Probert CS, Stepankova R, et al. Effects of microflora on the neonatal development of gut mucosal T cells and myeloid cells in the mouse. Immunology 2006; 119:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41205/abstract/24\">",
"      Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122:107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5905 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.14-E9FFDB1ABC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41205=[""].join("\n");
var outline_f40_15_41205=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CEPHALOCAUDAD DIFFERENTIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LEFT-RIGHT ASYMMETRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIGESTION AND ABSORPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      VASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NEURAL AND MOTOR FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HORMONAL REGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HOST DEFENSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5905\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5905|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/24/23941\" title=\"figure 1\">",
"      Foregut formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/58/11176\" title=\"figure 2\">",
"      Midgut formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/42/25251\" title=\"figure 3\">",
"      Hindgut formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/63/41977\" title=\"figure 4\">",
"      Digestive organ development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/24/18822\" title=\"figure 5\">",
"      Anatomy embryology pancreas div",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/58/27556\" title=\"figure 6\">",
"      GI vascular development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5905|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/13/28892\" title=\"table 1\">",
"      Maturation of GI tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3431?source=related_link\">",
"      Anatomy and clinical significance of pancreas divisum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=related_link\">",
"      Constipation in children: Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22520?source=related_link\">",
"      Disorders of ventilatory control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20232?source=related_link\">",
"      Intestinal malrotation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/37/9817?source=related_link\">",
"      Primary ciliary dyskinesia (immotile-cilia syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_15_41206="Rickets wrist";
var content_f40_15_41206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anteroposterior radiograph of the wrist and hand in a child with rickets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteroposterior radiograph of the wrist and hand in a 3-year-old child with nutritional rickets. The child had been put on a strict diet without dairy products. Note the widening, cupping, and fraying of the distal radius and ulna metaphyses with an associated increase in the thickness of the growth plate. These changes are the consequence of disordered endochondral growth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rao SB, Crawford AH. Traumatic and Acquired Wrist Disorders in Children. In: The Wrist and its Disorders, Lichtman Alexander (Ed), WB Saunders, 1999. Copyright &copy; 1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41206=[""].join("\n");
var outline_f40_15_41206=null;
var title_f40_15_41207="Clinical features and evaluation of nausea and vomiting of pregnancy";
var content_f40_15_41207=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and evaluation of nausea and vomiting of pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41207/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41207/contributors\">",
"     Jerrie S Refuerzo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41207/contributors\">",
"     Judith A Smith, Pharm D, BCOP, CPHQ, FCCP, FISOPP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41207/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41207/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41207/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41207/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41207/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/15/41207/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea with or without vomiting is so common in early pregnancy that mild symptoms may be considered part of the normal physiology of the first trimester. However, these symptoms can significantly impact the pregnant woman&rsquo;s quality of life, especially when persistent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/1\">",
"     1",
"    </a>",
"    ]. Hyperemesis gravidarum is the term used to describe the severe end of the symptom spectrum (weight loss exceeding 5 percent of prepregnancy body weight), but there are no universally accepted criteria for demarcating between mild and severe disease.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnostic evaluation of women with nausea and vomiting of pregnancy will be reviewed here. Treatment of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/20/29002?source=see_link\">",
"     \"Treatment and outcome of nausea and vomiting of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83693262\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some degree of nausea with or without vomiting occurs in 50 to 90 percent of all pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The incidence of women with severe symptoms is not well-documented; reports vary from 0.3 to 2 percent of pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Ethnic differences and differences in the definition of the disease may account, in part, for the variability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83691113\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of pregnancy-related nausea and vomiting remains unclear, but the disorder appears to be more common in Western nations and urban areas than in Africa and Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Younger primigravid women are more likely to be affected than older multiparous women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/9\">",
"     9",
"    </a>",
"    ], but data have not been consistent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83691120\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpregnant women who experience nausea and vomiting related to estrogen&ndash;based medication, motion, or migraine are more likely to experience pregnancy-related nausea and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/10\">",
"     10",
"    </a>",
"    ]. Women who are supertasters are also at increased risk; in contrast, anosmic women appear to be at low risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nausea and vomiting are more common in women with multiple gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], women with hydatidiform mole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/14\">",
"     14",
"    </a>",
"    ], women who did not take multivitamins either prior to 6 weeks of gestation or during the peri-conceptional period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], and women with heartburn and acid reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of risk factors specifically for hyperemesis gravidarum have generally included only a small number of affected women, and results have not been definitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/9,18-20\">",
"     9,18-20",
"    </a>",
"    ]. Risk factors appear to be similar as those for milder disease. In addition, genetic factors appear to play a role. A population-based cohort study found that daughters of women with hyperemesis were at significantly higher risk of developing hyperemesis in their own pregnancy compared to daughters of women without hyperemesis (3 versus 1 percent), while female partners of sons of women with hyperemesis were not at increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/21\">",
"     21",
"    </a>",
"    ]. Other studies have reported a significantly higher risk of hyperemesis gravidarum in women whose sister or mother experienced the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], in monozygotic twins compared with dizygotic twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/24\">",
"     24",
"    </a>",
"    ], and in women with certain genetically determined conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/22,25,26\">",
"     22,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interestingly, studies consistently report a preponderance of female fetuses among pregnancies complicated by hyperemesis (odds of female fetus 1.27, 95% CI 1.21-1.34) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alcohol use and cigarette smoking (perhaps due to the effect of nicotine) appear to be protective factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83693497\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of nausea and vomiting in pregnancy is unknown. The predominant theories are described below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Psychologic factors",
"      </strong>",
"      &mdash; Two general theories are that hyperemesis reflects (1) a conversion or somatization disorder or (2) a response to stress [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/28\">",
"       28",
"      </a>",
"      ]. A feeling of ambivalence about the pregnancy has also been proposed as an etiologic or contributing factor. Although no study has definitively demonstrated that the psychologic makeup of patients with hyperemesis gravidarum differs from those without the disorder, the woman&rsquo;s psychological response to persistent nausea and vomiting may exacerbate her symptoms as a result of conditioning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Hormonal changes",
"      </strong>",
"      &mdash; No single hormonal profile can accurately predict the presence of hyperemesis gravidarum. Elevated serum concentrations of estrogen and progesterone have long been implicated in the pathogenesis of this disorder. These hormones relax smooth muscle and thus slow gastrointestinal transit time and may alter gastric emptying. Although several lines of evidence support a role, especially for estrogen, the fact that sex hormone levels peak in the third trimester, long after symptoms of hyperemesis gravidarum have typically resolved, is inconsistent with this theory [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      By comparison, serum concentrations of human chorionic gonadotropin (hCG) peak during the first trimester, the time when hyperemesis gravidarum is typically seen. The observations that serum hCG concentration is higher in women with hyperemesis than in other pregnant women and that nausea and vomiting are worse in women with multiple gestations and hydatidiform moles, conditions associated with high hCG levels, also support a possible etiologic role for this hormone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. However, others have not found a relationship between hCG levels and nausea and vomiting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/34\">",
"       34",
"      </a>",
"      ]. One theory is that hCG isoforms or hCG receptor mutations explain the differences in symptoms among women with similar hCG levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/32,35\">",
"       32,35",
"      </a>",
"      ]. A causal association between hCG levels and hyperemesis gravidarum has not been firmly established.",
"      <br/>",
"      <br/>",
"      The role of several other hormones in the pathogenesis of hyperemesis has been studied, but no consistent relationship has been determined [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Abnormal gastrointestinal motility",
"      </strong>",
"      &mdash; Gastric motility may be abnormal (delayed or dysrhythmic) in women with hyperemesis gravidarum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/2\">",
"       2",
"      </a>",
"      ]. Studies addressing motility disturbances have shown conflicting results, suggesting that these abnormalities are not highly predictive of the disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14312?source=see_link\">",
"       \"Pathogenesis of delayed gastric emptying\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <br/>",
"      The lower esophageal sphincter is relaxed in pregnancy, leading to an increase in gastroesophageal reflux. Gastroesophageal reflux results in heartburn and, in some individuals, nausea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/36\">",
"       36",
"      </a>",
"      ]. However, if this were the mechanism for hyperemesis, symptoms should worsen as pregnancy advances, rather than improve.",
"     </li>",
"     <li>",
"      <strong>",
"       Helicobacter pylori",
"      </strong>",
"      &mdash; Most women with H. pylori do not develop severe nausea and vomiting in pregnancy, but the infection may play a role in pathogenesis of disease in some women. A systematic review and meta-analysis of 25 epidemiological studies examining H. pylori infection and hyperemesis gravidarum reported a significant association (OR 3.32, 95% CI 2.25-4.90) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/37\">",
"       37",
"      </a>",
"      ]. However, there was significant heterogeneity among studies and most studies did not distinguish between active infection and past infection or strain of H. pylori. Case reports and small series have reported improvement in symptoms in women with severe disease after treatment of the infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/38\">",
"       38",
"      </a>",
"      ]. Although these observations support the hypothesis, confirmatory evidence from controlled trials is needed.",
"     </li>",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"      &mdash; Several other theories to explain hyperemesis have been suggested, including specific nutrient deficiencies (eg, zinc), alterations in lipid levels, changes in the autonomic nervous system, genetic factors, and immunologic dysregulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/2,18\">",
"       2,18",
"      </a>",
"      ]. None is consistently associated with, or highly predictive of, the disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea and vomiting of",
"    <span class=\"nowrap\">",
"     pregnancy/hyperemesis",
"    </span>",
"    gravidarum are clinical diagnoses without uniform criteria.",
"   </p>",
"   <p>",
"    The mean onset of symptoms is at 5 to 6 weeks of gestation, peaking at about 9 weeks, and usually abating by 16 to 20 weeks of gestation; however, symptoms may continue until the third trimester in 15 to 20 percent of gravida and until delivery in 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/10,39,40\">",
"     10,39,40",
"    </a>",
"    ]. Sixty percent of women are asymptomatic six weeks after onset of nausea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/39\">",
"     39",
"    </a>",
"    ]. If vomiting persists beyond a few days postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/41\">",
"     41",
"    </a>",
"    ], other etiologies should be investigated.",
"   </p>",
"   <p>",
"    Although the lay term for mild pregnancy-related nausea and vomiting is \"morning sickness,\" the symptoms may occur at any time of day and often (80 percent) persist throughout the day.",
"   </p>",
"   <p>",
"    Women with the common form of nausea and vomiting of pregnancy maintain normal vital signs and have normal physical and laboratory examinations.",
"   </p>",
"   <p>",
"    Hyperemesis gravidarum is considered the severe end of the spectrum of nausea and vomiting, although there is no clear demarcation between common pregnancy-related \"morning sickness\" and the infrequent pathologic disorder. Common criteria for diagnosis of hyperemesis are persistent vomiting accompanied by weight loss exceeding 5 percent of prepregnancy body weight and ketonuria unrelated to other causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/42\">",
"     42",
"    </a>",
"    ]. Alternatively, the diagnosis can be made in women with pregnancy-related vomiting that occurs greater than three times per day with weight loss greater than 3 kg or 5 percent of body weight and ketonuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to women with mild disease, women with hyperemesis have orthostatic hypotension, laboratory abnormalities, and physical signs of dehydration, and often require hospitalization for stabilization. In addition, many women with hyperemesis hypersalivate (ptyalism) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83693828\">",
"    <span class=\"h2\">",
"     Scoring systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Motherisk-PUQE scoring index and the Rhodes Index are tools for quantifying the severity of nausea and vomiting in pregnancy and following the course of the condition; they have been used predominantly in research studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. These indices use a point system to assign points for the number of hours each day the woman feels nauseated, the number of times she vomits, and the number of times she has dry heaves. A high score indicates the woman should be evaluated for dehydration and her serum electrolyte levels should be checked. Some clinicians find that these tools are helpful in assessing symptoms in their patients, but they have not been validated for guiding management of nausea and vomiting of pregnancy in the clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83693861\">",
"    <span class=\"h2\">",
"     Laboratory tests and imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation is indicated in women with persistent nausea and vomiting to determine the severity of disease and to exclude other diagnoses that could account for the symptoms.",
"   </p>",
"   <p>",
"    The standard initial evaluation of pregnant women with persistent nausea and vomiting includes measurement of weight, orthostatic blood pressures, heart rate, serum electrolytes, and urine ketones and specific gravity. An obstetrical ultrasound examination is performed to look for gestational trophoblastic disease and multiple gestation, both of which are associated with these symptoms.",
"   </p>",
"   <p>",
"    Based on patient-specific factors, such as severity of disease and associated symptoms, we selectively order one or more of the following additional blood tests to assess the woman&rsquo;s",
"    <span class=\"nowrap\">",
"     volume/metabolic",
"    </span>",
"    status or to exclude other diagnoses: blood urea nitrogen, creatinine, complete blood count, liver function tests, thyroid function tests,",
"    <span class=\"nowrap\">",
"     amylase/lipase,",
"    </span>",
"    and calcium level. Ultrasound examination of the liver is indicated if liver disease is suspected. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83691773\">",
"    <span class=\"h3\">",
"     Findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory abnormalities that can be caused by nausea and vomiting of pregnancy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Electrolyte and acid-base derangements",
"      </strong>",
"      , such as hypokalemia and hypochloremic metabolic alkalosis, from vomiting gastric secretions. Ketosis can occur if caloric intake is minimal.",
"     </li>",
"     <li>",
"      An",
"      <strong>",
"       increase in hematocrit",
"      </strong>",
"      , indicating hemoconcentration due to plasma volume depletion. The degree of hemoconcentration may be underestimated unless the physiologic decline in hematocrit seen in normal pregnancies is considered.",
"      <br/>",
"      <br/>",
"      Other signs of dehydration include an elevated blood urea nitrogen and urine specific gravity.",
"     </li>",
"     <li>",
"      <strong>",
"       Abnormal liver enzyme",
"      </strong>",
"      values occur in approximately 50 percent of patients who are hospitalized with hyperemesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/48\">",
"       48",
"      </a>",
"      ]. The most striking abnormality is an increase in serum aminotransferases. Alanine aminotransferase (ALT) is typically elevated to a greater degree than aspartate aminotransferase (AST). Values for both are typically only mildly elevated, eg, in the low hundreds or two to three times the upper limit of normal, and rarely as high as 1000",
"      <span class=\"nowrap\">",
"       U/L.",
"      </span>",
"      Hyperbilirubinemia also can occur, but rarely exceeds 4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/49\">",
"       49",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      <br/>",
"      The degree of abnormality in liver tests correlates with severity of vomiting; the highest elevations are seen in patients with the most severe or protracted vomiting. Abnormal liver biochemical tests resolve promptly upon resolution of vomiting.",
"      <br/>",
"      <br/>",
"      Given the characteristic clinical manifestations of hyperemesis gravidarum, a liver biopsy is not needed in women with abnormal liver function tests to exclude other causes for the laboratory findings. When a liver biopsy has been performed, it was either normal or showed nonspecific findings. Inflammation was absent, but necrosis with cell drop out, steatosis centrilobular vacuolization, and rare bile plugs have been seen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. These changes help to explain the mechanism for the liver test abnormalities.",
"     </li>",
"     <li>",
"      Serum",
"      <strong>",
"       amylase and lipase",
"      </strong>",
"      may increase as much as 5-fold (as opposed to a 5- to 10-fold increase in acute pancreatitis) and are of salivary rather than pancreatic origin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Mild hyperthyroidism",
"      </strong>",
"      , possibly due to high serum concentrations of human chorionic gonadotropin which has thyroid-stimulating activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/32\">",
"       32",
"      </a>",
"      ]. One report noted low serum TSH concentrations more often in women with hyperemesis gravidarum than in normal pregnant women; TSH was suppressed in 60 percent of hyperemesis patients versus 9 percent of controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/33\">",
"       33",
"      </a>",
"      ]. Some of these women had elevated serum free T4 concentrations and therefore met the definition of hyperthyroidism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42760?source=see_link\">",
"       \"Hyperthyroidism during pregnancy: Treatment\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Features that distinguish the transient hyperthyroidism of hyperemesis gravidarum from hyperthyroidism of other causes (which in a pregnant woman is most likely due to Graves' disease) are the vomiting, absence of goiter and ophthalmopathy, and absence of the common symptoms and signs of hyperthyroidism (heat intolerance, muscle weakness, tremor). In addition, serum free T4 concentrations are only minimally elevated and serum T3 concentrations are not elevated in women with hyperemesis gravidarum, whereas both are usually unequivocally elevated in pregnant women with true hyperthyroidism. Treatment of hyperthyroidism should",
"      <strong>",
"       not",
"      </strong>",
"      be undertaken without clear evidence of a primary thyroid disorder (eg, goiter, elevated free thyroid hormone or elevated TSH receptor antibody levels). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42760?source=see_link\">",
"       \"Hyperthyroidism during pregnancy: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea and",
"    <span class=\"nowrap\">",
"     vomiting/hyperemesis",
"    </span>",
"    is generally a diagnosis of exclusion, based on its first occurrence in early pregnancy, with gradual resolution over weeks. Nausea and vomiting that develop after 10 weeks of gestation are not likely due to this disorder.",
"   </p>",
"   <p>",
"    The presence of associated signs and symptoms, such as bilious emesis, abdominal pain, fever, headache, abnormal neurologic findings, diarrhea, constipation, leukocytosis, goiter, or hypertension, also suggests another diagnosis is likely; many conditions unrelated to pregnancy can cause persistent nausea and vomiting (",
"    <a class=\"graphic graphic_table graphicRef78422 \" href=\"mobipreview.htm?42/41/43678\">",
"     table 1",
"    </a>",
"    ). The differential diagnosis of these conditions, including indications for endoscopy, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the adult with nausea and vomiting\", section on 'Approach to management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple gestation and hydatidiform mole are associated with nausea and",
"    <span class=\"nowrap\">",
"     vomiting/hyperemesis",
"    </span>",
"    of pregnancy. (See",
"    <a class=\"local\" href=\"#H83691120\">",
"     'Risk factors'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Preeclampsia, HELLP syndrome (Hemolysis, Elevated Liver function tests, Low Platelets), and acute fatty liver of pregnancy are also causes of pregnancy-related nausea and vomiting, but onset is in the latter half of pregnancy (usually the third trimester), hypertension is usually present, and thrombocytopenia is common. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24166?source=see_link\">",
"     \"Acute fatty liver of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperparathyroidism in pregnancy is uncommon, but should be considered, as hypercalcemia may contribute to vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41207/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/39/1650?source=see_link\">",
"       \"Patient information: Morning sickness (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/7/4210?source=see_link\">",
"       \"Patient information: Hyperemesis gravidarum (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/55/23411?source=see_link\">",
"       \"Patient information: Pregnancy symptoms (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/63/37874?source=see_link\">",
"       \"Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some degree of nausea with or without vomiting occurs in most pregnancies, typically with onset at 5 to 6 weeks of gestation, then peaking at 9 weeks, and usually abating by 16 to 18 weeks of gestation. Hyperemesis gravidarum represents the severe end of the spectrum of symptoms. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis and clinical course'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H83693262\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpregnant women who experience nausea and vomiting after estrogen exposure, from motion sickness, with migraine, or with exposure to certain tastes (supertasters) are more likely to have pregnancy-related nausea and vomiting. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of hyperemesis gravidarum is made clinically in a woman with onset of persistent vomiting accompanied by weight loss exceeding 5 percent of prepregnancy body weight and ketonuria in the first trimester, unrelated to other causes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis and clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The standard initial evaluation of pregnant women with persistent vomiting includes measurement of weight, orthostatic blood pressures, serum electrolytes, urine ketones and specific gravity, and an ultrasound examination to look for gestational trophoblastic disease or multiple gestation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/1\">",
"      Lacasse A, Rey E, Ferreira E, et al. Nausea and vomiting of pregnancy: what about quality of life? BJOG 2008; 115:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/2\">",
"      Lee NM, Saha S. Nausea and vomiting of pregnancy. Gastroenterol Clin North Am 2011; 40:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/3\">",
"      K&auml;ll&eacute;n B. Hyperemesis during pregnancy and delivery outcome: a registry study. Eur J Obstet Gynecol Reprod Biol 1987; 26:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/4\">",
"      Hallak M, Tsalamandris K, Dombrowski MP, et al. Hyperemesis gravidarum. Effects on fetal outcome. J Reprod Med 1996; 41:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/5\">",
"      Tsang IS, Katz VL, Wells SD. Maternal and fetal outcomes in hyperemesis gravidarum. Int J Gynaecol Obstet 1996; 55:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/6\">",
"      Bailit JL. Hyperemesis gravidarium: Epidemiologic findings from a large cohort. Am J Obstet Gynecol 2005; 193:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/7\">",
"      Gazmararian JA, Petersen R, Jamieson DJ, et al. Hospitalizations during pregnancy among managed care enrollees. Obstet Gynecol 2002; 100:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/8\">",
"      Lacasse A, Rey E, Ferreira E, et al. Epidemiology of nausea and vomiting of pregnancy: prevalence, severity, determinants, and the importance of race/ethnicity. BMC Pregnancy Childbirth 2009; 9:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/9\">",
"      Klebanoff MA, Koslowe PA, Kaslow R, Rhoads GG. Epidemiology of vomiting in early pregnancy. Obstet Gynecol 1985; 66:612.",
"     </a>",
"    </li>",
"    <li>",
"     Association of professors of gynecology and obstetrics. Nausea and vomiting of pregnancy. Association of professors of gynecology and obstetrics, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/11\">",
"      Heinrichs L. Linking olfaction with nausea and vomiting of pregnancy, recurrent abortion, hyperemesis gravidarum, and migraine headache. Am J Obstet Gynecol 2002; 186:S215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/12\">",
"      Basso O, Olsen J. Sex ratio and twinning in women with hyperemesis or pre-eclampsia. Epidemiology 2001; 12:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/13\">",
"      Brandes JM. First-trimester nausea and vomiting as related to outcome of pregnancy. Obstet Gynecol 1967; 30:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/14\">",
"      Hou JL, Wan XR, Xiang Y, et al. Changes of clinical features in hydatidiform mole: analysis of 113 cases. J Reprod Med 2008; 53:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/15\">",
"      Emelianova S, Mazzotta P, Einarson A, Koren G. Prevalence and severity of nausea and vomiting of pregnancy and effect of vitamin supplementation. Clin Invest Med 1999; 22:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/16\">",
"      Czeizel AE, Dudas I, Fritz G, et al. The effect of periconceptional multivitamin-mineral supplementation on vertigo, nausea and vomiting in the first trimester of pregnancy. Arch Gynecol Obstet 1992; 251:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/17\">",
"      Gill SK, Maltepe C, Koren G. The effect of heartburn and acid reflux on the severity of nausea and vomiting of pregnancy. Can J Gastroenterol 2009; 23:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/18\">",
"      Goodwin TM. Nausea and vomiting of pregnancy: an obstetric syndrome. Am J Obstet Gynecol 2002; 186:S184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/19\">",
"      Schiff MA, Reed SD, Daling JR. The sex ratio of pregnancies complicated by hospitalisation for hyperemesis gravidarum. BJOG 2004; 111:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/20\">",
"      Weigel MM, Weigel RM. The association of reproductive history, demographic factors, and alcohol and tobacco consumption with the risk of developing nausea and vomiting in early pregnancy. Am J Epidemiol 1988; 127:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/21\">",
"      Vikanes A. Recurrence of hyperemesis gravidarum across generations: population based cohort study. BMJ 2010; 340:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/22\">",
"      Zhang Y, Cantor RM, MacGibbon K, et al. Familial aggregation of hyperemesis gravidarum. Am J Obstet Gynecol 2011; 204:230.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/23\">",
"      Fejzo MS, Ingles SA, Wilson M, et al. High prevalence of severe nausea and vomiting of pregnancy and hyperemesis gravidarum among relatives of affected individuals. Eur J Obstet Gynecol Reprod Biol 2008; 141:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/24\">",
"      Corey LA, Berg K, Solaas MH, Nance WE. The epidemiology of pregnancy complications and outcome in a Norwegian twin population. Obstet Gynecol 1992; 80:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/25\">",
"      Outlaw WM, Ibdah JA. Impaired fatty acid oxidation as a cause of liver disease associated with hyperemesis gravidarum. Med Hypotheses 2005; 65:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/26\">",
"      Innes AM, Seargeant LE, Balachandra K, et al. Hepatic carnitine palmitoyltransferase I deficiency presenting as maternal illness in pregnancy. Pediatr Res 2000; 47:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/27\">",
"      Veenendaal MV, van Abeelen AF, Painter RC, et al. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. BJOG 2011; 118:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/28\">",
"      Buckwalter JG, Simpson SW. Psychological factors in the etiology and treatment of severe nausea and vomiting in pregnancy. Am J Obstet Gynecol 2002; 186:S210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/29\">",
"      Matteson S, Roscoe J, Hickok J, Morrow GR. The role of behavioral conditioning in the development of nausea. Am J Obstet Gynecol 2002; 186:S239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/30\">",
"      Lagiou P, Tamimi R, Mucci LA, et al. Nausea and vomiting in pregnancy in relation to prolactin, estrogens, and progesterone: a prospective study. Obstet Gynecol 2003; 101:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/31\">",
"      O'Leary P, Boyne P, Flett P, et al. Longitudinal assessment of changes in reproductive hormones during normal pregnancy. Clin Chem 1991; 37:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/32\">",
"      Kimura M, Amino N, Tamaki H, et al. Gestational thyrotoxicosis and hyperemesis gravidarum: possible role of hCG with higher stimulating activity. Clin Endocrinol (Oxf) 1993; 38:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/33\">",
"      Goodwin TM, Montoro M, Mestman JH, et al. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 1992; 75:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/34\">",
"      Soules MR, Hughes CL Jr, Garcia JA, et al. Nausea and vomiting of pregnancy: role of human chorionic gonadotropin and 17-hydroxyprogesterone. Obstet Gynecol 1980; 55:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/35\">",
"      Yamazaki K, Sato K, Shizume K, et al. Potent thyrotropic activity of human chorionic gonadotropin variants in terms of 125I incorporation and de novo synthesized thyroid hormone release in human thyroid follicles. J Clin Endocrinol Metab 1995; 80:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/36\">",
"      Brzana RJ, Koch KL. Gastroesophageal reflux disease presenting with intractable nausea. Ann Intern Med 1997; 126:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/37\">",
"      Sandven I, Abdelnoor M, Nesheim BI, Melby KK. Helicobacter pylori infection and hyperemesis gravidarum: a systematic review and meta-analysis of case-control studies. Acta Obstet Gynecol Scand 2009; 88:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/38\">",
"      Mansour GM, Nashaat EH. Role of Helicobacter pylori in the pathogenesis of hyperemesis gravidarum. Arch Gynecol Obstet 2011; 284:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/39\">",
"      Goodwin TM. Hyperemesis gravidarum. Obstet Gynecol Clin North Am 2008; 35:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/40\">",
"      Fell DB, Dodds L, Joseph KS, et al. Risk factors for hyperemesis gravidarum requiring hospital admission during pregnancy. Obstet Gynecol 2006; 107:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/41\">",
"      Kirshon B, Lee W, Cotton DB. Prompt resolution of hyperthyroidism and hyperemesis gravidarum after delivery. Obstet Gynecol 1988; 71:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/42\">",
"      Goodwin TM. Hyperemesis gravidarum. Clin Obstet Gynecol 1998; 41:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/43\">",
"      Golberg D, Szilagyi A, Graves L. Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review. Obstet Gynecol 2007; 110:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/44\">",
"      Godsey RK, Newman RB. Hyperemesis gravidarum. A comparison of single and multiple admissions. J Reprod Med 1991; 36:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/45\">",
"      Koren G, Boskovic R, Hard M, et al. Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. Am J Obstet Gynecol 2002; 186:S228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/46\">",
"      Lacasse A, Rey E, Ferreira E, et al. Validity of a modified Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) scoring index to assess severity of nausea and vomiting of pregnancy. Am J Obstet Gynecol 2008; 198:71.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/47\">",
"      Rhodes VA, McDaniel RW. The Index of Nausea, Vomiting, and Retching: a new format of the lndex of Nausea and Vomiting. Oncol Nurs Forum 1999; 26:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/48\">",
"      Abell TL, Riely CA. Hyperemesis gravidarum. Gastroenterol Clin North Am 1992; 21:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/49\">",
"      Larrey D, Rueff B, Feldmann G, et al. Recurrent jaundice caused by recurrent hyperemesis gravidarum. Gut 1984; 25:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/50\">",
"      Abell TL. Nausea and vomiting of pregnancy and the electrogastrogram: old disease, new technology. Am J Gastroenterol 1992; 87:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/51\">",
"      Knox TA, Olans LB. Liver disease in pregnancy. N Engl J Med 1996; 335:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/52\">",
"      Robertson C, Millar H. Hyperamylasemia in bulimia nervosa and hyperemesis gravidarum. Int J Eat Disord 1999; 26:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/53\">",
"      Budd DC, Kumka MM, Suda AK, Fink DL. Hyperparathyroidism masquerading as hyperemesis gravidarum. N J Med 1988; 85:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41207/abstract/54\">",
"      Pedersen NT, Permin H. Hyperparathyroidism and pregnancy. Report of a case and review of the literature. Acta Obstet Gynecol Scand 1975; 54:281.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6792 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41207=[""].join("\n");
var outline_f40_15_41207=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83693262\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83691113\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83691120\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83693497\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS AND CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83693828\">",
"      Scoring systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83693861\">",
"      Laboratory tests and imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83691773\">",
"      - Findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6792\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6792|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/41/43678\" title=\"table 1\">",
"      Differential dx of nausea and vomiting",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42760?source=related_link\">",
"      Hyperthyroidism during pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14312?source=related_link\">",
"      Pathogenesis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/7/4210?source=related_link\">",
"      Patient information: Hyperemesis gravidarum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/39/1650?source=related_link\">",
"      Patient information: Morning sickness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/63/37874?source=related_link\">",
"      Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/55/23411?source=related_link\">",
"      Patient information: Pregnancy symptoms (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/20/29002?source=related_link\">",
"      Treatment and outcome of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_15_41208="Religion, spirituality, and end of life care";
var content_f40_15_41208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Religion, spirituality, and end of life care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41208/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41208/contributors\">",
"     Christina M Puchalski, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41208/contributors\">",
"     Rabbi Elliot Dorff, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41208/contributors\">",
"     Balaji N Hebbar, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41208/contributors\">",
"     Yahya Hendi, MA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41208/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41208/contributors\">",
"     Linda Emanuel, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41208/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41208/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/15/41208/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spiritual, religious, and cultural beliefs and practices play a significant role in the lives of patients who are seriously ill and dying. In addition to providing an ethical foundation for clinical decision making, spiritual and religious traditions provide a conceptual framework for understanding the human experience of death and dying, and the meaning of illness and suffering [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of spiritual and religious beliefs in coping with illness, suffering, and dying is supported by clinical studies as well as individual narrative descriptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/1-9\">",
"     1-9",
"    </a>",
"    ]. Most patients derive comfort from their",
"    <span class=\"nowrap\">",
"     religious/spiritual",
"    </span>",
"    beliefs as they face the end of life, and some find reassurance through a belief in continued existence after physical death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/10\">",
"     10",
"    </a>",
"    ]. However, religious concerns can also be a source of pain and spiritual distress, for example, if a patient feels punished or abandoned by God [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/11\">",
"     11",
"    </a>",
"    ]. Furthermore, beyond the role of religious faith in coping and adjusting to illness, religion also influences patient's medical decisions, both about active treatment and end of life care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/7,12-14\">",
"     7,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A common goal for the dying patient, family members, and the health care professional is for a meaningful dying experience, in which loss is framed in the context of a life legacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/15\">",
"     15",
"    </a>",
"    ]. Such an experience includes support for the patient's suffering, the avoidance of undesired artificial prolongation of life, involvement of family",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    close friends, resolution of remaining life conflicts, and attention to spiritual issues that surround the meaning of illness and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians can and should help dying patients find meaning and hope through recognition of the spiritual dimension of their experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/6\">",
"     6",
"    </a>",
"    ]. Although they may lack the expertise to address spiritual concerns in depth, healthcare professionals should be able to discuss spirituality with their patients and identify those in spiritual distress so that appropriate referral may be made to spiritual care providers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/11\">",
"     11",
"    </a>",
"    ]. These include chaplains, community-based clergy, spiritual directors, pastoral counselors, and culturally based healers.",
"   </p>",
"   <p>",
"    Spiritual care is recognized as a necessary domain of palliative care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/17\">",
"     17",
"    </a>",
"    ]. Guidelines for interprofessional spiritual care as well as an implementation model for spiritual care were developed by a national consensus conference of experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/18\">",
"     18",
"    </a>",
"    ]. In their report, practical tools as well as recommendations are presented to help clinicians integrate&nbsp;spirituality more fully into patient care.",
"   </p>",
"   <p>",
"    Here we will provide an overview of religion, spirituality, and spiritual care in patients who are terminally ill. This is followed by a brief summary of several major religious faiths and how their beliefs impact decision making and coping as patients approach the end of life. This topic is not intended to provide a comprehensive overview of all religious and spiritual perspectives, but to provide examples of how the practices of some religions influence the response to serious illness and end of life concerns. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RELIGION AND SPIRITUALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms religion and spirituality are not interchangeable. The term \"religion\" usually refers to an organized faith system of beliefs, practices, rituals, and language that characterize a community searching for transcendent meaning in a particular way, generally based upon belief in a divine being [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/19\">",
"     19",
"    </a>",
"    ]. Religion represents only one of many forms of spiritual expression.",
"   </p>",
"   <p>",
"    Broadly defined, spirituality is that which gives ultimate meaning and purpose in an individual's life. Although spirituality can be expressed in religious beliefs and practices, it can also more broadly include a relationship with",
"    <span class=\"nowrap\">",
"     God/Divine",
"    </span>",
"    or a higher power, or with family, or with cultural communities. People may be in touch with their spirituality through formal religious rituals or sacraments, or through interaction with nature, humanity, or the arts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spirituality is a continuous process that changes over a person's lifetime, and is affected by illness and dying. Terminally ill patients generally acknowledge a greater spiritual perspective or orientation than either nonterminally ill or healthy patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT AND MANAGEMENT OF SPIRITUAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians find it difficult to initiate a discussion with patients about spirituality. Clinicians are often reluctant to talk about spiritual issues with their patients because they believe it is not their role to do so, or that patients might consider such discussion intrusive or evangelical. Furthermore, physicians may feel overwhelmed and unsure of how to respond if a patient turns to them in spiritual distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Yet, most studies indicate that patients want their health care professionals to ask about spiritual concerns and that they benefit from discussions of these issues with their physicians and from the provision of spiritual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/25-30\">",
"     25-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     The interdisciplinary nature of spiritual care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spiritual care requires an interdisciplinary focus, with participation of all members of the healthcare team. This can include the clinician, nurse, chaplains, social worker, counselors, dietitians, housekeeping staff, and other allied health care workers. In addition, members of the community (clergy, parish nurses, others) may also interact with all or some members of the healthcare team, with the patient,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with the patient's family.",
"   </p>",
"   <p>",
"    In the collaborative interdisciplinary team model of patient care, each member of the team has an area of expertise. Although all members may discuss overlapping issues such as diet, physical symptoms, spiritual issues, and social concerns, the trained professionals in each of these areas will usually pursue certain issues in greater depth (",
"    <a class=\"graphic graphic_figure graphicRef77632 \" href=\"mobipreview.htm?29/51/30512\">",
"     figure 1",
"    </a>",
"    ). For example, a chaplain may discover that a patient is bothered by pain or nausea, and then relay these concerns to the doctor or nurse so that they can make appropriate recommendations for treatment. Any member of the team may discuss spiritual issues with the patient. However, it is usually the chaplain or other spiritual care professional who can address these issues in depth, and make treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    follow-up recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Spiritual care providers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spiritual care providers may be chaplains who work in healthcare settings such as hospitals, hospices, and long term care facilities, or members of the community (eg, clergy, parish nurses, spiritual directors). All are trained to address the spiritual and existential issues faced by patients in the context of serious illness and death. However, there are some differences in the focus and capabilities of different types of spiritual care providers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chaplains, who must have a graduate level theological degree, are certified by one of five organizations after they complete a two-year training program called Clinical Pastoral Education (CPE) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/31\">",
"       31",
"      </a>",
"      ]. Chaplains are qualified to work with patients of any religious denomination, as well as with those who are not religious or who don't identify themselves as spiritual.",
"     </li>",
"     <li>",
"      Non-chaplain clergy typically provide more religiously oriented care, usually with a patient of the same religious denomination.",
"     </li>",
"     <li>",
"      Pastoral counselors are mental health counselors with an advanced degree (masters, PhD) who have additional training in spiritual, existential and religious issues.",
"     </li>",
"     <li>",
"      Spiritual directors work with patients to deepen their relationship with the divine",
"      <span class=\"nowrap\">",
"       power/higher",
"      </span>",
"      <span class=\"nowrap\">",
"       being/transcendent,",
"      </span>",
"      however the individual patient understands that concept.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine inquiry about spirituality should be incorporated into the initial or interim history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/23,32,33\">",
"     23,32,33",
"    </a>",
"    ]. A spiritual history tool with the acronym FICA (which stands for",
"    <span class=\"nowrap\">",
"     Faith/beliefs,",
"    </span>",
"    <span class=\"nowrap\">",
"     Importance/Influence,",
"    </span>",
"    Community, Address in care) can be a helpful starting point to open a conversation with patients about the importance of their beliefs, faith community, and their intersection with health care (",
"    <a class=\"graphic graphic_table graphicRef63804 \" href=\"mobipreview.htm?39/1/39964\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Other clinically useful assessment tools include HOPE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/36\">",
"     36",
"    </a>",
"    ] and SPIRIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/37\">",
"     37",
"    </a>",
"    ]. Another potentially useful tool is the Functional Assessment of Chronic Illness Therapy-Spiritual (FACIT-Sp) instrument [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/38\">",
"     38",
"    </a>",
"    ], although this tool is used mainly for research studies.",
"   </p>",
"   <p>",
"    Spiritual issues should be periodically readdressed over the course of the illness because of their dynamic nature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/39\">",
"     39",
"    </a>",
"    ]. Clinicians should be particularly sensitive to comments that might indicate spiritual need or distress. Often, patients express spiritual need with discernible cues such as fear, despair, desire for a hastened death, hopelessness, feeling useless or isolated, loss of meaning or dignity, or death anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/16,40\">",
"     16,40",
"    </a>",
"    ]. These cues should be followed up with further discussion, support and appropriate referral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Management of spiritual issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;A practical guide for discussing and managing spiritual and religious issues that arise during end of life care is available from a working group on religious and spiritual issues at the end of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/24\">",
"     24",
"    </a>",
"    ]. It details active listening and supportive dialogue to help patients work through existential issues and find peace. Important goals for the clinician are to listen carefully and empathetically, clarify the patient's concerns, beliefs and spiritual needs, be sensitive to comments that may indicate spiritual distress, and to mobilize supportive resources such as spiritual care providers, when necessary (see above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Importance of symptom control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical symptoms are common at the end of life, and if severe or uncontrolled, may impact psychological well being and quality of life. Many terminally ill patients report that physical discomfort is one of their greatest concerns as they face the prospect of death. Effective management of physical symptoms (particularly pain) can help allay patient's fears, and is essential in addition to addressing issues related to spiritual distress.",
"   </p>",
"   <p>",
"    Pain is typically multifactorial, with physical, emotional, social, and spiritual components. Each dimension must be addressed. A patient may appear to suffer from unrelenting physical pain and, even though appropriate medication is given for the physical pain, the patient continues to be in distress. Emotional, social or spiritual pain or distress may be contributing to the expression of pain. It is therefore important to address all dimensions of pain and other symptoms, including the spiritual dimension, in order to provide the patient with optimal symptom management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     The clinician-patient relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important component of spiritual care has to do with the relational aspect of the healthcare professional-patient partnership [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/24,41\">",
"     24,41",
"    </a>",
"    ]. All clinicians should strive to deliver relationship-focused care that is delivered in a compassionate, caring manner. Compassion means \"to suffer with\", and to render compassionate care requires a commitment on the part of the healthcare professional to be a partner with the patient in the midst of their suffering. This means:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Being fully present and attentive to the patient during the time that the healthcare professional has with that patient.",
"     </li>",
"     <li>",
"      Creating an atmosphere of trust where patients and their family members can share their deepest concerns.",
"     </li>",
"     <li>",
"      Instead of focusing on agenda-driven conversations about treatments and outcomes, being more open to the patient and listening to his or her concerns, beliefs, hopes, fears, and dreams. The focus of care should be on the whole person, including the physical, emotional, social and spiritual aspects of the individual. Treatment plans should be formulated that incorporate what is important to the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important component of this exchange is listening fully to the patient's story: who they are, what they value, how they make decisions, who is important in their lives, what gives their lives meaning, and how they understand illness and dying.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Giving voice to patients who cannot speak for themselves. This comes from either knowing the patient from previous clinical encounters, or learning enough about him or her from family, friends,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      their spiritual or religious communities to be able to defend what is important to them, even if it conflicts with what may be the recommended evidence-based course of action.",
"     </li>",
"     <li>",
"      Focusing on the inherent dignity of all people regardless of their physical condition.",
"     </li>",
"     <li>",
"      Providing the patient and his or her family with opportunities for closure, forgiveness, and the best quality of life that can be achieved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PRAYING WITH PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients may request that the healthcare professional pray with him or her. The extent to which this is possible or appropriate depends on the clinical setting and circumstance and the individual beliefs of the patient and healthcare professional [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/42\">",
"     42",
"    </a>",
"    ]. Clinicians or other healthcare professionals should never feel obliged to pray with patients; some clinicians and healthcare professionals may feel comfortable with the requests, while others may not. A clinician or healthcare professional should never coerce a patient into praying or into accepting the prayers of the clinician. That could potentially violate the trust a patient places in the clinician and be outside the boundaries of legitimate medical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Christianity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Especially with dying patients, a request for the health care professional to pray with him or her is usually very profound for the patient. If he or she is uncomfortable with the request to pray with the patient, the clinician or healthcare professional can sit by in silence as the patient prays in the patient's own language or tradition. Alternatively, the clinician or healthcare professional can suggest that a chaplain be invited to lead a joint prayer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Islam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doctors may pray for patients, and they are encouraged to. Patients may also pray either for themselves or for other fellow patients or family members as it is believed that the prayers of suffering patients are especially welcomed by God because of their suffering. Praying may either be performed individually or in a group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hinduism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hindu religion does not have specific guides on issues of physicians praying together with patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PRACTICES OF MAJOR WORLD RELIGIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, most patients express their spirituality in the form of religious beliefs and practices. What follows is a brief description of several major world religions, and individual issues within each faith that impact on healthcare decision making, and how patients respond to serious illness and dying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/6,45\">",
"     6,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Buddhism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buddhism is a non-theistic world religion that exists in several basic forms and many ethnic variations. The Buddha is not worshipped as a God; instead, his life and teachings are seen as a model to follow.",
"   </p>",
"   <p>",
"    The Four Noble Truths, the primary teachings of the Buddha, are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Life is ultimately unsatisfactory because of birth, sickness, old age, and death.",
"     </li>",
"     <li>",
"      The desire to cling to and hold on to the pleasant, and push away the unpleasant is a cause for suffering.",
"     </li>",
"     <li>",
"      Nirvana is the end of desire, craving, clinging, and suffering.",
"     </li>",
"     <li>",
"      The Noble Eightfold Path is the way leading to the end of suffering. The path consists of right view, right intention, right speech, right action, right livelihood, right effort, right mindfulness, and right concentration. This path combines personal discipline, mental purification, and wisdom to achieve ultimate happiness and a skillful way of living.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Meaning of suffering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buddhists believe that life is filled with pain and suffering, but that suffering can be overcome. Suffering originates from the mistaken belief that one can somehow hold on to all the good and push away all the bad. Buddhists use precept practice (ie, the practice of avoiding taking of a life, the avoidance of taking what is not given, the avoidance of sexual misconduct, lying, consumption of intoxicants in a way similar to the ten commandments) and meditation practice to achieve freedom from suffering, and ultimately nirvana (the end of suffering). When the Buddhist awakens to the ultimate reality of nirvana, desire and craving fall away, and suffering is ended. Nirvana, the end goal of life, is achieved during life but some will not achieve it while alive but will achieve pari-nirvana after death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Spiritual practices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meditation, contemplation, precept practice, yoga, and chanting provide guidance, comfort, and meaning to Buddhists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Dietary restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different branches of Buddhism have different dietary regulations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Death",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Buddhism, there is a belief in rebirth, heaven, hell, and pari-nirvana (nirvana after death).",
"   </p>",
"   <p>",
"    The dying person's state of mind is very important in the Buddhist religion. To help patients achieve peace of mind, family, friends and monks read religious texts and repeat mantras to the dying person. Some Buddhists believe that the dead person's consciousness remains near to or within the body for several days, so monks chant from sacred texts to assist the dead person's passing into the next life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Ethical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buddhists believe that it is good to continue living, but when the mind is no longer alert or the person is in excessive pain, a natural death is preferable. Allowing a person to die a natural and peaceful death is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Christianity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Christianity, which originally began as a Jewish sect, is a monotheistic religion that is centered on the life and teachings of Jesus Christ. Christians believe in the doctrine of the Holy Trinity, which affirms that there are actually three persons in one God &ndash; Father, Son (Jesus Christ) and Holy Spirit. Most Christians believe that Jesus is both fully divine and fully human. A basic tenet of Christianity is that Jesus, by his life, death, and resurrection (return to the divine), has broken the bonds of death and won eternal life for all. Following Christ's example, Christians strive to develop unconditional love for God and other people.",
"   </p>",
"   <p>",
"    Guidance and inspiration come from the Scriptures (Old and New Testaments) and from the traditions of the faith community. The words of the Gospels provide a framework for living a good Christian life.",
"   </p>",
"   <p>",
"    There are several traditions of Christianity, such as Roman Catholic, Anglican, various Protestant denominations, and Evangelical groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Suffering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jesus Christ provides a different model of suffering, in that His death and suffering are the means of redeeming humankind. This does not mean that suffering is to be endured as if it were a test of one's faith but rather it is accepted because by Jesus' suffering the effects of sin and evil have been removed. By sharing in His suffering, the Christian deepens his or her union with God on a mystical level, as St. Paul wrote: \"We are always carrying about in the body the dying of Jesus so that the life of Jesus may also be manifested on our body\" (2Cor 4:10). This does not deny that people have pain but it does help them cope with it.",
"   </p>",
"   <p>",
"    Some Christians see suffering as a punishment for sin, but many others do not see a causal relationship. There are many variations in how Christians come to understand this for themselves. Whether the illness is an opportunity for purification and redemption or whether it is just a part of nature we have to cope with is much debated. In the midst of the debate is the life of Christ, who shows us that pain and suffering, and even death, can be transcended. In that message, there is hope for humanity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Spiritual practices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prayer, sacraments, rituals, meditation, and formal religious services (such as masses) offer comfort and meaning, as well as an opportunity to express community worship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Dietary restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Christianity, diet varies with tradition. Some people choose to fast on particular religious holy days. Catholic Christians fast and abstain from eating meat on Ash Wednesday and Good Friday. Some but not all Catholics also abstain from meat on all the Fridays of the year. Hospitalized or ill patients are excused.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Death",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Christianity, death is seen as a natural part of life. Because Christians believe that an important goal of living a good Christian life is to achieve \"eternal life\" with God, some Christians welcome death as the opportunity to realize this full union with God.",
"   </p>",
"   <p>",
"    The Christian belief in the afterlife is based on the resurrection of Christ, that the Christian will also be raised and united with God in eternity.",
"   </p>",
"   <p>",
"    Family, friends, priests, or ministers pray or sing at the bedside of the dying person. For Catholic Christians, the sacrament of the Anointing of the Sick or the prayer ritual called Viaticum brings peace and comfort.",
"   </p>",
"   <p>",
"    After death, practices vary among the different Christian traditions, such as wake services, funeral masses, and graveside blessings. In Catholicism, people offer masses in remembrance of loved ones for many years after the person has died, particularly on the anniversary of their death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Ethical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influence of religious tenets on end of life care and organ donation decisions vary. Most Christians place emphasis on respect for and value of life but also view quality of life and dignity of the human person as central to decision making.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Islam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Islam is a monotheistic religion that is based on the teachings of the Prophet Muhammed. Muslims believe in one God (Allah) who is all-powerful, compassionate, and immortal, and that Muhammed is his last messenger. As in Christianity, after death, the soul is judged by Allah and remains in either heaven or hell. Guidance is provided by the Qur'an, prayer, rituals and fasting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Meaning of suffering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suffering is caused by alienation from the will of Allah and relieved by total surrender to His will, as embodied in the Qur'an.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Spiritual practices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muslims believe in the Five Pillars of Islam (the testimony of faith, ritual prayer several times daily, obligatory almsgiving, fasting and pilgrimage to Mecca, designated as the holy city of Islam by Muhammed). The Ten Commandments and the Golden Rule are principles to live by. The daily required periods of prayer are important for the spiritual well being of Muslims.",
"   </p>",
"   <p>",
"    When a patient is ill, he is still required to perform the five daily prayers by prostration and bowing as long as his condition allows. When he becomes too ill for physical exertion, prayer can be performed in the best position that is allowed by his condition.",
"   </p>",
"   <p>",
"    Mosques are places of worship, learning and meditation. Muslims are encouraged rather than mandated to attend mosque services not only to attain a higher level of spirituality but to also share a sense of community with their fellow Muslims.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Dietary restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most Muslims follow rigid dietary guidelines (no pork, no alcohol) and are required to wash specific parts of the body before each of the required daily periods of prayer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creation, death, and resurrection are linked. Life is viewed as a time of preparation for the soul to pass into life after death. To struggle against death is viewed as resisting the will of Allah.",
"   </p>",
"   <p>",
"    Muslims who are dying usually want to lie facing toward Mecca (in the appropriate direction depending on geographic location, East if the direction is not known, or if impractical, the head can be turned to the right) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/46\">",
"     46",
"    </a>",
"    ]. When a Muslim is dying, family members repeat prayers, reciting key verses of Islamic scripture (the Qur'an), and encourage the patient to repeat the statement of their faith.",
"   </p>",
"   <p>",
"    As concerns end of life rituals, the body is not considered dead until it has become cold and rigor mortis sets in. At the time of death, the eyelids are closed, and the jaw is closed or bound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/46\">",
"     46",
"    </a>",
"    ]. Within 24 hours of death, the body must be ritually washed, anointed, shrouded, prayed over, and buried. Burial rites are simple and austere. The dead are buried so that their heads are directed toward the city of Mecca.",
"   </p>",
"   <p>",
"    Islam encourages attending funeral services as a meritorious act, whether or not those who participate in the services personally knew the deceased. Many services may be held at the same time in different places for the same person. These services are considered spiritually beneficial for the dead, as well as for the people who participate in them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Ethical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human life is of the highest value in Islam. Physician-assisted suicide is prohibited.",
"   </p>",
"   <p>",
"    It is permissible to use life support to save and extend life. The purpose of aggressive medical intervention is to maintain life but not to cross the line and clearly interfere with the will of God and the natural course of life and death. It is not permissible to cause harm to the patient with equipment or drugs when the futility of such treatment is established by the medical team. Thus, withdrawing care is permissible in two circumstances: when the diagnosis of brain death has been made, and when the current treatment, be it curative or palliative, is no longer curing or palliating, but merely prolonging a natural and inevitable death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Organ donation is permissible. However, because of the traditional emphasis on burial within 24 hours, the family may believe that organ donation with unnecessarily delay burial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41208/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Hinduism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hinduism is a very complex faith. It encompasses a wide variety of beliefs, practices, and mythological stories of gods and goddesses, all of which have deep meaning and significance for Hindus. Hinduism is the majority religion in India, Nepal, and in the island of Bali (Indonesia). There is a substantial minority population of Hindus in Malaysia, Singapore, Fiji, Mauritius, Trinidad, Guyana, and Surinam.",
"   </p>",
"   <p>",
"    A basic tenet of Hinduism is that the true core of every individual being is a spiritual entity called the soul. This soul is not created by a God but is considered to be co-eternal with Him. The soul, because of its primal ignorance about things spiritual, is drawn toward the material world. This ignorant materialistic orientation of the soul creates desires, which in turn make the soul commit selfish deeds.",
"   </p>",
"   <p>",
"    The effects of these deeds (karma) accrue to the soul, and upon the death of the body, cause it to be reborn into another body in order to experience the consequences of its past deeds. Since the soul is gifted with free will by God, it ignorantly commits more selfish acts, thereby ensuring its rebirth again and again. To break from this seemingly endless cycle of births and deaths, the soul has to become spiritually oriented. This is called enlightenment (viveka). When this is achieved, the soul performs only selfless deeds which do not accrue any new karma to the soul. Once the previously accrued karma is exhausted, the soul is forever freed from the cycle of rebirths and deaths. According to a major school of Hindu thought, the freed soul then merges with God, just like a drop of water merges into the ocean.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Meaning of suffering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hindus believe that suffering is caused by karma, and is the direct result of an individual's bad deeds that were carried out either in this life or in a past life. Suffering can be either physical or mental.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Spiritual practices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hindus have four types of spiritual practices. These are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Devotion to God or gods (bhakti)",
"     </li>",
"     <li>",
"      Performing selfless good deeds (karma)",
"     </li>",
"     <li>",
"      Studying holy texts (jnana)",
"     </li>",
"     <li>",
"      Meditating on God or gods (dhyana)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A combination of these four is also acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Dietary restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most Hindus are vegetarian, avoiding all meat and fish. They believe that the taking of another life for one's own nourishment is wrong, and that making another living being suffer is creating bad karma for oneself. Furthermore, the bad \"vibes\" emanating from another living being that is about to die will have an effect upon one's own spiritual well being. Some Hindus will not even eat onions or garlic, not only because of their odor (which is viewed as unpleasant), but also because these foods are said to be unwholesome to one's spiritual progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death signifies only death of the body and separation of the eternal soul from the body. Depending upon the spiritual state of the deceased individual, the soul will either reenter another body or attain salvation. The mind accompanies the soul from one lifetime to the next. Because of the mind's ignorance about the soul, it is unable to know its past lives. However, when the soul is about to attain salvation, it gets permanently separated from the mind as well. To summarize:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In life &mdash; soul plus mind plus body",
"     </li>",
"     <li>",
"      At death &mdash; soul plus mind are separated from the body",
"     </li>",
"     <li>",
"      In salvation &mdash; soul separated forever from mind and body",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At the death of a Hindu, it is important to do the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remove the dead or dying individual from the bed; place",
"      <span class=\"nowrap\">",
"       him/her",
"      </span>",
"      on the ground",
"     </li>",
"     <li>",
"      Pour holy water (previously brought from the temple and kept in a bottle on the bedside table) into the mouth of the dying individual",
"     </li>",
"     <li>",
"      Recite the mantra of the favorite god of the dying individual",
"     </li>",
"     <li>",
"      Light a lamp at the head of the corpse when the person dies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Orthodox Hindus consider death and touching of the corpse as highly polluting. Death rites are performed by the priest. Funeral rites last for 3, 10, or 13 days, or a full year depending on the orthodoxy of the family.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Ethical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mercy killing, assisted suicide, and suicide are disapproved of, but allowing \"nature to take its course\" is acceptable. Having a living will and organ donation are both individual choices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Judaism",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the oldest world religions, dating back to Abraham in 1700 BCE, Judaism believes that every person is created in the image of God and carries that divine worth throughout life. All people are part of the Covenant God made with Noah; Jews are additionally part of the Covenant God made with the People Israel. God's commandments, announced first in the Torah (the Five Books of Moses) and then interpreted and applied by rabbis throughout the generations, help Jews to live a holy life dedicated to God and to God's mission for them. They seek to repair the world (tikkun olam) in all the ways it is broken: illness, poverty, ignorance, prejudice, etc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Meaning of suffering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suffering has no particular spiritual connotation. It is to be avoided as much as possible. Part of the way Jews attempt to repair the world, in fact, is by alleviating pain and suffering, their own and that of all other humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Spiritual practices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether selected from the traditional prayer book (the Siddur) or created on one's own, prayer is a staple of Jewish spiritual life. Another is study of Jewish sacred texts &ndash; the Bible, Mishnah, Talmud, or other Jewish literature. People visiting the ill may help them create a Jewish ethical will, which can be in writing or on audiotape or videotape, in which the person tells the family story, describes what is important to him or her (hence the name \"ethical will\"), articulates hopes for the future of the family and the world, and expresses love. Visitors can help patients create one by asking questions that call up memories of the patient's family, values, and life.",
"   </p>",
"   <p>",
"    Fasting is practiced during the solemn holy day of Yom Kippur, but is excused for severely ill patients, if intake of food is essential to life and well being (the concept of pikuach nefesh, or saving of the specific life, which supersedes all other religious mandates).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Dietary restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional Jews observe the dietary restrictions known as Kashrut; they \"keep Kosher\". That means that they eat only those fish, fowl, and animals allowed in Leviticus 11 and Deuteronomy 14: specifically, fish with scales and fins (no shell fish), domestic fowl (chicken, turkey, etc., no birds of prey), and animals whose hooves are parted and who chew their cud. Moreover, fowl and animals must be slaughtered in a specific way, the blood must be drained from the meat, and no dairy products may be served with a meat meal. Typically in a hospital setting this means that Jews who keep kosher must be given meals certified as kosher by a rabbinic authority. Not all Jews keep kosher. Some are vegetarian.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Death",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"There is a time to be born and a time to die\" (Ecclesiastes 3:2). Although Judaism demands that everything be done medically to save life and health, it recognizes that death is a natural part of life. Jews focus on improving things in this life, but Judaism does include beliefs about life after death, in which good will be rewarded and evil punished.",
"   </p>",
"   <p>",
"    After death, the Hevrah Kaddisha (\"the holy society\") prepares the body for burial. Men deal with male bodies, and women with female bodies; modesty is preserved even in death. The body is washed and clothed in linen shrouds (the same clothing for everyone, indicating equality in death). Someone stays with the body from the moment of death until burial, reciting Psalms. The body is ideally buried the same day before sundown, or as soon thereafter as is possible.",
"   </p>",
"   <p>",
"    Traditional Judaism does not permit embalming or cremation. Autopsy is also prohibited unless required by law, or in situations where there is clear and direct evidence that the resulting information would provide benefit to the deceased. In other words, for traditional Jews, an autopsy to \"benefit future patients\" or medical science in general would not be acceptable.",
"   </p>",
"   <p>",
"    The funeral service consists of eulogies and prayers. After the funeral, a seven-day period of mourning (Shivah, seven) ensues, during which time people come to the mourners' home both morning and evening to pray and share with the mourners memories of the deceased. Traditional Jews do not leave the house during that time, and mirrors in the home are covered.",
"   </p>",
"   <p>",
"    After burial, mourners are required to recite the kaddish prayer twice a day for 11 months, and this requires a minyan, or congregation of at least 10 adult Jews. During these 11 months, traditional Jews will not attend joyous or entertaining events where music is being played (eg, concerts, movies, wedding receptions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Ethical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabbis differ on issues of medical ethics at the end of life. Most prohibit assisted suicide but allow the withholding or withdrawal of life support systems. For some, that includes the removal of artificial nutrition and hydration. Donation of a person's organs for transplant is encouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spiritual and religious beliefs, values, and practices play a significant role in the lives of patients who are seriously ill and dying.",
"   </p>",
"   <p>",
"    Some important considerations for physicians and other healthcare professionals regarding spirituality include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A spiritual history should be recorded as part of a new patient evaluation, and spiritual issues readdressed periodically through the course of the illness. A spiritual history tool such as FICA (",
"      <a class=\"graphic graphic_figure graphicRef77632 \" href=\"mobipreview.htm?29/51/30512\">",
"       figure 1",
"      </a>",
"      ) can be a helpful starting point to open a conversation with patients about spiritual issues.",
"     </li>",
"     <li>",
"      For patients facing the end of life, spiritual care is interdisciplinary collaborative care, and requires the participation of all members of the healthcare team. Clinicians should clarify the patient's concerns, beliefs, fears, and spiritual needs, and be sensitive to comments that may indicate spiritual distress. Active listening and supportive dialogue may help patients work through existential issues and find peace. Patients who are in spiritual distress should be referred to certified and trained spiritual care professionals such as chaplains, spiritual directors, pastoral counselors and clergy.",
"     </li>",
"     <li>",
"      All clinicians should strive to deliver relationship-focused care that is delivered in a compassionate, caring manner. This includes being fully present and attentive to the needs of the patient and all aspects of the patient's suffering; the physical, emotional, social and spiritual, and creating an atmosphere of trust where patients can share their deepest concerns.",
"     </li>",
"     <li>",
"      Clinicians should be knowledgeable about and sensitive to the individual death practices and customs that characterize the major world faiths. Attending funeral services for patients who have died may mean a great deal to the family, but may also bring closure to the healthcare professional.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/1\">",
"      Daaleman TP, VandeCreek L. Placing religion and spirituality in end-of-life care. JAMA 2000; 284:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/2\">",
"      Moadel A, Morgan C, Fatone A, et al. Seeking meaning and hope: self-reported spiritual and existential needs among an ethnically-diverse cancer patient population. Psychooncology 1999; 8:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/3\">",
"      Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000; 284:2476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/4\">",
"      McClain CS, Rosenfeld B, Breitbart W. Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. Lancet 2003; 361:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/5\">",
"      Holland JC, Passik S, Kash KM, et al. The role of religious and spiritual beliefs in coping with malignant melanoma. Psychooncology 1999; 8:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/6\">",
"      Puchalski CM, Dorff RE, Hendi IY. Spirituality, religion, and healing in palliative care. Clin Geriatr Med 2004; 20:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/7\">",
"      Balboni TA, Vanderwerker LC, Block SD, et al. Religiousness and spiritual support among advanced cancer patients and associations with end-of-life treatment preferences and quality of life. J Clin Oncol 2007; 25:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/8\">",
"      McIllmurray MB, Francis B, Harman JC, et al. Psychosocial needs in cancer patients related to religious belief. Palliat Med 2003; 17:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/9\">",
"      Born W, Greiner KA, Sylvia E, et al. Knowledge, attitudes, and beliefs about end-of-life care among inner-city African Americans and Latinos. J Palliat Med 2004; 7:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/10\">",
"      McClain-Jacobson C, Rosenfeld B, Kosinski A, et al. Belief in an afterlife, spiritual well-being and end-of-life despair in patients with advanced cancer. Gen Hosp Psychiatry 2004; 26:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/11\">",
"      Hills J, Paice JA, Cameron JR, Shott S. Spirituality and distress in palliative care consultation. J Palliat Med 2005; 8:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/12\">",
"      Phelps AC, Maciejewski PK, Nilsson M, et al. Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA 2009; 301:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/13\">",
"      Silvestri GA, Knittig S, Zoller JS, Nietert PJ. Importance of faith on medical decisions regarding cancer care. J Clin Oncol 2003; 21:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/14\">",
"      True G, Phipps EJ, Braitman LE, et al. Treatment preferences and advance care planning at end of life: the role of ethnicity and spiritual coping in cancer patients. Ann Behav Med 2005; 30:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/15\">",
"      Block SD. Perspectives on care at the close of life. Psychological considerations, growth, and transcendence at the end of life: the art of the possible. JAMA 2001; 285:2898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/16\">",
"      Brown AE, Whitney SN, Duffy JD. The physician's role in the assessment and treatment of spiritual distress at the end of life. Palliat Support Care 2006; 4:81.",
"     </a>",
"    </li>",
"    <li>",
"     National Quality Forum: A National Framework and Preferred Practices for Palliative and Hospice Care: A Consensus Report. file://www.qualityforum.org/Publications/2006/12/A_National_Framework_and_Preferred_Practices_for_Palliative_and_Hospice_Care_Quality.aspx (Accessed on September 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/18\">",
"      Puchalski C, Ferrell B, Virani R, et al. Improving the quality of spiritual care as a dimension of palliative care: the report of the Consensus Conference. J Palliat Med 2009; 12:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/19\">",
"      Sinclair S, Pereira J, Raffin S. A thematic review of the spirituality literature within palliative care. J Palliat Med 2006; 9:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/20\">",
"      Hatch RL, Burg MA, Naberhaus DS, Hellmich LK. The Spiritual Involvement and Beliefs Scale. Development and testing of a new instrument. J Fam Pract 1998; 46:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/21\">",
"      Reed PG. Spirituality and well-being in terminally ill hospitalized adults. Res Nurs Health 1987; 10:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/22\">",
"      Thiel MM, Robinson MR. Physicians' collaboration with chaplains: difficulties and benefits. J Clin Ethics 1997; 8:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/23\">",
"      Post SG, Puchalski CM, Larson DB. Physicians and patient spirituality: professional boundaries, competency, and ethics. Ann Intern Med 2000; 132:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/24\">",
"      Lo B, Ruston D, Kates LW, et al. Discussing religious and spiritual issues at the end of life: a practical guide for physicians. JAMA 2002; 287:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/25\">",
"      Ehman JW, Ott BB, Short TH, et al. Do patients want physicians to inquire about their spiritual or religious beliefs if they become gravely ill? Arch Intern Med 1999; 159:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/26\">",
"      Daaleman TP, Nease DE Jr. Patient attitudes regarding physician inquiry into spiritual and religious issues. J Fam Pract 1994; 39:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/27\">",
"      McCord G, Gilchrist VJ, Grossman SD, et al. Discussing spirituality with patients: a rational and ethical approach. Ann Fam Med 2004; 2:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/28\">",
"      Kristeller JL, Rhodes M, Cripe LD, Sheets V. Oncologist Assisted Spiritual Intervention Study (OASIS): patient acceptability and initial evidence of effects. Int J Psychiatry Med 2005; 35:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/29\">",
"      Balboni TA, Paulk ME, Balboni MJ, et al. Provision of spiritual care to patients with advanced cancer: associations with medical care and quality of life near death. J Clin Oncol 2010; 28:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/30\">",
"      Winkelman WD, Lauderdale K, Balboni MJ, et al. The relationship of spiritual concerns to the quality of life of advanced cancer patients: preliminary findings. J Palliat Med 2011; 14:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/31\">",
"      Association of Professional Chaplains, Association for Clinical Pastoral Education, Canadian Association for Pastoral Practice and Education, et al. A White Paper. Professional chaplaincy: its role and importance in healthcare. J Pastoral Care 2001; 55:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/32\">",
"      Puchalski CM, Larson DB. Developing curricula in spirituality and medicine. Acad Med 1998; 73:970.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Approaching death: Improving care at the End-Of Life, National Press, Washington, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/34\">",
"      Puchalski CM. Spirituality and end-of-life care: a time for listening and caring. J Palliat Med 2002; 5:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/35\">",
"      Borneman T, Ferrell B, Puchalski CM. Evaluation of the FICA Tool for Spiritual Assessment. J Pain Symptom Manage 2010; 40:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/36\">",
"      Anandarajah G, Hight E. Spirituality and medical practice: using the HOPE questions as a practical tool for spiritual assessment. Am Fam Physician 2001; 63:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/37\">",
"      Maugans TA. The SPIRITual history. Arch Fam Med 1996; 5:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/38\">",
"      Peterman AH, Fitchett G, Brady MJ, et al. Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med 2002; 24:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/39\">",
"      American Academy of Hospice and Palliative Medicine, Center to Advance Palliative Care, Hospice and Palliative Nurses Association, et al. National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary. J Palliat Med 2004; 7:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/40\">",
"      Chibnall JT, Videen SD, Duckro PN, Miller DK. Psychosocial-spiritual correlates of death distress in patients with life-threatening medical conditions. Palliat Med 2002; 16:331.",
"     </a>",
"    </li>",
"    <li>",
"     A Time for Listening and Caring: Spirituality and The Care of the Chronically Ill and Dying, Puchalski CM (Ed), Oxford University Press, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/42\">",
"      Balboni MJ, Babar A, Dillinger J, et al. \"It depends\": viewpoints of patients, physicians, and nurses on patient-practitioner prayer in the setting of advanced cancer. J Pain Symptom Manage 2011; 41:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/43\">",
"      Astrow AB, Puchalski CM, Sulmasy DP. Religion, spirituality, and health care: social, ethical, and practical considerations. Am J Med 2001; 110:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/44\">",
"      Mann JR, McKay S, Daniels D, et al. Physician offered prayer and patient satisfaction. Int J Psychiatry Med 2005; 35:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/45\">",
"      Puchalski CM, O'Donnell E. Religious and spiritual beliefs in end of life care: how major religions view death and dying. Tech Reg Anesth Pain Manag 2005; 9:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41208/abstract/46\">",
"      Hedayat K. When the spirit leaves: Childhood death, grieving, and bereavement in Islam. J Palliat Med 2006; 9:1282.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2198 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41208=[""].join("\n");
var outline_f40_15_41208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RELIGION AND SPIRITUALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL ASSESSMENT AND MANAGEMENT OF SPIRITUAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      The interdisciplinary nature of spiritual care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Spiritual care providers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Management of spiritual issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Importance of symptom control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      The clinician-patient relationship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PRAYING WITH PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Christianity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Islam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hinduism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PRACTICES OF MAJOR WORLD RELIGIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Buddhism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Meaning of suffering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Spiritual practices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Dietary restrictions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Ethical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Christianity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Suffering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Spiritual practices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Dietary restrictions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Ethical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Islam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Meaning of suffering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Spiritual practices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Dietary restrictions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Ethical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Hinduism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Meaning of suffering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Spiritual practices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Dietary restrictions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Ethical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Judaism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Meaning of suffering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Spiritual practices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Dietary restrictions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Ethical issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2198\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2198|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/51/30512\" title=\"figure 1\">",
"      Interdisc spiritual care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2198|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/1/39964\" title=\"table 1\">",
"      Instruments spiritual history",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_15_41209="Pharmacology of nucleoside reverse transcriptase inhibitors";
var content_f40_15_41209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology of nucleoside reverse transcriptase inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41209/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41209/contributors\">",
"     Courtney V Fletcher, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41209/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41209/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41209/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41209/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/15/41209/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14340701\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of oral antiretroviral (ARV) drugs that are effective in reducing HIV viremia and in improving CD4 T cell counts. NRTIs are key components of antiretroviral therapy (ART) regimens, and are often referred to as the &ldquo;backbone&rdquo; of HIV treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The NRTI class includes seven agents: the adenosine-derived nucleotide reverse transcriptase inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    disoproxil fumarate (TDF); cytosine analogs",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    (FTC) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (3TC); the guanosine analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    sulfate (ABC); the thymidine analogs",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    (d4T) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (ZDV); the inosine derivative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    (ddI); and zalcitabine (ddC), which is no longer commercially available.",
"   </p>",
"   <p>",
"    The pharmacology of the NRTIs is discussed below; the agents are found in alphabetical order. However, certain NRTIs are preferred over other members in this class because of varying efficacy and toxicity profiles. The selection of ART for the treatment of HIV infection is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Information on the dosing of antiretroviral medications in patients with renal or hepatic impairment is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12759?source=see_link\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340708\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;NRTIs are usually given as paired agents with at least one other antiretroviral medication that has a different mechanism of action, such as a protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or an integrase inhibitor. The current preferred dual NRTI combination for the treatment-naive patient is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    because of its superior virologic efficacy, side effect profile, and low pill burden and dosing frequency, compared with other NRTI combinations (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340715\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC CHARACTERISTICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340724\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic active moiety for all NRTIs is an intracellular 5'-triphosphate compound. Intracellular phosphorylation is mediated by several host enzymes (cytoplasmic or mitochondrial kinases and phosphotransferases), which sequentially transform the parent drug to the monophosphate (MP), diphosphate (DP) and finally the active triphosphate (TP) forms. Structurally, all of the NRTIs are &ldquo;nucleosides&rdquo;, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , which contains one phosphate group within the parent molecule, is a nucleotide. Conventionally, the active form of tenofovir is referred to as &ldquo;tenofovir-diphosphate&rdquo; since only two phosphate groups have been added compared with three phosphates for other NRTIs. However, like all other drugs within this class, the active moiety is a triphosphate compound.",
"   </p>",
"   <p>",
"    The active NRTI triphosphate inhibits viral replication through competitive binding to the viral enzyme, reverse transcriptase; after incorporation of the NRTI phosphate, DNA chain elongation is terminated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. For some compounds, the triphosphate anabolite is also a potential source of toxicity through its inhibition of mitochondrial DNA polymerase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22198678\">",
"    <span class=\"h2\">",
"     Spectrum of activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of activity of NRTIs includes HIV-1 and HIV-2 viruses.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    also have activity against hepatitis B virus (HBV). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23030?source=see_link\">",
"     \"Investigational treatments of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340731\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major pharmacokinetic properties of the NRTIs, based upon concentrations in the plasma, are listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef50446 \" href=\"mobipreview.htm?12/3/12350\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71419 \" href=\"mobipreview.htm?33/47/34559\">",
"     table 2",
"    </a>",
"    ). Adult and pediatric dosing recommendations (including for patients with renal or hepatic insufficiency), and common adverse effects are given. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12759?source=see_link\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, all NRTIs are prodrugs, as they require intracellular phosphorylation to exert their antiviral effects. However, quantification of intracellular concentrations of the NRTIs is both difficult and expensive; thus, our understanding of the pharmacokinetics and pharmacodynamics of the NRTIs is largely based upon concentrations in plasma. The NRTIs have minimal binding to plasma and serum proteins; most of the NRTIs have short plasma half-lives, with the exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , which have plasma half-lives of 10 and 17 hours, respectively. The half-lives of intracellular NRTI triphosphates range from 7 hours for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    to approximately 150 hours for tenofovir. Depending on the plasma half-life, the current NRTIs are dosed either once or twice daily.",
"   </p>",
"   <p>",
"    The NRTIs are mainly eliminated renally and thus require dose adjustment for patients with impaired kidney function. In contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , which are metabolized in the liver, may require dose adjustments in patients with hepatic impairment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12759?source=see_link\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a class, NRTIs have few clinically significant drug-drug interactions, because they are not substrates, inhibitors, or inducers of hepatic cytochrome P450 (CYP) enzymes. Some relevant drug interactions are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef50446 \" href=\"mobipreview.htm?12/3/12350\">",
"     table 1",
"    </a>",
"    ), and are discussed in the individual sections below. In contrast, NNRTIs and PIs have a significant number of drug interactions due to their interactions with the CYP P450 system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340738\">",
"    <span class=\"h2\">",
"     Pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the era of potent ART, early clinical trials demonstrated that dual NRTIs were synergistic compared with NRTI monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/7\">",
"     7",
"    </a>",
"    ]. However, not all NRTI combinations are synergistic. Certain pairings of NRTIs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ) are not recommended due to demonstrated in vitro or in vivo antagonism, which arises from their competition for phosphorylation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. For the same reasons, combinations of cytosine analogs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , should not be used concomitantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/2\">",
"     2",
"    </a>",
"    ]. The combination of ddI and TDF is not recommended because of clinical studies showing high rates of early virologic failure, the rapid selection of resistance mutations, and evidence for CD4 cell",
"    <span class=\"nowrap\">",
"     toxicity/immunologic",
"    </span>",
"    nonresponse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Importantly, the adverse drug-drug interactions between these two NRTI pairings occur intracellularly and cannot be detected by measurement of plasma drug concentrations. (See",
"    <a class=\"local\" href=\"#H14340780\">",
"     'Didanosine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Certain NRTI pairs can also be associated with increased toxicities. For example, studies have shown",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    exhibit additive to synergistic toxicities when used together. (See",
"    <a class=\"local\" href=\"#H14340752\">",
"     'Class side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87047282\">",
"    <span class=\"h2\">",
"     Potency",
"    </span>",
"    &nbsp;&mdash;&nbsp;No direct comparisons of the potency of individual NRTIs are available. Comparisons across early treatment trials utilizing mono and dual NRTI therapy, however, can provide indirect information on the relative potency of the various members of the NRTI class [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. These data suggest that the potency of the available NRTIs (when given in the usual dose, as monotherapy to antiretroviral-na&iuml;ve individuals) would be:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    &asymp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    &asymp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    &gt;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    &asymp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    &asymp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    &gt;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    . &nbsp;",
"   </p>",
"   <p>",
"    Clinical investigations of various combinations of NRTIs also suggest differences in virologic potency. In a clinical trial (ie, AIDS Clinical Trial Group 5202), 1858 antiretroviral-na&iuml;ve persons were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    in combination with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"      atazanavir",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/17\">",
"     17",
"    </a>",
"    ]. Among the 797 individuals who had a baseline HIV RNA level &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    there was a higher rate of virologic failure with the",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"      abacavir",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"      lamivudine",
"     </a>",
"    </span>",
"    combination, and a lower rate of persons achieving HIV RNA &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at week 48 compared with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    combination. These efficacy data, along with safety and tolerance data, support the recommendation that tenofovir-emtricitabine is the preferred NRTI combination for the initiation of antiretroviral therapy in the treatment-na&iuml;ve patient, particularly those with high-level viremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340745\">",
"    <span class=\"h2\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The resistance patterns of individual NRTIs and combinations of NRTIs are well characterized. The prevalence of NRTI-associated drug resistance mutations observed in a given population is a reflection of the changing patterns of NRTI use over time. For example, mutations associated with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    have declined while mutations associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    have remained relatively constant.",
"   </p>",
"   <p>",
"    ARV drug resistance can be evaluated using genotypic or phenotypic tests, both of which have advantages as well as limitations. The International AIDS Society-USA (IAS-USA) maintains a list of updated significant resistance-associated mutations in the reverse transcriptase, protease, and envelope genes (see",
"    <a class=\"external\" href=\"file://www.iasusa.org/resistance_mutations\">",
"     file://www.iasusa.org/resistance_mutations",
"    </a>",
"    ). The IAS-USA and DHHS both provide recommendations on when resistance testing should be performed and what tests to use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340752\">",
"    <span class=\"h2\">",
"     Class side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark toxicity of the NRTI class is mitochondrial toxicity, which may manifest as peripheral neuropathy, pancreatitis, lipoatrophy, and hepatic steatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. All NRTIs also have \"black box\" warnings in their product labeling regarding the possibility of lactic acidosis syndrome, which is potentially fatal.",
"   </p>",
"   <p>",
"    However, the risk of mitochondrial toxicity depends on the affinity of the individual NRTI for mammalian mitochondrial DNA polymerase gamma. The NRTIs can be ranked based on their rates of incorporation and removal into mammalian mitochondrial DNA. For example, zalcitabine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    have 13- to 36-fold tighter binding and ineffective exonuclease removal relative to the other NRTIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/21\">",
"     21",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    are associated with minimal risk of mitochondrial toxicity. Based on enzyme affinity for mitochondrial DNA polymerase gamma, the rank order of NRTIs from highest to lowest risk of mitochondrial toxicity is: ddC &gt;&gt; ddI &gt; d4T &gt; ZDV &gt;&gt;&gt; TDF = 3TC = FTC = ABC. For this reason, the dideoxynucleosides (eg, zalcitabine, didanosine, and stavudine) are no longer recommended for the treatment of HIV.",
"   </p>",
"   <p>",
"    Clinical data also suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    increase the risk of mitochondrial toxicity compared with either drug alone. When didanosine was combined with stavudine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    , 21 percent of antiretroviral-na&iuml;ve subjects developed peripheral neurologic symptoms. In addition, a retrospective review of 1116 patients receiving ART showed a peripheral neuropathy rate of",
"    <span class=\"nowrap\">",
"     6.8/100",
"    </span>",
"    person-years for ddI,",
"    <span class=\"nowrap\">",
"     9.8/100",
"    </span>",
"    person-years for d4T and",
"    <span class=\"nowrap\">",
"     17.5/100",
"    </span>",
"    person-years for both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/22\">",
"     22",
"    </a>",
"    ]. The combination of didanosine and stavudine has also been implicated in the deaths of HIV-infected patients, including pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/23\">",
"     23",
"    </a>",
"    ]. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10794?source=see_link\">",
"     \"Adverse effects of antiretroviral therapy in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340766\">",
"    <span class=\"h1\">",
"     SPECIFIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the NRTI agents is discussed below in alphabetical order. The pharmacologic characteristics of the individual NRTIs, dosing recommendations, some drug-drug interactions, and the most common adverse reactions are found in the tables (",
"    <a class=\"graphic graphic_table graphicRef50446 \" href=\"mobipreview.htm?12/3/12350\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71419 \" href=\"mobipreview.htm?33/47/34559\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340773\">",
"    <span class=\"h2\">",
"     Abacavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     Abacavir",
"    </a>",
"    (ABC) is a dideoxy-guanosine analogue, which is converted intracellularly to its active metabolite, carbovir triphosphate. The mean absolute bioavailability of abacavir is 83 percent.",
"   </p>",
"   <p>",
"    Conflicting data have been published regarding the potency of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    among patients with a baseline viral load of &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL:",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The AIDS Clinical Trials Group (ACTG) study 5202 was a randomized controlled trial in more than 1800 participants, which evaluated the efficacy and safety of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"       abacavir-lamivudine",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      when used in combination with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      . Results from this trial indicated that participants randomized to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , who had pretreatment HIV RNA &gt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL,",
"      </span>",
"      had a shorter time to virologic failure compared with those who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      (HR = 2.33) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a smaller study of 688 patients (conducted by the manufacturer of ABC), no difference in the proportion of subjects achieving viral suppression after 48 and 96 weeks was demonstrated in the subset of patients with HIV RNA &gt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pending further data, HIV treatment guidelines suggest caution in using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    in patients with high-level viremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ABC can cause a hypersensitivity reaction characterized by fever, rash, gastrointestinal symptoms, generalized malaise, fatigue, achiness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory symptoms, which usually appear within six weeks of drug initiation. This hypersensitivity reaction can be fatal if not recognized early, and subjects who develop the hypersensitivity reaction should have",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    discontinued immediately and never be re-challenged with the drug. An important breakthrough in the safe use of this drug is the availability of a genetic test to predict the likelihood of a person developing ABC hypersensitivity (human leukocyte antigen [HLA]-B5701) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/25\">",
"     25",
"    </a>",
"    ]. The ABC hypersensitivity reaction and use of this genetic test are discussed in detail elsewhere in this program. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21049?source=see_link\">",
"     \"Abacavir hypersensitivity reaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are conflicting data as to whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    is associated with an increased risk of myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review of the D:A:D observational cohort with data for 33,308 patients showed the relative risk of a myocardial infarction among patients receiving ABC was 1.7 (95% CI 1.17-2.47) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a pooled descriptive analysis of 52 clinical trials conducted by the manufacturer of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      , no increased rate of myocardial infarction was found in the 9505 participants who received abacavir compared with the 4672 who did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis was performed by the Food and Drug Administration (FDA) of 26 randomized controlled trials that included 9832 subjects with a mean follow-up of 1.43 person years in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      group and 1.49 person years in the non-abacavir group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/29\">",
"       29",
"      </a>",
"      ]. There was no significant difference between these groups and the risk of MI: risk difference, 0.03 percent (95% CI, -0.24 to 0.30 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism by which ABC would increase the risk (if it does) has also not been elucidated, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    use has been associated with increases in serum lipids in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/30\">",
"     30",
"    </a>",
"    ]. Pending further data, HIV treatment guidelines suggest that abacavir should be used with caution among patients who are at increased risk for cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like most NRTIs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    has few clinically significant drug interactions. Concomitant administration of abacavir with some protease inhibitors results in a decrease in abacavir plasma concentrations (area under the curve, AUC): 40 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    , 17 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , and 32 percent with lopinavir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/31\">",
"     31",
"    </a>",
"    ]. No change in the concentrations of the protease inhibitors has been observed. The clinical significance of these findings is unknown, but clinicians using these combinations should be vigilant for a suboptimal therapeutic response, which could indicate insufficient concentrations of abacavir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340780\">",
"    <span class=\"h2\">",
"     Didanosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     Didanosine",
"    </a>",
"    (ddI) is an analogue of deoxyadenosine. The pharmacologically active moiety (dideoxyadenosine-triphosphate) has an elimination half-life of 25 to 40 hours and provides support for once-daily dosing. The available adult formulation is a capsule containing enteric-coated beadlets (Videx EC), which are designed to protect the drug from degradation by stomach acid. Plasma concentrations of didanosine are significantly reduced in the presence of food; thus didanosine should be taken on an empty stomach.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     Didanosine",
"    </a>",
"    is one of only two NRTIs that are dosed in adults based on body weight. The recommended dose is 400 mg once daily (delayed release capsule formulation) in adults who weigh more than 60 kg, and 250 mg once daily in adults who weigh &lt;60 kg. The dose of didanosine must also be adjusted in persons with renal insufficiency.",
"   </p>",
"   <p>",
"    The primary drug-limiting toxicities associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    include pancreatitis, peripheral neuropathy, hepatic steatosis, and lactic acidosis, which are manifestations of mitochondrial toxicity. The incidence of peripheral neuropathy is approximately 25 percent, while pancreatitis may occur in 1 percent to 7 percent of patients receiving didanosine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/32\">",
"     32",
"    </a>",
"    ]. The risk of pancreatitis appears to be increased according to dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/33\">",
"     33",
"    </a>",
"    ]; this observation led to recommendations for dosing by weight. Didanosine combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    increases the risk of mitochondrial toxicity. The narrow window between concentrations associated with therapeutic benefit and those associated with toxicity helps to explain the move away from didanosine and stavudine to safer NRTIs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14340752\">",
"     'Class side effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     Didanosine",
"    </a>",
"    should not be coadministered with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    due to drug interactions, which can lead to T cell depletion and virologic failure. The pharmacologic elimination of didanosine occurs in part through reversible phosphorolysis to hypoxanthine, a process that is catalyzed by purine nucleoside phosphorylase (PNP). Since tenofovir is an inhibitor of PNP, coadministration of didanosine and tenofovir results in an increase in didanosine plasma concentrations. It has been suggested that this interaction may also cause an excess of the intracellular purines, dATP and dGTP, which can impair T cell maturation and differentiation; this interaction may explain the CD4 T cell depletion was seen with this combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/10\">",
"     10",
"    </a>",
"    ]. Additionally, high rates of early virologic failure, drug resistance and a blunted CD4 response have been seen with a didanosine-tenofovir backbone regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     Didanosine",
"    </a>",
"    should also not be used with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for the treatment of hepatitis C in HIV-infected patients since this combination is associated with an increased risk of lactic acidosis syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340787\">",
"    <span class=\"h2\">",
"     Lamivudine and emtricitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    (3TC) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    (FTC) are both dideoxycytidine analogues, which have very similar pharmacokinetic and pharmacodynamic characteristics. Therapeutically, either lamivudine or emtricitabine are often used as components of dual NRTI backbones of ARV regimens, and are considered interchangeable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/2\">",
"     2",
"    </a>",
"    ]. Structurally, emtricitabine is very similar to lamivudine, only differing in the addition of a fluorine to emtricitabine. Lamivudine and emtricitabine cannot be combined, however, because they will compete for intracellular phosphorylation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14340738\">",
"     'Pharmacodynamics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The mean absolute bioavailability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    is approximately 86 percent. Lamivudine can be given once or twice daily without regard for food. Once daily dosing achieves a similar AUC, although maximum plasma concentrations (Cmax) are 66 percent higher and trough concentrations (Cmin) are 53 percent lower compared with twice-daily dosing. Intracellular 3TC-triphosphate AUC and Cmax are similar with once-daily and twice-daily dosing, but the intracellular trough is lower in the once- versus twice-daily regimen. The mean absolute bioavailability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    is 93 percent, and it may be taken without regard to meals. &nbsp;",
"   </p>",
"   <p>",
"    The mean plasma elimination half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ranges from five to seven hours and the half-life of intracellular 3TC-triphosphate is 22 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/4\">",
"     4",
"    </a>",
"    ]. Based on one clinical trial, there was no difference in the proportions of treatment-naive patients who attained a non-detectable viral load on twice-daily or once-daily lamivudine administration when combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    at 48 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/35\">",
"     35",
"    </a>",
"    ]. The plasma and intracellular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and FTC-triphosphate half-lives are 10 and 39 hours, respectively, and provide the pharmacokinetic basis for once-daily dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/36\">",
"     36",
"    </a>",
"    ]. The longer plasma half-life of emtricitabine compared with lamivudine may provide a therapeutic advantage related to viral suppression and decreasing the risk of drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    is primarily renally eliminated as unchanged drug in the urine; the dose of lamivudine should be adjusted in patients with renal impairment. Hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis have negligible effects on lamivudine clearance; no additional modifications appear necessary beyond creatinine clearance-guided adjustments. Lamivudine pharmacokinetics are not altered with impaired hepatic function and no dose adjustment appears necessary based upon pharmacokinetic data; the safety and efficacy in those with decompensated liver disease, however, have not been established.",
"   </p>",
"   <p>",
"    FTC is eliminated renally through a combination of active tubular secretion and glomerular filtration. Plasma concentrations are increased in renal impairment and thus dose adjustments are necessary in patients with creatinine clearance values &lt;50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12759?source=see_link\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both drugs are extremely well tolerated.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    has been associated with pancreatitis though the risk in adults is quite low, at 0.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/38\">",
"     38",
"    </a>",
"    ]. The risk of pancreatitis may be higher in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/38\">",
"     38",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     Emtricitabine",
"    </a>",
"    can cause skin discoloration that presents as a hyperpigmentation usually on the palms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    soles. The mechanism and clinical significance is unknown; the incidence appears to be approximately 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340794\">",
"    <span class=\"h2\">",
"     Stavudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     Stavudine",
"    </a>",
"    (d4T) is a thymidine analogue. Stavudine has a high oral bioavailability estimated at 86 percent and may be taken with or without food. Stavudine is dosed twice daily in adults based on body weight (40 mg for adults weighing &gt;60 kg and 30 mg in adults weighing &lt;60 kg).",
"   </p>",
"   <p>",
"    Approximately 40 percent of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    dose is eliminated via a combination of active tubular secretion and glomerular filtration. Concentrations are increased in patients with renal impairment; thus dosage adjustments are necessary for those with creatinine clearances of &lt;50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    The major drug-limiting adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    therapy include peripheral neuropathy, lipoatrophy, pancreatitis, hyperlipidemia, hepatic steatosis and lactic acidosis, all of which are manifestations of mitochondrial toxicity. In antiretroviral-na&iuml;ve persons who received stavudine with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    , 8 percent developed adverse peripheral neurologic symptoms. Treatment guidelines worldwide recommend against the use of stavudine when other options are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/1,40,41\">",
"     1,40,41",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     Stavudine",
"    </a>",
"    should be discontinued in patients who develop symptoms of peripheral neuropathy. After symptoms completely resolve, restarting stavudine should be done with extreme caution, if at all. Previously it was recommended that stavudine could be reintroduced at one-half the usual dose. However, the safety and efficacy of this approach has not been established, and the most recent prescribing information for stavudine has removed this recommendation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10696942\">",
"    <span class=\"h3\">",
"     Use of stavudine in resource-limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sometimes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    is used in resource-limited settings because of its lower cost and ease of administration as a coformulated medication. These coformulations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       Stavudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (available as 30 mg stavudine plus 150 mg lamivudine or 40 mg stavudine + 150 mg lamivudine)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       Stavudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      (30 mg or 40 mg of stavudine plus 150 mg lamivudine and 200 mg nevirapine)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 30 mg dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    available in these products reflects a World Health Organization recommendation that all adults should receive 30 mg twice daily regardless of body weight in an attempt to reduce the incidence of mitochondrial toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/43\">",
"     43",
"    </a>",
"    ]. This decision was supported by a systematic review of nine controlled trials and six cohort studies that supported efficacy of the 30 mg twice daily dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/44\">",
"     44",
"    </a>",
"    ]. The 2010 WHO Guidelines emphasize a need to eliminate use of stavudine whenever feasible due to its severe toxicity. Several of these products have received tentative approval under the expedited review provisions of the President's Emergency Plan for AIDS Relief with assistance by the Food and Drug Administration (FDA) (PEPFAR;",
"    <a class=\"external\" href=\"file://www.pepfar.gov/\">",
"     file://www.pepfar.gov/",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340801\">",
"    <span class=\"h2\">",
"     Tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    (TDF) is an acyclic nucleotide diester analog of adenosine monophosphate; the active drug is tenofovir-diphosphate. Tenofovir may be taken with or without food, although a high-fat meal increases tenofovir AUC by 40 percent. The plasma and intracellular half-lives of tenofovir and TFV-diphosphate (the active moiety) are 17 and 150 hours, respectively, providing the basis for once-daily dosing.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    is eliminated via a combination of glomerular filtration and active tubular secretion. The drug enters renal proximal tubule cells via human organic anion transporters 1 and 3, and exits the cells into the urine via multidrug resistance protein 4. The dose of tenofovir must be adjusted in patients who have renal insufficiency (creatinine clearance &lt;50",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    However, the safety and efficacy of tenofovir and dose adjustment guidelines for patients with pre-existing renal insufficiency have not been evaluated, and if possible, the use of an alternative NRTI not associated with renal toxicity, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    , is preferred. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    is a well-tolerated drug. The primary drug-limiting toxicity is nephrotoxicity, which is characterized by increases in serum creatinine, glycosuria, hypophosphatemia, and acute tubular necrosis. This constellation is known as Fanconi syndrome, which is rare. Among patients without pre-existing renal insufficiency, tenofovir is relatively safe; a mild decline of glomerular filtration rate may be seen, but the clinical impact is usually modest. Nevertheless, renal function, urinalysis, and electrolytes should be monitored every six to 12 months in patients who are receiving tenofovir. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10794?source=see_link\">",
"     \"Adverse effects of antiretroviral therapy in developing countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    should have a urinalysis and serum creatinine every 6 to 12 months.",
"   </p>",
"   <p>",
"    Among patients with pre-existing renal insufficiency, dose reduction is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/2\">",
"     2",
"    </a>",
"    ]; however, many experts prefer to use an alternative NRTI in this clinical scenario when feasible since the long-term safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in patients with renal insufficiency is not known. Use of other nephrotoxic drugs and underlying renal dysfunction appear to predispose patients to tenofovir-induced renal dysfunction; advanced HIV disease may be an additional risk factor.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    concentrations are increased by several protease inhibitors, which are all given with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    for pharmacokinetic boosting:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    , lopinavir and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    . The mechanism(s) of these interactions is not clear, though one study demonstrated that",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    decreased the renal clearance of tenofovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    on the plasma concentrations of protease inhibitors is mixed: lopinavir concentrations are decreased, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    concentrations are increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/46\">",
"     46",
"    </a>",
"    ]. The clinical importance of these interactions is unknown. However, the impact of tenofovir on unboosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    AUC is significant; tenofovir decreases the AUC of atazanavir by 25 percent and the trough concentration by 40 percent. Concomitant therapy with tenofovir and atazanavir is only recommended if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is given as well for pharmacokinetic boosting of atazanavir. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14340808\">",
"    <span class=\"h2\">",
"     Zidovudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    (ZDV; also known as AZT) was the first antiretroviral medication used for the treatment of HIV, which demonstrated a reduction in the morbidity and mortality associated with HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11286?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    is a synthetic analogue of the naturally occurring nucleoside, thymidine. The mean absolute bioavailability of this drug is 64 percent. Zidovudine is primarily eliminated via hepatic metabolism.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    is dosed twice daily, as pharmacokinetic and pharmacodynamic studies with once-daily dosing suggest that intracellular trough levels are lower and HIV RNA declines are less robust than with twice-daily dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Adverse reactions associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    include headache, malaise, anorexia, nausea, and vomiting. Administration of zidovudine with food improves the gastrointestinal tolerability. The major dose-limiting toxicities of zidovudine are anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neutropenia (bone marrow suppression).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233278\">",
"    <span class=\"h1\">",
"     USE IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a landmark placebo-controlled clinical trial in HIV-infected pregnant women, monotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    during pregnancy, labor, and delivery, with additional zidovudine in the infant, reduced perinatal transmission from 26 to 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since this landmark trial, other NRTIs have been used during pregnancy. The most extensive pharmacokinetic, safety, and efficacy data are available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , which is the preferred dual NRTI backbone for use in HIV-infected pregnant women according to the Perinatal Guidelines Working Group of the United States Public Health Service [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41209/abstract/50\">",
"     50",
"    </a>",
"    ]. Other NRTIs, with the exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , are considered alternative agents. Tenofovir is recommended for use only in special circumstances because of incomplete knowledge on the dose for pregnant woman and concerns for fetal safety. The use of NRTIs during pregnancy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42841?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11211178\">",
"    <span class=\"h1\">",
"     USE IN PATIENTS WITH RENAL OR HEPATIC INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of NRTIs in patients with renal or hepatic insufficiency is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12759?source=see_link\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87047650\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of oral antiretroviral (ARV) drugs effective in reducing HIV viremia and in improving CD4 T cell counts. NRTIs are key components of antiretroviral therapy (ART) regimens, and are often referred to as the &ldquo;backbone&rdquo; of HIV treatment. (See",
"      <a class=\"local\" href=\"#H14340701\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The NRTI class includes seven agents:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H14340701\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NRTIs are usually given as paired agents with at least one additional antiretroviral medication that has a different mechanism of action, such as a protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or an integrase inhibitor. (See",
"      <a class=\"local\" href=\"#H14340708\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The NRTI triphosphate inhibits viral replication through competitive binding to the viral enzyme, reverse transcriptase; after incorporation of the NRTI phosphate, DNA chain elongation is terminated. (See",
"      <a class=\"local\" href=\"#H14340724\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NRTIs have activity against HIV-1, HIV-2, and some medications (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ) have activity against hepatitis B viruses. (See",
"      <a class=\"local\" href=\"#H22198678\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some NRTI combinations are synergistic or additive, while others are antagonistic. (See",
"      <a class=\"local\" href=\"#H14340738\">",
"       'Pharmacodynamics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hallmark toxicity of the NRTI class is mitochondrial toxicity, which may manifest as peripheral neuropathy, pancreatitis, lipoatrophy, and",
"      <span class=\"nowrap\">",
"       hepatomegaly/steatosis",
"      </span>",
"      with lactic acidemia. The risk of toxicity varies substantially from drug to drug and is related to the affinity of the parent drug for host mitochondrial enzymes. (See",
"      <a class=\"local\" href=\"#H14340752\">",
"       'Class side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preferred agents for the treatment of HIV infection include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      due to their potency and overall tolerability.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      may be associated with an increased risk of myocardial infarction and should be used with caution in patients at high risk of cardiovascular disease until further data are available.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       Didanosine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      are considered alternative agents due to the risk of mitochondrial toxicity (didanosine and stavudine) and anemia (zidovudine). (See",
"      <a class=\"local\" href=\"#H14340766\">",
"       'Specific agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/1\">",
"      Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on February 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/3\">",
"      Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/4\">",
"      Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/5\">",
"      Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/6\">",
"      Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 1994; 74:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/7\">",
"      Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996; 335:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/8\">",
"      Havlir DV, Tierney C, Friedland GH, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 2000; 182:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/9\">",
"      Hoggard PG, Kewn S, Barry MG, et al. Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/10\">",
"      Kakuda TN, Anderson PL, Becker SL. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS 2004; 18:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/11\">",
"      Perez-Olmeda M, Garcia-Perez J, Mateos E, et al. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. J Med Virol 2009; 81:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/12\">",
"      Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 1996; 276:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/13\">",
"      Rousseau FS, Kahn JO, Thompson M, et al. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother 2001; 48:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/14\">",
"      Kuritzkes DR, Marschner I, Johnson VA, et al. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. AIDS 1999; 13:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/15\">",
"      Staszewski S, Katlama C, Harrer T, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998; 12:F197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/16\">",
"      Barditch-Crovo P, Deeks SG, Collier A, et al. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/17\">",
"      Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/18\">",
"      Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/19\">",
"      Coghlan ME, Sommadossi JP, Jhala NC, et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001; 33:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/20\">",
"      Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/21\">",
"      Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276:40847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/22\">",
"      Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 2000; 14:273.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. FDA/Bristol Myers Squibb issues caution for HIV combination therapy with Zerit and Videx in pregnant women. In: FDA USDoHaHS (Ed), 2001:Talk Paper T01-02.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/24\">",
"      Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/25\">",
"      Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/26\">",
"      D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/27\">",
"      Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/28\">",
"      Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20.",
"     </a>",
"    </li>",
"    <li>",
"     Ding X, Andraca-Carrera, Cooper C, et al. No association of myocardial infactions with ABC use: an FDA meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections. Boston 2011.",
"    </li>",
"    <li>",
"     Sax P, Tierney C, Collier AC, et al. ACTG 5202: shorter time to virologic failure with ABC/3TC than tenofovir/FTC in treatment-naive subjects with HIV RNA &gt;100,000. In: 17th International AIDS Conference; August 3-8, 2008; Mexico, City, Mexico 2008. p. THAB0303.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/31\">",
"      Waters LJ, Moyle G, Bonora S, et al. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther 2007; 12:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/32\">",
"      Floridia M, Vella S, Seeber AC, et al. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection. J Infect Dis 1997; 175:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/33\">",
"      Cooley TP, Kunches LM, Saunders CA, et al. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med 1990; 322:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/34\">",
"      Holdich T, Shiveley LA, Sawyer J. Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2007; 51:2943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/35\">",
"      DeJesus E, McCarty D, Farthing CF, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 2004; 39:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/36\">",
"      Wang LH, Begley J, St Claire RL 3rd, et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004; 20:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/37\">",
"      Marcelin AG, Charpentier C, Wirden M, et al. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. J Antimicrob Chemother 2012; 67:1475.",
"     </a>",
"    </li>",
"    <li>",
"     GlaxoSmithKline. Epivir (lamivudine) tablets and oral solution. Research Triangle Park, NC. 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/39\">",
"      Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/hiv/pub/arv/adult2010/en/index.html (Accessed on November 05, 2010).",
"    </li>",
"    <li>",
"     file://europeanaidsclinicalsociety.org/guidelines.asp (Accessed on November 05, 2010).",
"    </li>",
"    <li>",
"     Bristol-Myers Squibb Company. Zerit (stavudine) capsules and oral solution. Princeton, NJ 2010.",
"    </li>",
"    <li>",
"     file://www.who.int/hiv/pub/guidelines/en/ (Accessed on October 26, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/44\">",
"      Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/45\">",
"      Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/46\">",
"      Anderson PL. Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs. Curr Opin HIV AIDS 2008; 3:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/47\">",
"      Flynn PM, Rodman J, Lindsey JC, et al. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents Chemother 2007; 51:3516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/48\">",
"      Ruane PJ, Richmond GJ, DeJesus E, et al. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-na&iuml;ve patients infected with human immunodeficiency virus. Pharmacotherapy 2004; 24:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41209/abstract/49\">",
"      Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173.",
"     </a>",
"    </li>",
"    <li>",
"     Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. file://www.aidsinfo.hiv.gov (Accessed on August 01, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13978 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-ADE281C057-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41209=[""].join("\n");
var outline_f40_15_41209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H87047650\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14340701\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14340708\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14340715\">",
"      PHARMACOLOGIC CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14340724\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22198678\">",
"      Spectrum of activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14340731\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14340738\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87047282\">",
"      Potency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14340745\">",
"      Resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14340752\">",
"      Class side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14340766\">",
"      SPECIFIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14340773\">",
"      Abacavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14340780\">",
"      Didanosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14340787\">",
"      Lamivudine and emtricitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14340794\">",
"      Stavudine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10696942\">",
"      - Use of stavudine in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14340801\">",
"      Tenofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14340808\">",
"      Zidovudine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H233278\">",
"      USE IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11211178\">",
"      USE IN PATIENTS WITH RENAL OR HEPATIC INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87047650\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13978\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13978|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/3/12350\" title=\"table 1\">",
"      Drug interactions between NRTIs and other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/47/34559\" title=\"table 2\">",
"      Characteristics of NRTIs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10794?source=related_link\">",
"      Adverse effects of antiretroviral therapy in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42841?source=related_link\">",
"      Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11286?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12759?source=related_link\">",
"      Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23030?source=related_link\">",
"      Investigational treatments of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=related_link\">",
"      Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_15_41210="Pathogenesis of rheumatoid arthritis";
var content_f40_15_41210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41210/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41210/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41210/contributors\">",
"     Gary S Firestein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41210/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41210/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/15/41210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/15/41210/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/15/41210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis (RA) is the most common inflammatory arthritis and affects about one percent of the population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/1\">",
"     1",
"    </a>",
"    ]. It results from a complex interaction between genes and environment, leading to a breakdown of immune tolerance and synovial inflammation in a characteristic symmetric pattern. Distinct mechanisms regulate inflammation and matrix destruction, including damage to bone and cartilage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/2\">",
"     2",
"    </a>",
"    ]. Given the heterogeneous response to therapy, it is clear that RA in not just a single disease; instead many pathways can lead to autoreactivity with similar clinical presentations.",
"   </p>",
"   <p>",
"    The pathogenesis of RA is reviewed here. The etiology of this disorder, including putative genetic and environmental factors, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39593?source=see_link\">",
"     \"Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28538780\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation of RA is a combination of pre-determined (genetic) and stochastic (random) events. Susceptibility to RA is clearly defined by a pattern of inherited genes, with the HLA major histocompatability genes as the most important. However, scores of minor genes that include cytokine promoters, T cell signaling genes, and many others, contribute to susceptibility and severity. It is equally clear that genes are not the sole influence, since the concordance rate for identical twins is only 12 to 15 percent. Of the environmental stimuli that contribute, the best defined is smoking, which can interact with genes to increase susceptibility up to 20- to 40-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/3\">",
"     3",
"    </a>",
"    ]. Epigenetic influences, such as hypomethylation of DNA or expression of microRNAs, can also increase pro-inflammatory gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most likely mechanism for the environmental component is repeated activation of innate immunity. This process can take many years, with evidence of autoimmunity increasing gradually until some unknown process tips the balance toward clinically apparent disease. One key element is the induction of the peptidyl arginine deiminase (PAD) enzymes, which convert arginine to citrulline. Increased citrullination is not specific to RA and occurs regularly with any environmental stress, including in alveolar macrophages in cigarette smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/5\">",
"     5",
"    </a>",
"    ]. What is unique to RA is the propensity for immune reactivity to the neoepitopes created by protein citrullination with the production of anti-citrullinated protein antibodies.",
"   </p>",
"   <p>",
"    In &ldquo;pre-RA,&rdquo; ACPAs and other autoantibodies like rheumatoid factors (RFs) can appear more than 10 years before clinical arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/6\">",
"     6",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    The antibodies themselves may contribute to the initiation or exacerbation of synovitis but do not necessarily cause RA by themselves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/7\">",
"     7",
"    </a>",
"    ]. A pattern of systemic inflammation is also apparent in pre-RA patients as determined by multiplex analysis of cytokines in the serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/8\">",
"     8",
"    </a>",
"    ]. Like autoantibodies, levels of multiple cytokines gradually increase in the years before RA symptoms occur.",
"   </p>",
"   <p>",
"    Once the autoimmune process is fully established, the synovium in RA organizes itself into an invasive tissue that can degrade cartilage and bone. The rheumatoid synovium has many characteristics of a locally-invasive malignancy, but it never becomes completely unresponsive to antiinflammatory and antiproliferative factors. Fibroblast-like synoviocytes in the rheumatoid synovium can migrate from joint to joint, perhaps accounting for the symmetric and diffuse distribution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     T LYMPHOCYTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of innate immunity is probably the earliest process in RA, followed by citrullination, loading of antigen presenting cells (APCs) with autoantigens in the joint, then migration to central lymphoid organs. Once there, APCs present an array of antigens to T cells, which can then activate B cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    migrate back to the synovium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initial antigen(s) and the T lymphocyte",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells constitute about 50 percent or more of cells in most RA synovia; most of these are CD4+ with a memory phenotype, but only 5 percent or fewer are B lymphocytes or plasma cells. RA synovial T lymphocytes display an activated surface phenotype, with high expression of HLA-DR antigens and CD27. CD27+ CD4+ T cells provide B cell help that can potentially increase synovial antibody production. There appears to be a preponderance of T cells of the Th1 and Th17 subset, with deficiency of Th2 and regulatory T cells (Tregs).",
"   </p>",
"   <p>",
"    It is unlikely that a single &ldquo;rheumatoid antigen&rdquo; exists. Instead, a broad spectrum of joint specific antigens, such a type II collagen, or nonspecific citrullinated antigens, is responsible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/9\">",
"     9",
"    </a>",
"    ]. Examples of citrullinated peptides that have been implicated include fibrinogen, vimentin, enolase, and collagen, each of which can elicit immune responses more efficiently than the unmodified proteins. The initiating antigen(s) probably vary from patient to patient, perhaps from joint to joint, and from early to late disease in the same patient. This concept has important implications in the search for pathogenic T cells and the likelihood that a single approach to tolerizing lymphocytes might not be effective in all patients.",
"   </p>",
"   <p>",
"    For maximal T cell responses, second signals are generally required. Two of the co-stimulatory molecules through which such signals are provided are CD28 and CD40 ligand; both are highly expressed by synovial T cells in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Synergistic effects of CD40-CD40 ligand interaction and interleukin-1 on cytokine production may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another interesting cell type found in RA is CD4+ and CD8+, but CD28-. This cell has &ldquo;killer&rdquo; cell activity, but it provides no help for B-cell activation, and without CD28, cannot accept costimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/13\">",
"     13",
"    </a>",
"    ]. These autoreactive cells might reflect an immunosenescent state, resulting from continuous stimulation in the periphery of a restricted and limited repertoire of T-lymphocytes released from the thymus. A higher frequency of CD4+, CD28null T cells in rheumatoid patients has a predictive value (along with",
"    <span class=\"nowrap\">",
"     HLA-DRB1*04/04,",
"    </span>",
"    older age, and rheumatoid factor titers) for the risk of erosive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/14\">",
"     14",
"    </a>",
"    ]. These cells undergo pronounced clonal expansion and accumulate in large quantity in rheumatoid synovium and in peripheral blood of rheumatoid patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/15\">",
"     15",
"    </a>",
"    ]. Nonspecific cytokine stimulation, not antigen recognition, may trigger the transition of these cells from the lymph nodes to the synovium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of the physical structure of the \"shared epitope\" in the third hypervariable region of the HLA-DRB chains expressed on macrophages and B cells, the antigen presenting cells, has shed some light on the initial antigens likely to be responsible for RA. The risk for RA is encoded by amino acid substitutions at positions 72 to 74 and modulated by the amino acids at positions 70 and 71 of the HLA-DRB1 molecule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=see_link&amp;anchor=H3#H3\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\", section on 'Individual alleles and the shared epitope'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The three-dimensional reconstruction of the HLA class II antigen structure suggests that the shared epitope may not restrict the precise structure of antigens selected for presentation to T cells. Rather, the epitope alters the conformation of the antigen-DR complex presented to the T cell receptor. As a result, it probably is not relevant for the T cell which peptide is presented in the susceptibility epitope; recognition is likely to be peptide-dependent, but not peptide-specific. These &ldquo;arthritogenic&rdquo; antigen(s) may carry a net negative charge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/20\">",
"     20",
"    </a>",
"    ], and frequently the citrullinated peptides bind with greater affinity than the unmodified peptide. Fine structure analyses unexpectedly suggest that amino acids 11 and 13, which are in the antigen-binding groove of the HLA molecule, have the closest association with RA in patients with the susceptibility epitope. These amino acid residues could play a role by binding to arthritogenic citrullinated peptides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superantigens can activate multiple clones of T cells (1 in 10 cells) through a largely MHC-independent process. By comparison, a specific antigen presented in the context of the HLA class II cell surface antigens can activate only 1 in 10,000 T cells. A discussion of the possible role of superantigens (including heat shock proteins) in the etiology of RA is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39593?source=see_link\">",
"     \"Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Costimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Costimulation is an important aspect of T cell activation during the immune response in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Presentation of antigen to T cells by antigen-presenting cells (eg, dendritic cells, macrophages, B cells) without costimulation by",
"    <span class=\"nowrap\">",
"     receptor/coreceptors",
"    </span>",
"    (such as",
"    <span class=\"nowrap\">",
"     CD28/CD80,",
"    </span>",
"    CD86, intercellular-adhesion",
"    <span class=\"nowrap\">",
"     molecule-1/lymphocyte",
"    </span>",
"    function associated antigen-1), leads to anergy and death of insufficiently activated T cells. A B7-binding molecule, CTLA-4 fused with an immunoglobulin fragment (CTLA4-Ig or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    ), is used in the treatment of patients with RA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=see_link&amp;anchor=H5#H5\">",
"     \"T cell targeted therapies for rheumatoid arthritis\", section on 'Abatacept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intriguing evidence suggests that costimulatory molecules are present in excess within rheumatoid tissue, thereby implying that T cell activation may take place without specific antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. As a result, self-perpetuating cycles of T cell proliferation sufficient to sustain autoimmunity may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apoptosis (programmed cell death) has been investigated as a possible underlying defect among T cells in RA. As an example, deficiencies in normal programmed cell death due to an underlying T cell defect are a cause of autoimmune lymphoproliferation and arthritis in MRL",
"    <span class=\"nowrap\">",
"     lpr/lpr",
"    </span>",
"    mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, there is overexpression of a tumor suppressor gene p53 in rheumatoid synovium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/28\">",
"     28",
"    </a>",
"    ]. Mutations that have been identified in p53 may prevent normal DNA repair and interfere with apoptosis processes regulated by this gene product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/29\">",
"     29",
"    </a>",
"    ]. Dysregulation of p53 may contribute to resistance of peripheral blood mononuclear cells to radiation-induced apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/30\">",
"     30",
"    </a>",
"    ]. HMG-CoA reductase inhibitors (statins) block protein geranylgeranylation and some of the drugs can induce apoptosis in RA synoviocytes through mitochondrial- and caspase 3-dependent pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Autoantigen(s) and T-cell proliferation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the immune response is triggered by the inciting antigen(s), additional antigens also recognized by T cells may contribute to an ongoing response. Four autoantigens that have potential as pathogenic factors are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Type II collagen",
"    </span>",
"    &nbsp;&mdash;&nbsp;One commonly implicated antigen is type II collagen, which is uniquely found in articular cartilage and the vitreous of the eye. Autoreactivity to type II collagen occurs in RA, although anti-collagen antibodies are present in a minority of patients. Some evidence suggesting autoimmunity to collagen includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The resolution of synovitis following total joint arthroplasty suggests that some component of articular cartilage helps provoke an ongoing immune response.",
"     </li>",
"     <li>",
"      Citrullinated collagen activates T cells more effectively than native collage in patients with the RA-associated class II MHC genes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chronic joint inflammation can be induced in experimental models by immunization with type II collagen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/33\">",
"       33",
"      </a>",
"      ], and by administration of monoclonal antibodies with affinity for type II collagen plus an adjuvant (E. Coli lipopolysaccharide) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Synovial fluid from patients with RA is enriched with activated T-cells that proliferate in vitro in response to type II collagen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type II collagen that has been modified by oxidants present in the rheumatoid joint (eg, hydroxyl radical, hypochlorous acid and peroxynitrite) express neoantigenic epitopes that bind to antibodies in rheumatoid serum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cartilage antigen glycoprotein-39 (gp39)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This glycoprotein is secreted by both synovial cells and chondrocytes, and is selectively induced at sites of inflammation and tissue injury. Peptides derived from this protein (T cell epitopes of gp-39) that were defined in HLA-DR4 transgenic mice also stimulated T cells from human subjects that carried RA-associated HLA-DR4 alleles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/37\">",
"     37",
"    </a>",
"    ]. Cytokines produced subsequently by these activated T cells could help drive the chronic inflammatory process. Presentation of a fusion protein,",
"    <span class=\"nowrap\">",
"     HLA-DR4/gp39",
"    </span>",
"    peptide to rheumatoid patients is hypothesized to cause T cells with receptors for gp39 in the context of DR4 to become anergic. Binding of the complex to the T cell receptor in the absence of costimulation could lead to apoptosis or unresponsiveness (since no antigen-presenting cells are involved) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/38\">",
"     38",
"    </a>",
"    ]. Shared epitope-positive dendritic cells presenting an immunodominant human gp39 peptide (amino acids 263-275) may be more frequently found in the synovium of patients with RA than those with other inflammatory joint diseases or with osteoarthritis (61 versus 3 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Immunoglobulin G",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to IgG, called rheumatoid factors, have long been implicated in the pathogenesis of RA. Circulating lymphocytes from patients with RA recognize oxidatively modified IgG in vitro by initiating a proliferative response and secreting IL-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/40\">",
"     40",
"    </a>",
"    ]. Reactive oxygen and nitric oxide products secreted by inflammatory cells generate covalent crosslinked IgG aggregates with biologic properties of true immune complexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Citrullinated proteins and peptides",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, anti-citrullinated protein antibodies (ACPA) are relatively specific for RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/42\">",
"     42",
"    </a>",
"    ]. The citrullination is catalyzed by peptidyl arginine deiminase; arginine residues on fibrin and fibrinogen may be favored sites for deimination within rheumatoid joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. Intracellular citrullinated proteins colocalized with the deimidase in most of RA synovial samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/44\">",
"     44",
"    </a>",
"    ]. However, citrullinated proteins are also found in the synovium of other forms of arthritis, in nonsynovial tissue from patients with RA (eg, pulmonary rheumatoid nodules), in the lungs of patients with interstitial pneumonitis, in brain from patients with multiple sclerosis, and in normal brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Synovial citrullinated peptides are also found in most animal models of arthritis as well.",
"   </p>",
"   <p>",
"    The RA-associated HLA-DRB1*0404 allele is also associated with production of antibodies to citrullinated fibrinogen, and T cell proliferation in response to fibrinogen peptides is frequent in RA patients but rare in controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/49\">",
"     49",
"    </a>",
"    ]. In contrast, in another study the shared epitope was associated with antibodies to a citrullinated peptide derived from vimentin but not to a fibrinogen-derived citrullinated peptide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comparisons of the shared epitope (SE) frequencies on HLA-DRB1 alleles in healthy populations with RA patients who do or do not harbor ACPAs have shown that the SE is associated only with ACPA-positive disease and not with ACPA-negative disease. This indicates that the HLA-DRB1 alleles encoding the SE do not associate with RA as such, but rather with a particular phenotype, disease with ACPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=see_link\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A strong association between cigarette smoking, a known risk factor for RA, and the presence HLA-DBR1*0404 or other HLA alleles comprising the shared epitope has been noted for RA patients who have ACPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. As an example, in an epidemiologic study, the relative risk of developing RA was increased 20-fold in those who had two alleles for the SE, had ever smoked cigarettes, and were anti-cyclic citrullinated peptide (anti-CCP) positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/52\">",
"     52",
"    </a>",
"    ]. Citrullinated proteins were present in the bronchoalveolar lavage fluid from the lungs of cigarette smokers, but were not demonstrated by immunostaining of fluid from nonsmokers. This study connects two important risk factors for RA, namely smoking and genetic predisposition conferred by carriage of the SE. It also raises the possibility that smoking-induced citrullinated proteins may serve as a link in the process, possibly as neoantigens.",
"   </p>",
"   <p>",
"    The lack of an association between smoking and risk of RA in those who are ACPA-negative, suggests that these disease subsets (ACPA-positive versus ACPA-negative) differ in their pathogenesis. However, a large collaborative study that included 2476 Caucasian RA patients from North America confirmed a strong association between the presence of ACPA and the shared epitope, but found only a weak association between ACPA formation and smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/54\">",
"     54",
"    </a>",
"    ]. On the other hand another study of 216 patients demonstrated a moderately strong association between ACPA and tobacco exposure, irrespective of the presence of the SE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As citrullinated proteins are found in many sites of inflammation, it is not clear why patients with RA make such high titer antibodies to these proteins. As noted above, one hypothesis is that this antibody response is genetically mediated, but some patients with high titers of ACPA are SE negative. Another hypothesis is that in RA, unique citrullinated epitopes form, comprising the antigens to which most anti-citrullinated antibodies develop. In this respect some of these putative epitopes, recognized by rabbit and mouse antisera, colocalize in RA synovium with PAD2 (peptidyl arginine deiminase), the enzyme that converts arginine to citrulline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/47\">",
"     47",
"    </a>",
"    ]. Extensive research continues to identify the \"primary\" citrullinated epitope(s) and to address the question of why patients with RA generate high titers of ACPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANGIOGENESIS AND INFLAMMATORY CELL RECRUITMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     New blood vessel growths",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the earliest histopathologic responses in RA is the generation of new synovial blood vessels. This event is accompanied by the transudation of fluid and the transmigration of both lymphocytes into the synovium and of polymorphonuclear leukocytes into the synovial fluid. In the mature RA synovium, the mass of tissue is too much for even the multiple new capillaries to nourish, and local tissue ischemia is the result. The mean PO2 in rheumatoid synovial fluid is usually 30 mmHg, and occasionally is less than 15 mmHg.",
"   </p>",
"   <p>",
"    Relative synovial hypoxia is associated with an increased production of the transcription factor hypoxia-inducible factor 1 (HIF-1) that activates transcription of genes that are of fundamental importance for angiogenesis, including those for vascular endothelial growth factor (VEGF) and the VEGF receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Without new blood vessels, there would be no scaffold upon which synovitis could grow. RA can therefore be considered an \"angiogenesis-dependent disease\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. The angiogenic response is precise, reproducible, and identical in all tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/63\">",
"     63",
"    </a>",
"    ]. New capillary formation is induced",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stabilized by the transcription factor HIF-1 and by angiogenic factors generated by synovial cells. Such factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heparin-binding growth factors (HBGF) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/64-66\">",
"       64-66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Macrophage angiogenic factor (MAF) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vascular endothelial growth factor (VEGF) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/66,68\">",
"       66,68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prostaglandins E1 and E2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interleukin (IL)-8 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Epithelial neutrophil activating peptide 78 (ENA-78) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/71\">",
"       71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Angiopoietin-1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/72\">",
"       72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Heparanase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/73\">",
"       73",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When antibodies against IL-8 and ENA-78 were added to rheumatoid synovial tissue in vitro, virtually all the angiogenic activity in these explants was inhibited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The enhanced expression of specific adhesion molecules, such as the integrin alpha-v beta-3, is also required for effective angiogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the key proinflammatory cytokines, tumor necrosis factor-alpha (TNF) may indirectly stimulate angiogenesis. As an example, endothelial cells exposed to TNF upregulate the production of an angiopoietin 1 receptor (Tie2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/75\">",
"     75",
"    </a>",
"    ]. A complementary in-vitro finding is that the amount of angiopoietin 1 produced by cultured synovial cells is also increased by exposure to TNF. (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Cytokine networks in rheumatoid arthritis'",
"    </a>",
"    below)",
"   </p>",
"   <p>",
"    Balancing this angiogenic response are factors which tend to inhibit neovascular formation. These include interferon-gamma (IFN&gamma;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/76\">",
"     76",
"    </a>",
"    ], transforming growth factor-beta (TGF-&beta;), interleukin (IL)-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/77\">",
"     77",
"    </a>",
"    ], angiostatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/78\">",
"     78",
"    </a>",
"    ], endostatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/66,79\">",
"     66,79",
"    </a>",
"    ], and low-molecular weight substances in articular cartilage (one of the few avascular tissues in the body) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/63\">",
"     63",
"    </a>",
"    ]. While anti-angiogenesis approaches are effective in pre-clinical models of arthritis, at least one therapeutic intervention (anti-&alpha;v integrin antibody) did not meet its primary endpoint in an RA clinical trial. It is possible that other pathways are responsible or that therapeutic approaches that focus on blood vessel growth need to be used in combination with other agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cell migration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the new vessels develop, cytokines produced in the synovium in response to the driving force of TNF (including IL-1, IL-6, IFN&gamma;, and substance P) activate endothelial cells to produce adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), P-selectin, and E-selectin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. These cellular adhesion molecules expedite activation-dependent sticking of leukocytes, thereby facilitating diapedesis and extravasation into the synovium. It appears that IL-15 and IL-18 have a major role in stimulating production of TNF, which, as mentioned above, has a broad capacity to trigger biosynthesis of multiple effector proteins",
"   </p>",
"   <p>",
"    Although there appears to be redundancy within the cellular adhesion system, certain pairs of",
"    <span class=\"nowrap\">",
"     ligand/receptors",
"    </span>",
"    are very active in RA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once adherence occurs, chemokines, including",
"    <span class=\"nowrap\">",
"     CXCL8/IL-8",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     CXCL5/ENA-78,",
"    </span>",
"    are involved in enhancing transmigration of leukocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/80,82,83\">",
"     80,82,83",
"    </a>",
"    ]. Accumulation of mononuclear cells, particularly T lymphocytes of the Th1 subtype, may involve an interaction between CXCL16 derived from synovial macrophages and a receptor (CXCR6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the reasons that polymorphonuclear leukocytes are found in large numbers in synovial fluid but are rarely found in synovial tissue may be that neutrophils do not express VLA-4 (very late antigen-4). These cells therefore have no ligand for VCAM-1 that is highly expressed in the synovium. In contrast, VLA-4 is well-expressed on lymphocytes and can bind both VCAM-1 and synovial alternatively-spliced fibronectin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/82\">",
"     82",
"    </a>",
"    ], assuring an abundant number of synovial tissue lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A positive correlation can be made between the expression of adhesion molecules on endothelial cells and the appearance of these cells on histologic sections. Both vascular proliferation and high endothelial venules are found in rheumatoid joints with proliferating, invasive synovitis, but not in clinically uninvolved joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although much attention has been focused on the presence of lymphocytes in the synovium, similar lymphoid accumulation also occurs in the juxtaarticular bone marrow. This was illustrated in a study of bone sample and synovium from patients with RA obtained at the time of joint replacement surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/88\">",
"     88",
"    </a>",
"    ]. The degree of inflammatory infiltration of the marrow was correlated with the density of osteoclasts. Increased osteoclast number and activity may account for the radiographic finding of juxtaarticular demineralization that occurs in RA.",
"   </p>",
"   <p>",
"    Targeting chemokines has been attempted in RA, including anti-chemokine antibodies or chemokine receptor antagonists, but few have been successful. This is most likely due to the redundant nature of the chemokine system, which makes it difficult to block cell recruitment. In one phase II trial, an anti-CXCL10 antibody demonstrated efficacy when used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/89\">",
"     89",
"    </a>",
"    ]. Other potential approaches might include blocking signaling molecules that regulate a broad range of chemokine functions, such as PI3K&gamma; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CYTOKINE NETWORKS IN RHEUMATOID ARTHRITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17859215\">",
"    <span class=\"h2\">",
"     Role of cytokines in synovitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autocrine and paracrine communication through the elaboration of pro-inflammatory cytokines play a key role in initiation and perpetuation of RA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/8/4231?source=see_link\">",
"     \"Role of cytokines in the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A cascade network of cytokines has a pivotal role in synovitis, including granulocyte macrophage colony-stimulating factor (GM-CSF), IL-2, IL-15, IL-13, IL-17, IL-18, IFN&gamma;, TNF, and TGF-&beta;:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GM-CSF",
"      <span class=\"nowrap\">",
"       &mdash;Granulocyte/macrophage",
"      </span>",
"      colony-stimulating factor (GM-CSF), produced constitutively by synovial macrophages, may be sufficient to activate expression of HLA-DR molecules on antigen-presenting cells, thereby initiating T cell activation in the presence of antigen or superantigen and the beginnings of an immune response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-2 and IFN&gamma; &mdash; IL-2 and IFN-&gamma;, the characteristic lymphokines generated by activated T cells, are found in small quantities in rheumatoid tissues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/92\">",
"       92",
"      </a>",
"      ]. These prototypical Th1 cytokines are present in much higher concentrations in established Th1-mediated diseases, such as tuberculous pleuritis. Instead, cytokines associated with Th17 cells appear to play a more prominent role (see below).",
"     </li>",
"     <li>",
"      TNF &mdash; Tumor necrosis factor (TNF) is a key cytokine in a subset of patients. It induces GM-CSF production by antigen-presenting cells, enhances proliferation of T cells, increases proliferation and differentiation of B cells, induces expression of adhesion molecules on endothelium, and generates expression of collagenase, stromelysin (matrix metalloproteinase-3) and prostaglandins by synovial cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/93\">",
"       93",
"      </a>",
"      ] and may interfere with antigen specific and nonspecific suppressive effects of regulatory T cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/94\">",
"       94",
"      </a>",
"      ]. Although synergistic in many roles with interleukin-1 beta (IL-1&beta;), TNF induces synthesis of IL-1&beta; in synovial cells, whereas the reverse is not true. The administration of anti-TNF antibodies or a TNF receptor fusion protein decreases the activity of the disease. In addition, anti-TNF therapies produce a favorable decrease in the ratio of two osteoclast modulating factors: receptor activator of nuclear factor kB ligand (RANKL) and osteoprotegerin (OPG) a soluble receptor that competitively binds RANKL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/95\">",
"       95",
"      </a>",
"      ]. The resulting decrease in",
"      <span class=\"nowrap\">",
"       RANKL/OPG",
"      </span>",
"      ratio is consistent with a decrease in local bone resorption. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/22/16746?source=see_link&amp;anchor=H14#H14\">",
"       \"Cytokine networks in rheumatic diseases: Implications for therapy\", section on 'Inhibition of cytokine action'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link\">",
"       \"Normal skeletal development and regulation of bone formation and resorption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IL-15 &mdash; IL-15, produced by macrophages, can induce TNF production through activation of synovial T cells in RA via a cell-contact-dependent mechanism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/96\">",
"       96",
"      </a>",
"      ]. Local IL-15 production can lead to increased TNF synthesis in an autocrine and antigen-independent fashion. IL-15 RNA is also abundant in synovial specimens from patients with early RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/97\">",
"       97",
"      </a>",
"      ]. IL-15 neutralization has some efficacy in RA, but less than most other biologic agents currently approved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-17 &mdash; IL-17 is produced by Th17 cells, and in human synovial tissue in culture, added IL-17 enhanced IL-6 production and collagen destruction. Cyclooxygenase -2 (COX-2) expression and prostaglandin E2 production by cultured synovial fibroblast-like synovial cells and freshly collected monocytes are increased by exposure to IL-17 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/99,100\">",
"       99,100",
"      </a>",
"      ]. This cytokine also increased bone resorption by enhancing osteoclast activation and decreased bone formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/101\">",
"       101",
"      </a>",
"      ]. Increased levels of IL-17 in the synovium of patients with RA may be associated with an increased risk of radiographic progression despite treatment with traditional (nonbiologic) disease modifying antirheumatic drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/102\">",
"       102",
"      </a>",
"      ]. Of interest, a significant portion of synovial IL-17A is actually produced by mast cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/103\">",
"       103",
"      </a>",
"      ]. Recently, an anti-IL-17A antibody demonstrated modest efficacy in patients with RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-18 and IL-33 &mdash; IL-18 and IL-33 are a members of the IL-1 family and can sustain the Th1 phenotype that is associated with RA. The former is synergistic with IL-12 and IL-15 in production of proinflammatory cytokines. Unlike many such destructive cytokines, IL-18 may actually inhibit osteoclast formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/105\">",
"       105",
"      </a>",
"      ]. It may drive the local production of TNF and IL-1&beta;, as a result of its ability to augment monocyte activation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/106\">",
"       106",
"      </a>",
"      ]. Expression of IL-18 in rheumatoid synovial tissue correlates with the acute-phase response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/107\">",
"       107",
"      </a>",
"      ]. IL-33 is an &ldquo;alarmin&rdquo; that is expressed in RA synovium. Blocking this cytokine is effective in animal models of arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interleukin-13 and IL-4 &mdash; Interleukin-13 (IL-13) and IL-4 are prototypical Th2 cytokines that play a role in antibody class switching and allergic diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/109\">",
"       109",
"      </a>",
"      ]. Both cytokines are either absent or present in only very low concentrations in RA synovium.",
"     </li>",
"     <li>",
"      Macrophage colony stimulating factor (M-CSF) &mdash; This cytokine plays a major role in osteoclast development. In the presence of parathyroid hormone, vitamin D, and PGE2, osteoblasts produce Receptor Activator for NfkB Ligand (RANKL) that, in the presence of M-CSF, binds to its receptor on",
"      <span class=\"nowrap\">",
"       monocyte/macrophages",
"      </span>",
"      and induces these cells to become osteoclasts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interleukin-7 &mdash; Interleukin-7 (IL-7) is increased in the synovial fluid of patients with RA compared to those with osteoarthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/111\">",
"       111",
"      </a>",
"      ]. Synovial macrophages appear to be the major source of IL-7 in RA synovium, though production by synovial fibroblasts has also been noted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/111,112\">",
"       111,112",
"      </a>",
"      ]. Promotion of bone erosion as a result of stimulation of osteoclast formation is a potentially pathogenically important effect of this cytokine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TGF-&beta; &mdash; TGF-&beta; can be considered a \"reparative cytokine.\" As a member of the growth factor family, this cytokine inhibits T cell activation and proliferation, down-regulates B cell proliferation and differentiation, inhibits biosynthesis of metalloproteinases (except for activation of biosynthesis of IL-1&beta; by chondrocytes), protects articular cartilage from the degradative influences of IL-1, inhibits TNF secretion from macrophages, and accelerates wound repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/114\">",
"       114",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Systemic administration of TGF-&beta; diminished acute and chronic phases of inflammation in experimental arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/115\">",
"       115",
"      </a>",
"      ]. As yet, however, there have been no therapeutic trials of recombinant TGF-&beta; in patients with RA, in part because active TGF-&beta; (in contrast to the latent form) has a very short half-life in vivo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cytokines associated with Th1 and Th17 cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA was generally considered a Th1 cell-driven disease characterized by increased activity of TNF, IL-2, IFN&gamma;, and IL-12. This appears to be due to a local, rather than a systemic, stimulus that favors the accumulation of Th1 cells in affected joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/116\">",
"     116",
"    </a>",
"    ]. By comparison, Th2 cell-dominated processes (eg, asthma) are associated with enhanced activity of IL-4, IL-5, and IL-10, thereby resulting in immunoglobulin production. However, the notion that Th17 cells are the dominant T cell subset in RA has supplanted the Th1 hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/117\">",
"     117",
"    </a>",
"    ].(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Functionally, the interactions of cytokines in RA can be considered as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/118\">",
"     118",
"    </a>",
"    ]. Inflammatory cells are recruited to the bland synovium by the actions of IL-17A, TNF, IL-1, IL-6, IL-18, VEGF, and chemokines. Retention in the synovium is facilitated by inhibition of apoptosis and other innate immunity mechanisms by IFN&alpha; and &beta;, IL-15, and TNF. The T-cells become organized and activated in the presence of IL-23, IL-27, IL-12, IL-15, IL-18, and chemokines. Simultaneously, the",
"    <span class=\"nowrap\">",
"     proliferative/destructive",
"    </span>",
"    component of synovitis is generated by TNF, IL-17, bone morphogenic proteins, and TGF&beta;.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mast cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mice that lack mast cells are resistant to inflammatory and erosive arthritis induced by arthritogenic serum, and re-engraftment with mast cells restores their susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/119\">",
"     119",
"    </a>",
"    ]. Combining several channels of information, it has been posited that after mast cells are activated by complement, autoantibodies, and cytokines their secreted products (eg, histamine, TNF, IL-17, potent proteases tryptase and chymase, etc.) activate chondrocytes, synovial fibroblasts, and macrophages to produce metalloproteinases, cytokines and prostaglandins that all contribute to joint destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/120\">",
"     120",
"    </a>",
"    ]. In addition, these products (especially histamine) induce localized tissue edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9030106\">",
"    <span class=\"h1\">",
"     TISSUE REACTION AND MATRIX REMODELING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Fibroblast-like synoviocytes in the intimal lining",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative contributions of resident synovial cells and infiltrating inflammatory cells from beyond the joint have been debated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. Data from a",
"    <span class=\"nowrap\">",
"     K/BxN",
"    </span>",
"    mouse model indicate that far from serving as an innocent bystander in immune-mediated arthritis, the synovium regulates the entry and behavior of inflammatory cells and also its own capacity to damage specific parts of its environment. An integral membrane protein known as cadherin-11 appears to play a critical role in these processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. The following points are relevant to this discussion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cadherin-11 mediates the organization and invasion of fibroblast-like synoviocytes into synovial tissue through cell-cell interactions.",
"     </li>",
"     <li>",
"      Cadherin-11 appears to mediate the migration of fibroblast-like synoviocytes over the articular cartilage, leading to damage.",
"     </li>",
"     <li>",
"      In the absence of cadherin-11, the synovium is disorganized and demonstrates diminished production of extracellular matrix molecules.",
"     </li>",
"     <li>",
"      Mice deficient in cadherin-11 are resistant to inflammatory arthritis.",
"     </li>",
"     <li>",
"      Cadherin-11 is a cell-surface molecule. Thus, it represents a potential therapeutic target for controlling inflammatory arthritis because it is relative accessible to exogenous agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of multiple cytokines, induced via transcription factors, such as nuclear factor kappa B (NF-kB) and MAP kinase results in a \"transformed phenotype\" of synovial lining cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. This phenotype also arises in part by the induction of Fos and Jun (by NF-kB) which act as transactivators and induce the biosynthesis of metalloproteinases that destroy cartilage, tendons, and bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/126\">",
"     126",
"    </a>",
"    ]. Mitogen-activated protein kinase (MAPK) cascades are involved in inflammation and tissue destruction in RA, as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/127\">",
"     127",
"    </a>",
"    ]. In particular, c-Jun N-terminal kinase (JNK) is a critical MAPK pathway for IL-1-induced collagenase gene expression, and therefore could be an important therapeutic target for RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/128\">",
"     128",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17846?source=see_link&amp;anchor=H7#H7\">",
"     \"Principles of molecular genetics\", section on 'RNA transcription'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MAP kinase activators (eg, c-Raf-1) and one of its downstream transcription factors, c-Myc, appear to act additively to induce the growth and invasiveness of rheumatoid synovium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/129\">",
"     129",
"    </a>",
"    ]. Other cytokine independent pathways of synovial cell activation include endogenous retroviral elements and Toll-like receptors connected by a complex network of autocrine and paracrine acting factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although exhibiting some evidence reminiscent of transformed cells, the synoviocytes are distinguished from truly transformed cells by the fact that they are not immortalized. However, they have a powerful capacity to invade connective tissue of cartilage and tendon, may stimulate the differentiation and activation of osteoclasts, and can migrate from joint to joint in pre-clinical models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/131-133\">",
"     131-133",
"    </a>",
"    ]. It is also notable that the embryonic growth and differentiation factor pleiotrophin that is expressed in certain human cancers is also expressed in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike synovial fibroblasts from healthy people, the cells from patients with RA when transferred to immunodeficient mice invade and destroy cartilage and bone. Despite evidence for damaged DNA in synovial cells, sensitive techniques only rarely show evidence for apoptosis (programmed cell death) in synovial lining cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/135\">",
"     135",
"    </a>",
"    ]. Limited apoptosis may contribute to the synovial lining cell hyperplasia in the rheumatoid tissues. This possibly is related to somatic mutations in p53 tumor suppressor, a key regulator of DNA repair and cell replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/29\">",
"     29",
"    </a>",
"    ]. The loss of p53 function enhances synoviocyte proliferation in animal models and increases the invasiveness of inflamed synovium into cartilage explants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of these properties may be related to expression of particular hyaluronate binding proteins due to variant splicing of mRNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/137\">",
"     137",
"    </a>",
"    ]. Many of these synovial lining cells are of fibroblast not macrophage lineage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/126\">",
"     126",
"    </a>",
"    ]. Those cells with a macrophage phenotype may accumulate due to a resistance to Fas-mediated apoptosis, mediated by the expression of the Fas-associated death domain-like interleukin-1&beta;- converting enzyme-inhibitory protein (FLIP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/138\">",
"     138",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3754?source=see_link\">",
"     \"Synovial pathology in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When fibroblast-like synovial cells are cultured on articular cartilage, MMP-13 (collagenase 3) is produced by the cells; this may be the mechanism by which the rheumatoid synovial pannus is attracted to and begins invading cartilage at the periphery of inflamed joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/139\">",
"     139",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Cartilage destruction'",
"    </a>",
"    below.) MMP-13 has close homologies of structure and similarities of action with the first collagenase described, MMP-1. Because of its avidity for type II collagen as a substrate, however, and its induction by cell attachment to cartilage, it may be the primary MMP involved in joint destruction. MMP-13 is produced by synovial fibroblasts, not macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/140\">",
"     140",
"    </a>",
"    ]. A chemokine, stromal cell-derived factor (SDF)-1, found to be produced in significant quantity in rheumatoid synovitis, increases the secretion of MMP-13 in cultured human chondrocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with many other biologic systems, there is a metalloproteinase cascade. For example, collagenase-1 (MMP-1) is released from cells as a pro-enzyme. Subsequently, MMP-3 (stromelysin), which has no collagenolytic activity but can degrade multiple other substrates including break-down products of collagen and type IV (basement membrane) collagen, activates procollagenase to collagenase, often in concert with plasmin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another feature of fibroblast-like synoviocytes from rheumatoid synovium that may be related to treatment is their elevated adenosine deaminase 1 activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/143\">",
"     143",
"    </a>",
"    ]. Adenosine has antiinflammatory properties that could be decreased by such enzyme activity, and enhancement of adenosine production by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy is one mechanism that has been postulated to explain the efficacy of this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/143\">",
"     143",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link&amp;anchor=H3#H3\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cartilage destruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activated rheumatoid synovium eventually destroys cartilage at the cartilage-pannus junction. There are several different ways in which cartilage is degraded:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most common is direct invasion by the synovial cells into cartilage. Using electron microscopy, a 0.5 &ndash; 1.0 micron amorphous zone can be found between the cell processes and relatively intact cartilage, indicating that proteases released from the invasive cells are bringing about the degradation of the glycosaminoglycans and collagen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/144\">",
"       144",
"      </a>",
"      ]. Proteoglycans (chondroitin sulfate, keratan sulfate, etc) are degraded early in the inflammatory process; the loss of collagen takes longer.",
"     </li>",
"     <li>",
"      Rarely, pockets of neutrophils are observed at the",
"      <span class=\"nowrap\">",
"       cartilage/pannus",
"      </span>",
"      junction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/145\">",
"       145",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rare are areas of rapid chondrolysis; these areas include synovial lining cells which have phagolysosomes containing engulfed fragments of cartilage collagen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/146\">",
"       146",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One major quandary in rheumatology has been attempting to understand the forces that attract proliferative synovium to destroy cartilage. After a critical mass of synovitis has accumulated within a joint, the synovium invades the edge of cartilage at the joint capsule. Possible reasons for this invasion, which are not mutually exclusive, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune complexes deposited with activated complement components within superficial layers of cartilage that become attractants for synovial tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/147\">",
"       147",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inflammatory mediators (principally metalloproteinases) deplete the superficial layer of proteoglycans in cartilage, thereby exposing collagen and fibronectin that readily bind synovial cells to the residual cartilage matrix and induce MMP-13 production [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/139,148\">",
"       139,148",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The strong reactivity of T lymphocytes for chondrocyte membranes (exposed by action of proteases on the cartilage) may attract these cells along with accompanying connective tissue cells and synovial matrix [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gene transfer studies in vitro have shown that a cell surface-targeted plasmin inhibitor can retard synovial fibroblast-dependent cartilage degradation, confirming the importance of the plasminogen activation system in synovial fibroblasts in the invasion of articular cartilage in RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/150\">",
"       150",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autoimmune activation by citrullinated peptides (eg, citrullinated fibrin) in the synovium.",
"     </li>",
"     <li>",
"      Fibroblast-like synoviocytes that express cadherin-11 bind to and invade into cartilage. Animal models of arthritis show that depletion of these cells prevents cartilage damage even though bone erosions continue to progress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Simultaneous with degradation of cartilage is the cellular destruction of subchondral bone. Osteoclasts and chondroclasts activated by synovial cytokines and cathepsins B and L add to the destructive capacity of metalloproteinases in destroying bone. The role of immune cells in osteoclast activation is now widely recognized. Activated T cells and bone marrow stromal cells produce receptor activator of nuclear factor kB ligand (RANKL), that is essential for the differentiation, activation, and survival of osteoclasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/151\">",
"     151",
"    </a>",
"    ]. IL-18, mainly produced by macrophages in RA, has similar proinflammatory effects as does TNF-alpha, and also induces RANKL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monocyte migration is also enhanced by RANKL an effect that could favor the accumulation of osteoclast precursors in the synovium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/153\">",
"     153",
"    </a>",
"    ]. A modulator of this is osteoprotegerin (OPG), a soluble receptor that competitively binds RANKL. An anti-RANKL antibody decreases bone erosion in RA, but has no effect on clinical signs and symptoms or cartilage damage in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Metalloproteinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The destruction of cartilage, bone, and tendons in RA is initiated largely by metalloproteinases. As noted above, stromelysin (metalloproteinase-3, MMP-3) is an important protease because it degrades cartilage proteoglycans, fibronectin, type IV collagen in basement membrane, and activates collagenase. Patients who are homozygous for a polymorphism in the promoter region of the gene for MMP-3 have more rapid radiographic progression of erosive disease than those without this genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/155\">",
"     155",
"    </a>",
"    ]. The role of MMP-13 has already been discussed. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Fibroblast-like synoviocytes in the intimal lining'",
"    </a>",
"    above.) Macrophage elastase (MMP 12) and mRNA for this MMP are elevated in rheumatoid synovium in comparison with osteoarthritis tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These enzymes are generated principally by the proliferating synovial lining cells at the invasive margin of synovium. Invasive tenosynovium may produce larger amounts of metalloproteinases than adjacent but noninvasive synovial tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/157\">",
"     157",
"    </a>",
"    ]. Increased expression of receptors for immunoglobulin is associated with enhanced production of these enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/158\">",
"     158",
"    </a>",
"    ]. Despite abundant evidence suggesting that metalloproteinases are critical for matrix destruction, several inhibitors have been ineffective in RA. Stromelysin deficient mice also have normal amounts of bone destruction in animal models of arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Glycosidases and Aggrecanase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enzymes that are capable of removing portions of the carbohydrate side-chains of glycosaminoglycans (glycosidases) might also play a role in cartilage destruction in RA. In vitro, exposure of human articular cartilage to glycosidases results in depletion of glycosaminoglycans to a similar extent as does digestion with MMPs 1 and 9 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/159\">",
"     159",
"    </a>",
"    ]. ADAMTS-4 is the major aggrecanase that degrades the interglobular domain of glycosaminoglycans, producing an aggrecanase-specific neoepitope. It is a valid target for inhibitory molecules for future therapy in joint diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/160\">",
"     160",
"    </a>",
"    ]. Aggrecanase deficiency protects mice from osteoarthritis, suggesting that this might be a better target than metalloproteinases for protecting the extracellular matrix in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bone destruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of joint pathology in RA is one of progressive bone and joint destruction with the absence of any sign of bone repair in response to inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/162,163\">",
"     162,163",
"    </a>",
"    ]. At sites of active RA, there is a dramatic imbalance of bone turnover in which local bone resorption outweighs bone formation.",
"   </p>",
"   <p>",
"    This pattern contrasts dramatically with that observed in other forms of destructive arthritis (eg, ankylosing spondylitis and psoriatic arthritis), which are characterized by new bone formation even as joint destruction progresses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/164\">",
"     164",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several major contributors to the destruction of bone in RA have been elucidated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor necrosis factor &mdash; TNF promotes the destruction of bone by increasing the number of osteoclasts and decreasing the number of osteoblasts at the site of inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/165\">",
"       165",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RANK ligand &mdash; The receptor activator of NF-kappa B ligand (RANK ligand) regulates osteoclast-mediated destruction of the joint architecture.",
"     </li>",
"     <li>",
"      Cathepsin K &mdash; This protease is active at acidic pH and is unusual for its ability to degrade native collagen fibrils as do certain of the MMP family. It is found in osteoclasts and is induced in osteoarthritic cartilage and in inflamed synovial tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/166\">",
"       166",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Wnt pathway &mdash; In contrast to TNF and RANK ligand, the Wnt signaling pathway serves as a master controller of bone formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/167,168\">",
"       167,168",
"      </a>",
"      ]. Wnt signaling represses the differentiation of mesenchymal progenitors into adipocytes and chondrocytes and promotes their differentiation into osteoblasts, the cells that lay down bone.",
"      <br/>",
"      <br/>",
"      Wnt also inhibits osteoclast formation by positively regulating osteoblast expression of osteoprotegerin (OPG), a soluble inhibitor of RANKL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/164,169,170\">",
"       164,169,170",
"      </a>",
"      ]. Thus, the Wnt pathway both boosts bone formation by fostering osteoblast activity in RA and impairs bone resorption through inhibition of osteoclasts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/171\">",
"       171",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Dickkopf (DKK) family &mdash; The DKK family, particularly DKK-1, is a group of secreted proteins that inhibits the Wnt pathway by binding to the Wnt receptor and a cell surface coreceptor,",
"      <span class=\"nowrap\">",
"       Kremen-1/2.",
"      </span>",
"      DKK binding induces internalization of the receptor complex, thereby reducing Wnt signaling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/167,168\">",
"       167,168",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of three different laboratory models of RA, a rat monoclonal antibody to mouse DKK-1 was employed to inhibit DKK-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/164\">",
"     164",
"    </a>",
"    ]. In all three models, DKK-1 inhibition protected against bone erosions and structural damage of the joint, even in the presence of ongoing inflammation.",
"   </p>",
"   <p>",
"    In human disease, DKK-1 levels are elevated in the sera of patients with RA and within inflamed RA synovium. In contrast, serum levels of DKK-1 in ankylosing spondylitis are low compared with those of healthy controls. The well established demonstration of inhibition of bone erosions by anti-TNF therapy in RA may in part be explained by the observation that circulating DKK-1 levels are normalized by this intervention, with consequential restoration of Wnt signaling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/164\">",
"     164",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     B LYMPHOCYTES AND AUTOANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid factors are immunoglobulins (Ig) reactive against epitopes on the Fc portion of IgG. Compared to those with \"seronegative\" RA, patients with polyarticular symmetrical arthritis who have a persistently positive test for rheumatoid factor (RF) are likely to have more erosions of bones and joints, more extraarticular manifestations, and worse function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/172\">",
"     172",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The production of rheumatoid factors results in part from the help provided from a specific subset of T cells to rheumatoid factor precursor B cells. Since T cells reactive with autologous IgG have not been identified in patients with RA, it is likely that these T cells react with antigen(s), and then bind to specific B lymphocytes which proliferate.",
"   </p>",
"   <p>",
"    One such putative antigen is p205, a protein of unknown function that is present in synovium and synovial fluid. It has been reported to be a very effective stimulator of T-cells of patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/173\">",
"     173",
"    </a>",
"    ]. p205 possesses sequences of peptides with a high degree of similarity to those of the 3rd and 4th constant regions of the heavy chain of immunoglobulins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/174\">",
"     174",
"    </a>",
"    ]. This \"molecular mimicry\" may promote the development of rheumatoid factors.",
"   </p>",
"   <p>",
"    The helper T cells are probably",
"    <span class=\"nowrap\">",
"     CD4+/CD45RA-/CD45RO+/CD45RB(dim)/CD27-",
"    </span>",
"    cells. Such cells are terminally differentiated, produce little IL-2, and presumably have differentiated in synovium in response to recurrent stimulation by arthritogenic peptides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/175\">",
"     175",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IL-10 is generally considered to be a Th2 cell product that, in concert with IL-4, can downregulate inflammatory arthritis (see above). The levels of this cytokine are elevated in RA, although it is probably made by macrophages in the synovium, and it may have a role in activating B cells by inducing their proliferation and immunoglobulin production in the absence of specific antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/176,177\">",
"     176,177",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed in more detail elsewhere, anti-citrullinated peptide antibodies (ACPA) are relatively specific for RA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"    </a>",
"    .) Citrulline is formed by the action of peptidylarginine deiminases (PADIs) on peptidylarginine. PADIs are expressed at high levels in inflamed rheumatoid synovium; one major substrate appears to be fibrin. The immunoreactivity of citrullinated fibrin with IgA and IgM in the RA synovium and the colocalization of PADI and citrullinated peptides supports the notion that citrullinated fibrin is a potential autoantigen of RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/44,178\">",
"     44,178",
"    </a>",
"    ]. A second system of antibodies against proteins modified by carbamylation rather than citrullination has been described in ACPA-negative patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/179\">",
"     179",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACPAs are present in the earliest stages of disease in almost 70 percent of rheumatoid patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/180\">",
"     180",
"    </a>",
"    ]. B cell precursors for ACPAs are present in patients with RA and in healthy controls and can be stimulated by activation to produce these antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/181\">",
"     181",
"    </a>",
"    ]. Thus, it follows that such deiminated antigens formed in the synovium could be involved in driving the local antibody response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Affinity maturation of autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatic rearrangement of germline genes is a crucial factor in the eventual development of rheumatoid factors with a higher affinity for IgG than the original rheumatoid factors. This \"affinity maturation\" is probably an antigen-driven process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/182\">",
"     182",
"    </a>",
"    ]. During this process, rheumatoid factors change from being polyreactive with low affinity for many antigens (eg, insulin, tetanus toxoid, beta-2-microglobulin) to being monoreactive with a much higher affinity for human Fc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/183\">",
"     183",
"    </a>",
"    ]. In addition, the tight complexes between monoreactive rheumatoid factor and IgG can activate complement. Additional polyreactive rheumatoid factors are generated as a secondary response, and via reactivity with epitopes such as type II collagen, may focus and enhance joint inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Rheumatoid factor and immune complexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another factor that amplifies the inflammatory potential of rheumatoid factors is the propensity for IgG RF to self-associate into large lattice-like complexes. These complexes can be found in all tissues of the rheumatoid joint, and may help concentrate additional material within this structure. As an example, within the superficial layers of articular cartilage in rheumatoid joints are rheumatoid factor-IgG complexes, antibodies against native and denatured type II cartilage collagen, and activated components of complement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/184\">",
"     184",
"    </a>",
"    ]. Cartilage destruction is facilitated by proteolytic degradation of matrix components by enzymes such as neutrophil elastase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/185\">",
"     185",
"    </a>",
"    ]. In addition, immune complexes isolated from synovial fluids may stimulate the production of TNF from",
"    <span class=\"nowrap\">",
"     monocytes/macrophages",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/186\">",
"     186",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Cytokine networks in rheumatoid arthritis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Galactose and IgGs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no data implicate it as a causative factor for RA, IgG from rheumatoid patients have fewer galactose residues at certain sites in the constant region at the Fc position. This finding is a probable consequence of a B cell deficiency of galactosyl-transferase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/187,188\">",
"     187,188",
"    </a>",
"    ], and may be associated with more active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/189\">",
"     189",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Antibodies to glucose-6-phosphate isomerase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serendipitous discovery of a strain of T-cell receptor transgenic mice that spontaneously develop chronic arthritis with histologic features similar to RA led to identification of a widely distributed enzyme, glucose-6-phosphate isomerase (GPI), as an autoantigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/190\">",
"     190",
"    </a>",
"    ]. Antibodies to this protein probably do not play a major role in RA, although they provide lessons on how autoreactivity against a ubiquitous antigen might result in joint specific inflammation. In this case, the protein probably coats the surface of cartilage and is displayed in a way that optimizes complement fixation in the presence of antibody. Anti-GPI antibodies are present in a relatively low percentage of RA patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/191\">",
"     191",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data suggest that the prevalence of anti-GPI antibodies may correlate with extraarticular manifestations of RA. As an example, in a study of 131 Dutch patients, the proportions with anti-GPI antibodies were as follows: in uncomplicated disease: 5 percent; in those with rheumatoid nodules: 18 percent; rheumatoid vasculitis: 45 percent; and Felty syndrome: 92 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/192\">",
"     192",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Clinical effect of B lymphocyte depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional support for a role of B lymphocytes in the pathogenesis of RA comes from beneficial effects on joint inflammation observed in clinical trials of B lymphocyte depletion. A more detailed discussion of the clinical application of B cell depletion is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Synovial biopsy studies before and after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy show that synovial B cell depletion is less effective than in the blood and that tissue depletion is necessary but not sufficient for clinical efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/193\">",
"     193",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9030247\">",
"    <span class=\"h1\">",
"     SYNOVIAL FLUID IN RHEUMATOID ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial fluid characteristics are much different from those in the synovium. For example, neutrophils are rarely seen in RA synovium but are abundant in RA synovial effusions. Also, the CD4:CD8 cell ratio is reversed in synovial effusions, with a predominance of CD4+ T cells in the tissue while CD8+ cells are more prevalent in the fluid.",
"   </p>",
"   <p>",
"    Polymorphonuclear leukocytes are attracted to the joint, penetrate through synovial blood vessels, and quickly move into the joint space. In very active disease, up to one billion cells may gain access to a rheumatoid knee joint each day, while few if any leave the joint and are degraded.",
"   </p>",
"   <p>",
"    Polymorphonuclear leukocytes subsequently deposit gene products (released from the cells after being synthesized) and the contents of granules (from three types: azurophil, specific, and \"C\") in the synovial fluid. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myeloperoxidase",
"     </li>",
"     <li>",
"      Elastase",
"     </li>",
"     <li>",
"      Lysozyme",
"     </li>",
"     <li>",
"      Collagenase",
"     </li>",
"     <li>",
"      Acid hydrolases",
"     </li>",
"     <li>",
"      Matrix metalloproteinases",
"     </li>",
"     <li>",
"      Interleukin-1 beta",
"     </li>",
"     <li>",
"      Prostaglandins",
"     </li>",
"     <li>",
"      Platelet activating factor (PAF)",
"     </li>",
"     <li>",
"      Leukotrienes, including leukotriene B4",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These products, once released into the synovial fluid, can cause considerable damage and potentiate inflammation in the adjacent synovium. In addition, since leukotriene B4 and PAF are among the most potent chemoattractants known, activated neutrophils are able to recruit additional neutrophils in an autocrine fashion.",
"   </p>",
"   <p>",
"    Activated leukocytes also produce oxygen-derived free radicals, which are atoms or molecules with an unpaired electron occupying an outer orbit. Such products are very damaging. The most toxic, hydroxyl ion, is very short-lived. Ferrous iron, abundant in synovium because of microhemorrhages, helps catalyze hydroxyl ion formation and enhances metalloproteinase biosynthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/194\">",
"     194",
"    </a>",
"    ]. Additional reactive species, including N-chloramines and hypochlorous acid (eg, bleach) are also formed, and may have deleterious effects upon cells and proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/195\">",
"     195",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been known for more than 40 years that rheumatoid synovial fluid has a low oxygen tension. It has become appreciated that hypoxia is an important factor in aggravating the inflammatory lesion in RA through increased production of COX-2-derived nociceptive eicosanoids and increased production by synovial cells of MMPs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/196\">",
"     196",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     COMPLEMENT ACTIVATION AND IMMUNE COMPLEXES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement activation and its interactions with immune complexes are important in RA, especially in synovial effusions and at the cartilage-interface. They could also play a role in the initiation of RA through complement fixation by ACPAs in the tissue. Their importance is implied by at least two observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activated complement components have intrinsic inflammatory activity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=see_link\">",
"       \"Overview and clinical assessment of the complement system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Activation of complement often indicates the presence of immune complexes of sufficient size to independently activate the entire system. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11190?source=see_link\">",
"       \"Complement pathways\"",
"      </a>",
"      .) Immune complexes can also generate secondary antibody responses towards T cell-dependent antigens, and activate memory B cells and plasma cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific receptors for the Fc portion of Ig (eg, Fcg-RI, -RII, and -RIII) are found on most inflammatory cells. These complexes help clear immune complexes from the plasma after the immune complexes have fixed complement.",
"   </p>",
"   <p>",
"    In patients with active rheumatoid synovitis, but few extraarticular manifestations, C3, C4, and CH50 levels are usually normal or increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/197\">",
"     197",
"    </a>",
"    ]. However, the concentration in plasma of covalently bound complexes of C1q-C4, a putative marker of complement activation, appears to increase in conjunction with more active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/198\">",
"     198",
"    </a>",
"    ]. In joint fluids, for example, polymorphonuclear leukocytes often have inclusions containing IgG, IgM, and",
"    <span class=\"nowrap\">",
"     C3/C4",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/199\">",
"     199",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C3a is a product of C3 activation which increases capillary permeability. C3a is inactivated by an enzyme that cleaves its terminal arginine residue (C3adesArg). Levels of both C3a and C3adesArg are elevated in rheumatoid synovial fluids; furthermore, the levels correlate with C-reactive protein (CRP) levels, ESR, and disease activity indices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/200\">",
"     200",
"    </a>",
"    ]. Complement activation mediated by CRP may be decreased during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/201\">",
"     201",
"    </a>",
"    ]. As mentioned above, the deposition of rheumatoid factor-IgG complexes along with complement in superficial layers of articular cartilage may be a major force in attracting invasive synovial cells into cartilage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/184\">",
"     184",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFLAMMATORY MEDIATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional factors, including nitric oxide, neuropeptides, and arachidonic acid metabolites, may play a contributory role in the pathogenesis of RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide (NO) is an uncharged molecule with an unpaired electron generated by NO synthase that catalyzes the conversion of L-arginine and O2 into citrulline and NO. NO synthesis is induced by cytokines in macrophages, synovial cells and chondrocytes. Although well recognized as endothelial-derived relaxing factor, NO has a less well-defined role in inflammatory states. NO may reduce endothelial expression of endothelial adhesion molecules. On the other hand, NO also may interact with superoxide to produce toxic peroxynitrite and, in concert with neutrophils, may be toxic to endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/202,203\">",
"     202,203",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Articular chondrocytes may produce and respond to NO. Induction of NO synthase (iNOS) and subsequent production of NO is stimulated in vitro by fragments of the matrix protein, fibronectin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/204\">",
"     204",
"    </a>",
"    ]; an effect that requires the presence of CD44, a receptor for hyaluronan on the chondrocyte surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Neuropeptides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substance P (SP) is one of several neuropeptides that are released during reverse (antidromic) sensory nerve activation within joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/205\">",
"     205",
"    </a>",
"    ]. SP can activate macrophages, stimulate B cell differentiation, cause fibroblast proliferation, attract neutrophils, and increase expression of cytokines, prostaglandins, and metalloproteinases. SP acts by binding to the neurokinin-1 receptor (NK-1R). Increased levels of SP are found in the synovial fluid and serum of RA patients, and NK &ndash;1R mRNA is upregulated in RA synoviocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/206\">",
"     206",
"    </a>",
"    ]. Continuous external application of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    can deplete substance P from nerve endings, and suppress neurogenic inflammation, thereby benefiting occasional patients with joint pain of diverse etiology.",
"   </p>",
"   <p>",
"    Corticotropin-releasing hormone (CRH) may play a local, proinflammatory role in rheumatoid synovium. Higher concentrations of CRH are found in synovial fluid of patients with RA compared to those with osteoarthritis and a higher density of CRH receptors in synovium is also present in those with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/207,208\">",
"     207,208",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcitonin gene related peptide (CGRP), in contrast to SP and CRH, may have antiinflammatory properties and CGRP containing nerve fiber density is lower in samples of synovium of patient with RA compared to those with OA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/209\">",
"     209",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Arachidonic acid metabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arachidonic acid (AA) is a cell membrane fatty acid that is oxidized to prostaglandins, leukotrienes, and lipoxins; the enzyme responsible for releasing AA from membrane phospholipids is phospholipase A2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/210\">",
"     210",
"    </a>",
"    ]. When injected into animal joints, phospholipase A2 causes a marked inflammatory and proliferative synovitis. Phospholipase A2 is increased in rheumatoid synovial fluids and is inhibited by glucocorticoids; in addition, its synthesis is induced by IL-1 and TNF.",
"   </p>",
"   <p>",
"    Prostaglandins are generated by the actions of cyclooxygenase (COX) on AA. A major role of prostaglandin E2 in RA is to stimulate periarticular bone resorption early in disease, before the development of erosions of bone or cartilage. In one animal model of erosive arthritis, the effect of prostaglandin E2 on bone and cartilage resorption appeared to be mediated through the PGE2 type 4 receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/211\">",
"     211",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the prostaglandins enhance the manifestations of acute inflammation in joints. They incite pain, increase vascular permeability, and potentiate inflammatory effects of other mediators.",
"   </p>",
"   <p>",
"    COX-1 is constitutively expressed by many cells, but COX-2 is inducible by IL-1, TNF, and other cytokines in rheumatoid synovium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/212\">",
"     212",
"    </a>",
"    ]. Knockout mice lacking the COX-2 gene are relatively resistant to the development of collagen-induced arthritis, while those without the COX-1 gene have similar characteristics to wild type mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/213\">",
"     213",
"    </a>",
"    ]. Selective COX-2 inhibitors are currently being used in some patients because they do not inhibit the formation of prostaglandins that protect the stomach and duodenum from acid, and are less likely to produce ulcers or upper gastrointestinal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .) One of these selective COX-2 inhibitors, rofecoxib, has been withdrawn from the market because of an increased frequency of cardiovascular events in patients taking this drug. As yet, there is no definite evidence for a class effect involving other COX-2 inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    5-lipoxygenase also uses arachidonic acid as a substrate. One of its final products, LTB4, is a potent neutrophil chemoattractant (along with IL-8, C5a, and PAF). Specific or useful lipoxygenase inhibitors have not yet been developed for use in RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Clotting factors and fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors responsible for clotting and fibrinolysis may have a role in RA. In addition to serving as the final activator of clot formation by cleaving fibrinogen to fibrin, thrombin is mitogenic for synovial cells, has angiogenic properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/214\">",
"     214",
"    </a>",
"    ], enhances endothelial adhesion molecules and arachidonic acid synthesis, and promotes platelet aggregation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/215\">",
"     215",
"    </a>",
"    ]. Fibrin itself may facilitate cell growth and adhesion within the synovial pannus.",
"   </p>",
"   <p>",
"    Serine proteases that are mediators of fibrinolysis, including plasminogen activators and plasmin, may also contribute to cartilage degradation. Plasminogen activator is present in synovial fluid from patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/216\">",
"     216",
"    </a>",
"    ]. This results in the generation of plasmin which has a major role in the activation of synovial metalloproteinases.",
"   </p>",
"   <p>",
"    Thus, minimizing fibrinolysis with various inhibitors may be beneficial in RA. As an example, the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    to animals with type II collagen-induced arthritis and patients with RA decreased excretion of collagen crosslink fragments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/217\">",
"     217",
"    </a>",
"    ]. In addition, the in vitro transfer of a gene for a serine protease inhibitor to synoviocytes from patients with RA decreased the destructive and invasive capacity of such cells when incubated with human cartilage in vitro or in immunosuppressed (SCID) mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/15/41210/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1656072\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initiation of rheumatoid arthritis (RA) results from a combination of predetermined (genetic) and stochastic (random environmental) events. The HLA major histocompatability genes are the most important, but many other genes are involved and contribute to susceptibility and severity. The most likely mechanism for the environmental component is repeated activation of innate immunity. There is a propensity in RA for immune reactivity to develop to the neoepitopes created by the protein citrullination that results from environmental stressors, such as smoking; this leads to the production of anti-citrullinated protein antibodies (ACPA) that could initiate inflammation by fixing complement in the tissues. Like autoantibodies, levels of multiple cytokines gradually increase in the years before RA symptoms occur. (See",
"      <a class=\"local\" href=\"#H28538780\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the autoimmune process is established, the synovium in RA organizes itself into an invasive tissue that can degrade cartilage and bone. The rheumatoid synovium has many characteristics of a locally-invasive malignancy, but it never becomes completely unresponsive to antiinflammatory and antiproliferative factors. (See",
"      <a class=\"local\" href=\"#H28538780\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Activation of innate immunity is probably the earliest process in RA, followed by citrullination, loading of antigen presenting cells (APCs) with autoantigens in the joint, and then migration to central lymphoid organs. Once there, APCs present an array of antigens to T cells, which can then activate B cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      can migrate back to the synovium. It is unlikely that a single &ldquo;rheumatoid antigen&rdquo; exists. Instead, a broad spectrum of joint specific antigens, such a type II collagen or nonspecific citrullinated antigens, is responsible. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'T lymphocytes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One of the earliest histopathologic responses in RA is the generation of new synovial blood vessels, which is accompanied by the transudation of fluid and the transmigration of both lymphocytes into the synovium and of polymorphonuclear leukocytes into the synovial fluid. As the new vessels develop, cytokines produced in the synovium in response to tumor necrosis factor (TNF) activate endothelial cells to produce adhesion molecules, which expedite activation-dependent sticking of leukocytes, thereby facilitating diapedesis and extravasation into the synovium. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Angiogenesis and inflammatory cell recruitment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autocrine and paracrine communication through the elaboration of a cascading network of proinflammatory cytokines plays a key role in initiation and perpetuation of RA and result in a &ldquo;transformed phenotype&rdquo; of synovial lining cells. Inflammatory cells are recruited to the bland synovium by the actions of interleukin (IL)-17A, TNF, IL-1, IL-6, IL-18, vascular endothelial growth factor, and chemokines. Retention in the synovium is facilitated by inhibition of apoptosis and other innate immunity mechanisms by interferon (IFN)-&alpha; and -&beta;, IL-15, and TNF. The T cells become organized and activated in the presence of IL-23, IL-27, IL-12, IL-15, IL-18, and chemokines. Simultaneously, the",
"      <span class=\"nowrap\">",
"       proliferative/destructive",
"      </span>",
"      component of synovitis is generated by TNF, IL-17, bone morphogenic proteins, and transforming growth factor-&beta;. Mast cell products may also have an important role. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cytokine networks in rheumatoid arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cadherin-11, a synovial fibroblast membrane protein, may mediate the organization and invasion of fibroblast-like synoviocytes into synovial tissue. Activated rheumatoid synovium eventually destroys cartilage at the cartilage-pannus junction. The destruction of cartilage, bone, and tendons in RA is initiated largely by metalloproteinases. At sites of active RA, there is a dramatic imbalance of bone turnover in which local bone resorption outweighs bone formation. (See",
"      <a class=\"local\" href=\"#H9030106\">",
"       'Tissue reaction and matrix remodeling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The precise role of B cells and autoantibodies, such as rheumatoid factors and ACPA, is uncertain, although antibody complexes may initiate or enhance joint inflammation. The role of B cells is further supported by the therapeutic effect of B cell targeted biologic agents. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'B lymphocytes and autoantibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cellular components of rheumatoid synovial fluid differ from those in the synovium. As examples, neutrophils are rarely seen in RA synovium but are abundant in RA synovial effusions, and there is a predominance of CD4+ T cells in the tissue while CD8+ cells are typically more prevalent in the fluid. Products of neutrophils that are released into the synovial fluid can cause considerable damage and can potentiate inflammation in the adjacent synovium. (See",
"      <a class=\"local\" href=\"#H9030247\">",
"       'Synovial fluid in rheumatoid arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complement activation and its interactions with immune complexes are important in RA, especially in synovial effusions and at the cartilage interface. Additional factors, including nitric oxide, neuropeptides, and arachidonic acid metabolites, may play a contributory role in the pathogenesis of RA. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Complement activation and immune complexes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Additional inflammatory mediators'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/1\">",
"      Rothschild BM, Turner KR, DeLuca MA. Symmetrical erosive peripheral polyarthritis in the Late Archaic Period of Alabama. Science 1988; 241:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/2\">",
"      Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/3\">",
"      Lundstr&ouml;m E, K&auml;llberg H, Alfredsson L, et al. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum 2009; 60:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/4\">",
"      Maciejewska Rodrigues H, J&uuml;ngel A, Gay RE, Gay S. Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. Mol Immunol 2009; 47:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/5\">",
"      Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008; 67:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/6\">",
"      Wegner N, Lundberg K, Kinloch A, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010; 233:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/7\">",
"      Arend WP, Firestein GS. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol 2012; 8:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/8\">",
"      Deane KD, O'Donnell CI, Hueber W, et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum 2010; 62:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/9\">",
"      Snir O, Widhe M, Hermansson M, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010; 62:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/10\">",
"      Liu MF, Kohsaka H, Sakurai H, et al. The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Arthritis Rheum 1996; 39:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/11\">",
"      MacDonald KP, Nishioka Y, Lipsky PE, Thomas R. Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest 1997; 100:2404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/12\">",
"      Rissoan MC, Van Kooten C, Chomarat P, et al. The functional CD40 antigen of fibroblasts may contribute to the proliferation of rheumatoid synovium. Clin Exp Immunol 1996; 106:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/13\">",
"      Warrington KJ, Takemura S, Goronzy JJ, Weyand CM. CD4+,CD28- T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arthritis Rheum 2001; 44:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/14\">",
"      Goronzy JJ, Matteson EL, Fulbright JW, et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2004; 50:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/15\">",
"      Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996; 97:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/16\">",
"      Zhang X, Nakajima T, Goronzy JJ, Weyand CM. Tissue trafficking patterns of effector memory CD4+ T cells in rheumatoid arthritis. Arthritis Rheum 2005; 52:3839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/17\">",
"      de Vries N, Tijssen H, van Riel PL, van de Putte LB. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67-74 of the HLA-DRB1 molecule. Arthritis Rheum 2002; 46:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/18\">",
"      du Montcel ST, Michou L, Petit-Teixeira E, et al. New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheum 2005; 52:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/19\">",
"      Michou L, Croiseau P, Petit-Teixeira E, et al. Validation of the reshaped shared epitope HLA-DRB1 classification in rheumatoid arthritis. Arthritis Res Ther 2006; 8:R79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/20\">",
"      Woulfe SL, Bono CP, Zacheis ML, et al. Negatively charged residues interacting with the p4 pocket confer binding specificity to DRB1*0401. Arthritis Rheum 1995; 38:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/21\">",
"      Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/22\">",
"      Liu Y, Linsley PS. Costimulation of T-cell growth. Curr Opin Immunol 1992; 4:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/23\">",
"      Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/24\">",
"      Jenkins MK, Ashwell JD, Schwartz RH. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol 1988; 140:3324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/25\">",
"      Nelson JL, Hughes KA, Smith AG, et al. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med 1993; 329:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/26\">",
"      Verwilghen J, Lovis R, De Boer M, et al. Expression of functional B7 and CTLA4 on rheumatoid synovial T cells. J Immunol 1994; 153:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/27\">",
"      Mountz JD, Zhou T, Long RE, et al. T cell influence on superantigen-induced arthritis in MRL-lpr/lpr mice. Arthritis Rheum 1994; 37:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/28\">",
"      Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 1996; 39:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/29\">",
"      Firestein GS, Echeverri F, Yeo M, et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 1997; 94:10895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/30\">",
"      Maas K, Westfall M, Pietenpol J, et al. Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. Arthritis Rheum 2005; 52:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/31\">",
"      Nagashima T, Okazaki H, Yudoh K, et al. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 2006; 54:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/32\">",
"      B&auml;cklund J, Carlsen S, H&ouml;ger T, et al. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci U S A 2002; 99:9960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/33\">",
"      Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977; 146:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/34\">",
"      Terato K, Harper DS, Griffiths MM, et al. Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 1995; 22:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/35\">",
"      He X, Kang AH, Stuart JM. Accumulation of T cells reactive to type II collagen in synovial fluid of patients with rheumatoid arthritis. J Rheumatol 2000; 27:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/36\">",
"      Nissim A, Winyard PG, Corrigall V, et al. Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint. Arthritis Rheum 2005; 52:3829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/37\">",
"      Cope AP, Patel SD, Hall F, et al. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. Arthritis Rheum 1999; 42:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/38\">",
"      Kavanaugh A, Genovese M, Baughman J, et al. Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial. J Rheumatol 2003; 30:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/39\">",
"      Baeten D, Steenbakkers PG, Rijnders AM, et al. Detection of major histocompatibility complex/human cartilage gp-39 complexes in rheumatoid arthritis synovitis as a specific and independent histologic marker. Arthritis Rheum 2004; 50:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/40\">",
"      Grinnell S, Yoshida K, Jasin HE. Responses of lymphocytes of patients with rheumatoid arthritis to IgG modified by oxygen radicals or peroxynitrite. Arthritis Rheum 2005; 52:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/41\">",
"      Uesugi M, Hayashi T, Jasin HE. Covalent cross-linking of immune complexes by oxygen radicals and nitrite. J Immunol 1998; 161:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/42\">",
"      De Rycke L, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004; 63:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/43\">",
"      Masson-Bessi&egrave;re C, Sebbag M, Girbal-Neuhauser E, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001; 166:4177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/44\">",
"      De Rycke L, Nicholas AP, Cantaert T, et al. Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arthritis Rheum 2005; 52:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/45\">",
"      Takizawa Y, Suzuki A, Sawada T, et al. Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 2006; 65:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/46\">",
"      Kinloch A, Lundberg K, Wait R, et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum 2008; 58:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/47\">",
"      Cantaert T, De Rycke L, Bongartz T, et al. Citrullinated proteins in rheumatoid arthritis: crucial...but not sufficient! Arthritis Rheum 2006; 54:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/48\">",
"      Bongartz T, Cantaert T, Atkins SR, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2007; 46:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/49\">",
"      Auger I, Sebbag M, Vincent C, et al. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 2005; 52:3424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/50\">",
"      Verpoort KN, Cheung K, Ioan-Facsinay A, et al. Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum 2007; 56:3949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/51\">",
"      Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005; 52:3433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/52\">",
"      Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/53\">",
"      Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006; 65:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/54\">",
"      Lee HS, Irigoyen P, Kern M, et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum 2007; 56:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/55\">",
"      Verpoort KN, Papendrecht-van der Voort EA, van der Helm-van Mil AH, et al. Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles. Arthritis Rheum 2007; 56:2913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/56\">",
"      Holers VM. Are anti-cyclic citrullinated peptide antibodies pathogenic in rheumatoid arthritis? Nat Clin Pract Rheumatol 2006; 2:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/57\">",
"      Hansotia T, Maida A, Flock G, et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007; 117:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/58\">",
"      van Gaalen F, Ioan-Facsinay A, Huizinga TW, Toes RE. The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis. J Immunol 2005; 175:5575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/59\">",
"      Distler JH, Wenger RH, Gassmann M, et al. Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2004; 50:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/60\">",
"      Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992; 51:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/61\">",
"      Firestein GS. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 1999; 103:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/62\">",
"      Szekanecz Z, Besenyei T, Szentp&eacute;tery A, Koch AE. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2010; 22:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/63\">",
"      Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996; 87:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/64\">",
"      Vlodavsky I, Folkman J, Sullivan R, et al. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A 1987; 84:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/65\">",
"      Sano H, Forough R, Maier JA, et al. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol 1990; 110:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/66\">",
"      Nagashima M, Asano G, Yoshino S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol 2000; 27:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/67\">",
"      Koch AE, Polverini PJ, Leibovich SJ. Stimulation of neovascularization by human rheumatoid synovial tissue macrophages. Arthritis Rheum 1986; 29:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/68\">",
"      Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152:4149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/69\">",
"      Form DM, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Med 1983; 172:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/70\">",
"      Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/71\">",
"      Koch AE, Volin MV, Woods JM, et al. Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum 2001; 44:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/72\">",
"      Gravallese EM, Pettit AR, Lee R, et al. Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 2003; 62:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/73\">",
"      Li RW, Freeman C, Yu D, et al. Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum 2008; 58:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/74\">",
"      Storgard CM, Stupack DG, Jonczyk A, et al. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 1999; 103:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/75\">",
"      DeBusk LM, Chen Y, Nishishita T, et al. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003; 48:2461.",
"     </a>",
"    </li>",
"    <li>",
"     Dayer JM, Arend WP. Cytokines and growth factors. In: Textbook of Rheumatology, Fifth Edition, Kelley WN, Harris ED Jr, Ruddy S (Eds), WB Saunders, Philadelphia 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/77\">",
"      Norioka K, Hara M, Kitani A, et al. Inhibitory effect of human recombinant interleukin-1 alpha and beta on growth of human vascular endothelial cells. Biochem Biophys Res Commun 1987; 145:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/78\">",
"      O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/79\">",
"      O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/80\">",
"      Gerritsen ME, Kelley KA, Ligon G, et al. Regulation of the expression of intercellular adhesion molecule 1 in cultured human endothelial cells derived from rheumatoid synovium. Arthritis Rheum 1993; 36:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/81\">",
"      Lally F, Smith E, Filer A, et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum 2005; 52:3460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/82\">",
"      Gimbrone MA Jr, Obin MS, Brock AF, et al. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Science 1989; 246:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/83\">",
"      Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: the key to inflammation? Ann Rheum Dis 2004; 63:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/84\">",
"      van der Voort R, van Lieshout AW, Toonen LW, et al. Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum 2005; 52:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/85\">",
"      Ruth JH, Haas CS, Park CC, et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum 2006; 54:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/86\">",
"      Morales-Ducret J, Wayner E, Elices MJ, et al. Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J Immunol 1992; 149:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/87\">",
"      FitzGerald O, Soden M, Yanni G, et al. Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. Ann Rheum Dis 1991; 50:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/88\">",
"      Bugatti S, Caporali R, Manzo A, et al. Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment. Arthritis Rheum 2005; 52:3448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/89\">",
"      Yellin M, Paliienko I, Balanescu A, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/90\">",
"      Rommel C. Taking PI3K&delta; and PI3K&gamma; one step ahead: dual active PI3K&delta;/&gamma; inhibitors for the treatment of immune-mediated inflammatory diseases. Curr Top Microbiol Immunol 2010; 346:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/91\">",
"      Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Cytokines in chronic inflammatory arthritis. IV. Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med 1989; 170:865.",
"     </a>",
"    </li>",
"    <li>",
"     Firestein GS. Pathogenesis of rheumatoid arthritis. In: Textbook of Rheumatology, Fifth Edition, Kelley WN, Harris ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/93\">",
"      Brennan FM, Maini RN, Feldmann M. TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/94\">",
"      Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/95\">",
"      Catrina AI, af Klint E, Ernestam S, et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006; 54:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/96\">",
"      McInnes IB, Leung BP, Sturrock RD, et al. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997; 3:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/97\">",
"      Kotake S, Schumacher HR Jr, Yarboro CH, et al. In vivo gene expression of type 1 and type 2 cytokines in synovial tissues from patients in early stages of rheumatoid, reactive, and undifferentiated arthritis. Proc Assoc Am Physicians 1997; 109:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/98\">",
"      Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005; 52:2686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/99\">",
"      Stamp LK, Cleland LG, James MJ. Upregulation of synoviocyte COX-2 through interactions with T lymphocytes: role of interleukin 17 and tumor necrosis factor-alpha. J Rheumatol 2004; 31:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/100\">",
"      Stamp LK, James MJ, Cleland LG. Paracrine upregulation of monocyte cyclooxygenase-2 by mediators produced by T lymphocytes: role of interleukin 17 and interferon-gamma. J Rheumatol 2004; 31:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/101\">",
"      Chabaud M, Lubberts E, Joosten L, et al. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001; 3:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/102\">",
"      Kirkham BW, Lassere MN, Edmonds JP, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006; 54:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/103\">",
"      Hueber AJ, Asquith DL, Miller AM, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010; 184:3336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/104\">",
"      Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2:52ra72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/105\">",
"      Dayer JM. Interleukin-18, rheumatoid arthritis, and tissue destruction. J Clin Invest 1999; 104:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/106\">",
"      Dai SM, Matsuno H, Nakamura H, et al. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum 2004; 50:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/107\">",
"      Joosten LA, Radstake TR, Lubberts E, et al. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2003; 48:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/108\">",
"      Xu D, Jiang HR, Li Y, et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010; 184:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/109\">",
"      Sato K, Nagayama H, Tadokoro K, et al. Interleukin-13 is involved in functional maturation of human peripheral blood monocyte-derived dendritic cells. Exp Hematol 1999; 27:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/110\">",
"      Ziolkowska M, Kurowska M, Radzikowska A, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002; 46:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/111\">",
"      van Roon JA, Verweij MC, Wijk MW, et al. Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4(+) T cells and macrophages. Arthritis Rheum 2005; 52:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/112\">",
"      Harada S, Yamamura M, Okamoto H, et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 1999; 42:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/113\">",
"      Toraldo G, Roggia C, Qian WP, et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A 2003; 100:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/114\">",
"      Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/115\">",
"      Brandes ME, Allen JB, Ogawa Y, Wahl SM. Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991; 87:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/116\">",
"      Berner B, Ak&ccedil;a D, Jung T, et al. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 2000; 27:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/117\">",
"      Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/118\">",
"      McInnes IB, Liew FY. Cytokine networks--towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2005; 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/119\">",
"      Lee DM, Friend DS, Gurish MF, et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002; 297:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/120\">",
"      Woolley DE. The mast cell in inflammatory arthritis. N Engl J Med 2003; 348:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/121\">",
"      Lipsky PE. Why does rheumatoid arthritis involve the joints? N Engl J Med 2007; 356:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/122\">",
"      Lee DM, Kiener HP, Agarwal SK, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007; 315:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/123\">",
"      Kiener HP, Niederreiter B, Lee DM, et al. Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. Arthritis Rheum 2009; 60:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/124\">",
"      Joosten LA, Lubberts E, Durez P, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/125\">",
"      Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995; 38:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/126\">",
"      Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996; 39:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/127\">",
"      Korb A, Tohidast-Akrad M, Cetin E, et al. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum 2006; 54:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/128\">",
"      Han Z, Boyle DL, Chang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001; 108:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/129\">",
"      Pap T, Nawrath M, Heinrich J, et al. Cooperation of Ras- and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2004; 50:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/130\">",
"      Ospelt C, Neidhart M, Gay RE, Gay S. Synovial activation in rheumatoid arthritis. Front Biosci 2004; 9:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/131\">",
"      Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/132\">",
"      Shigeyama Y, Pap T, Kunzler P, et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000; 43:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/133\">",
"      Lef&egrave;vre S, Knedla A, Tennie C, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 2009; 15:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/134\">",
"      Pufe T, Bartscher M, Petersen W, et al. Expression of pleiotrophin, an embryonic growth and differentiation factor, in rheumatoid arthritis. Arthritis Rheum 2003; 48:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/135\">",
"      Catrina AI, Ulfgren AK, Lindblad S, et al. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis 2002; 61:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/136\">",
"      Aupperle KR, Boyle DL, Hendrix M, et al. Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. Am J Pathol 1998; 152:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/137\">",
"      Wibulswas A, Croft D, Pitsillides AA, et al. Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints. Arthritis Rheum 2002; 46:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/138\">",
"      Perlman H, Pagliari LJ, Liu H, et al. Rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein and are refractory to Fas-mediated apoptosis. Arthritis Rheum 2001; 44:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/139\">",
"      Wernicke D, Schulze-Westhoff C, Br&auml;uer R, et al. Stimulation of collagenase 3 expression in synovial fibroblasts of patients with rheumatoid arthritis by contact with a three-dimensional collagen matrix or with normal cartilage when coimplanted in NOD/SCID mice. Arthritis Rheum 2002; 46:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/140\">",
"      Shiozawa S, Yoshihara R, Kuroki Y, et al. Pathogenic importance of fibronectin in the superficial region of articular cartilage as a local factor for the induction of pannus extension on rheumatoid articular cartilage. Ann Rheum Dis 1992; 51:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/141\">",
"      Chiu YC, Yang RS, Hsieh KH, et al. Stromal cell-derived factor-1 induces matrix metalloprotease-13 expression in human chondrocytes. Mol Pharmacol 2007; 72:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/142\">",
"      Okada Y, Nagase H, Harris ED Jr. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem 1986; 261:14245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/143\">",
"      Nakamachi Y, Koshiba M, Nakazawa T, et al. Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts. Arthritis Rheum 2003; 48:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/144\">",
"      Marone G. Mast cells in rheumatic disorders: mastermind or workhorse? Clin Exp Rheumatol 1998; 16:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/145\">",
"      Lees M, Taylor DJ, Woolley DE. Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinases A and B. Eur J Biochem 1994; 223:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/146\">",
"      Harris ED Jr, DiBona DR, Krane SM. A mechanism for cartilage destruction in rheumatoid arthritis. Trans Assoc Am Physicians 1970; 83:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/147\">",
"      Mohr W, Wessinghage D. The relationship between polymorphonuclear granulocytes and cartilage destruction in rheumatoid arthritis. Z Rheumatol 1978; 37:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/148\">",
"      Harris ED Jr, Glauert AM, Murley AH. Intracellular collagen fibers at the pannus-cartilage junction in rheumatoid arthritis. Arthritis Rheum 1977; 20:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/149\">",
"      Cooke TD, Hurd ER, Jasin HE, et al. Identification of immunoglobulins and complement in rheumatoid articular collagenous tissues. Arthritis Rheum 1975; 18:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/150\">",
"      van der Laan WH, Pap T, Ronday HK, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor. Arthritis Rheum 2000; 43:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/151\">",
"      Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/152\">",
"      Dai SM, Shan ZZ, Xu H, Nishioka K. Cellular targets of interleukin-18 in rheumatoid arthritis. Ann Rheum Dis 2007; 66:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/153\">",
"      Mosheimer BA, Kaneider NC, Feistritzer C, et al. Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum 2004; 50:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/154\">",
"      Deodhar A, Dore RK, Mandel D, et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2010; 62:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/155\">",
"      Constantin A, Lauwers-Canc&egrave;s V, Navaux F, et al. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: Association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum 2002; 46:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/156\">",
"      Liu M, Sun H, Wang X, et al. Association of increased expression of macrophage elastase (matrix metalloproteinase 12) with rheumatoid arthritis. Arthritis Rheum 2004; 50:3112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/157\">",
"      Jain A, Nanchahal J, Troeberg L, et al. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. Arthritis Rheum 2001; 44:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/158\">",
"      Blom AB, Radstake TR, Holthuysen AE, et al. Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase. Arthritis Rheum 2003; 48:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/159\">",
"      Ortutay Z, Polg&aacute;r A, G&ouml;m&ouml;r B, et al. Synovial fluid exoglycosidases are predictors of rheumatoid arthritis and are effective in cartilage glycosaminoglycan depletion. Arthritis Rheum 2003; 48:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/160\">",
"      Thomas M, Sabatini M, Bensaude F, et al. A microplate assay for the screening of ADAMTS-4 inhibitors. Matrix Biol 2006; 25:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/161\">",
"      Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005; 434:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/162\">",
"      Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/163\">",
"      Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005; 208:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/164\">",
"      Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/165\">",
"      Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/166\">",
"      Salminen-Mankonen HJ, Morko J, Vuorio E. Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 2007; 8:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/167\">",
"      Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/168\">",
"      Baron R, Rawadi G, Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol 2006; 76:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/169\">",
"      Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/170\">",
"      Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95:3597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/171\">",
"      Goldring SR, Goldring MB. Eating bone or adding it: the Wnt pathway decides. Nat Med 2007; 13:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/172\">",
"      van Zeben D, Hazes JM, Zwinderman AH, et al. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992; 51:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/173\">",
"      Bl&auml;ss S, Schumann F, Hain NA, et al. p205 is a major target of autoreactive T cells in rheumatoid arthritis. Arthritis Rheum 1999; 42:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/174\">",
"      Bl&auml;ss S, Engel JM, Burmester GR. The immunologic homunculus in rheumatoid arthritis. Arthritis Rheum 1999; 42:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/175\">",
"      Kohem CL, Brezinschek RI, Wisbey H, et al. Enrichment of differentiated CD45RBdim,CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/176\">",
"      Cush JJ, Splawski JB, Thomas R, et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/177\">",
"      He X, Goronzy JJ, Weyand CM. The repertoire of rheumatoid factor-producing B cells in normal subjects and patients with rheumatoid arthritis. Arthritis Rheum 1993; 36:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/178\">",
"      Chang X, Yamada R, Suzuki A, et al. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/179\">",
"      Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011; 108:17372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/180\">",
"      Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/181\">",
"      Reparon-Schuijt CC, van Esch WJ, van Kooten C, et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 2001; 44:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/182\">",
"      Randen I, Brown D, Thompson KM, et al. Clonally related IgM rheumatoid factors undergo affinity maturation in the rheumatoid synovial tissue. J Immunol 1992; 148:3296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/183\">",
"      Lafyatis R, Flipo RM, Duquesnoy B, Capron A. Antibodies in rheumatoid synovial fluids bind to a restricted series of protein antigens in rheumatoid synovial tissue. Arthritis Rheum 1992; 35:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/184\">",
"      Jasin HE. Autoantibody specificities of immune complexes sequestered in articular cartilage of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1985; 28:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/185\">",
"      Jasin HE, Taurog JD. Mechanisms of disruption of the articular cartilage surface in inflammation. Neutrophil elastase increases availability of collagen type II epitopes for binding with antibody on the surface of articular cartilage. J Clin Invest 1991; 87:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/186\">",
"      Mathsson L, Lampa J, Mullazehi M, R&ouml;nnelid J. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther 2006; 8:R64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/187\">",
"      Mullinax F, Hymes AJ, Mullinax GL. Molecular site and enzymatic origin of IgG galactose deficiency in rheumatoid arthritis and SLE. Arthritis Rheum 1976; 19:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/188\">",
"      Axford JS, Mackenzie L, Lydyard PM, et al. Reduced B-cell galactosyltransferase activity in rheumatoid arthritis. Lancet 1987; 2:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/189\">",
"      Young A, Sumar N, Bodman K, et al. Agalactosyl IgG: an aid to differential diagnosis in early synovitis. Arthritis Rheum 1991; 34:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/190\">",
"      Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999; 286:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/191\">",
"      Matsumoto I, Lee DM, Goldbach-Mansky R, et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum 2003; 48:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/192\">",
"      van Gaalen FA, Toes RE, Ditzel HJ, et al. Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis. Arthritis Rheum 2004; 50:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/193\">",
"      Kavanaugh A, Rosengren S, Lee SJ, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008; 67:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/194\">",
"      Konttinen YT, Ainola M, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999; 58:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/195\">",
"      Konttinen YT, Salo T, Hanemaaijer R, et al. Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. Matrix Biol 1999; 18:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/196\">",
"      Demasi M, Cleland LG, Cook-Johnson RJ, James MJ. Effects of hypoxia on the expression and activity of cyclooxygenase 2 in fibroblast-like synoviocytes: interactions with monocyte-derived soluble mediators. Arthritis Rheum 2004; 50:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/197\">",
"      Franco AE, Schur PH. Hypocomplementemia in rheumatoid arthritis. Arthritis Rheum 1971; 14:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/198\">",
"      Wouters D, Voskuyl AE, Molenaar ET, et al. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products. Arthritis Rheum 2006; 54:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/199\">",
"      Britton MC, Schur PH. The complement system in rheumatoid synovitis. II. Intracytoplasmic inclusions of immunoglobulins and complement. Arthritis Rheum 1971; 14:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/200\">",
"      Winchester RJ, Agnello V, Kunkel HG. Gamma globulin complexes in synovial fluids of patients with rheumatoid arthritis. Partial characterization and relationship to lowered complement levels. Clin Exp Immunol 1970; 6:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/201\">",
"      Familian A, Voskuyl AE, van Mierlo GJ, et al. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/202\">",
"      Halliwell B. Oxygen radicals, nitric oxide and human inflammatory joint disease. Ann Rheum Dis 1995; 54:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/203\">",
"      Bratt J, Gyllenhammar H. The role of nitric oxide in lipoxin A4-induced polymorphonuclear neutrophil-dependent cytotoxicity to human vascular endothelium in vitro. Arthritis Rheum 1995; 38:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/204\">",
"      Yasuda T, Kakinuma T, Julovi SM, et al. COOH-terminal heparin-binding fibronectin fragment induces nitric oxide production in rheumatoid cartilage through CD44. Rheumatology (Oxford) 2004; 43:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/205\">",
"      Levine JD, Goetzl EJ, Basbaum AI. Contribution of the nervous system to the pathophysiology of rheumatoid arthritis and other polyarthritides. Rheum Dis Clin North Am 1987; 13:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/206\">",
"      O'Connor TM, O'Connell J, O'Brien DI, et al. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/207\">",
"      Crofford LJ, Sano H, Karalis K, et al. Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. J Immunol 1993; 151:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/208\">",
"      McEvoy AN, Bresnihan B, FitzGerald O, Murphy EP. Corticotropin-releasing hormone signaling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1 alpha corticotropin-releasing hormone receptor. Arthritis Rheum 2001; 44:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/209\">",
"      Dirmeier M, Capellino S, Schubert T, et al. Lower density of synovial nerve fibres positive for calcitonin gene-related peptide relative to substance P in rheumatoid arthritis but not in osteoarthritis. Rheumatology (Oxford) 2008; 47:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/210\">",
"      Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/211\">",
"      McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 2002; 110:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/212\">",
"      Crofford LJ, Wilder RL, Ristim&auml;ki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994; 93:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/213\">",
"      Myers LK, Kang AH, Postlethwaite AE, et al. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum 2000; 43:2687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/214\">",
"      Carney DH, Mann R, Redin WR, et al. Enhancement of incisional wound healing and neovascularization in normal rats by thrombin and synthetic thrombin receptor-activating peptides. J Clin Invest 1992; 89:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/215\">",
"      Grober JS, Bowen BL, Ebling H, et al. Monocyte-endothelial adhesion in chronic rheumatoid arthritis. In situ detection of selectin and integrin-dependent interactions. J Clin Invest 1993; 91:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/216\">",
"      Kikuchi H, Tanaka S, Matsuo O. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1987; 14:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/15/41210/abstract/217\">",
"      Ronday HK, Te Koppele JM, Greenwald RA, et al. Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis. Br J Rheumatol 1998; 37:34.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7513 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41210=[""].join("\n");
var outline_f40_15_41210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1656072\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28538780\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      T LYMPHOCYTES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initial antigen(s) and the T lymphocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Costimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Apoptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Autoantigen(s) and T-cell proliferation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Type II collagen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cartilage antigen glycoprotein-39 (gp39)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Immunoglobulin G",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Citrullinated proteins and peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANGIOGENESIS AND INFLAMMATORY CELL RECRUITMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      New blood vessel growths",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cell migration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CYTOKINE NETWORKS IN RHEUMATOID ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17859215\">",
"      Role of cytokines in synovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cytokines associated with Th1 and Th17 cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mast cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9030106\">",
"      TISSUE REACTION AND MATRIX REMODELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Fibroblast-like synoviocytes in the intimal lining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cartilage destruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Metalloproteinases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Glycosidases and Aggrecanase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bone destruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      B LYMPHOCYTES AND AUTOANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Affinity maturation of autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Rheumatoid factor and immune complexes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Galactose and IgGs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Antibodies to glucose-6-phosphate isomerase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Clinical effect of B lymphocyte depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9030247\">",
"      SYNOVIAL FLUID IN RHEUMATOID ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      COMPLEMENT ACTIVATION AND IMMUNE COMPLEXES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ADDITIONAL INFLAMMATORY MEDIATORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Neuropeptides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Arachidonic acid metabolites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Clotting factors and fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1656072\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/22/16746?source=related_link\">",
"      Cytokine networks in rheumatic diseases: Implications for therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39593?source=related_link\">",
"      Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17846?source=related_link\">",
"      Principles of molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/8/4231?source=related_link\">",
"      Role of cytokines in the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3754?source=related_link\">",
"      Synovial pathology in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_15_41211="Prevalence of syncope I";
var content_f40_15_41211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of syncope in pooled data from five population-based studies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean prevalence, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Neurally mediated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vasovagal",
"       </td>",
"       <td class=\"sublist_other\">",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Situational (eg, cough, micturition, defecation, swallow)",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Carotid sinus syncope",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orthostatic hypotension",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Organic heart disease",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Arrhythmia",
"       </td>",
"       <td class=\"sublist_other\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Linzer M, Yang EH, Estes M, et al. Ann Intern Med 1997; 126:989. Includes 1002 unselected patients with syncope, including those from hospital-based referrals, emergency departements, and outpatient clinics between 1984 and 1990.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41211=[""].join("\n");
var outline_f40_15_41211=null;
var title_f40_15_41212="ACC AHA Rx asym LV dysfunction";
var content_f40_15_41212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Management of patients with asymptomatic left ventricular (LV) dysfunction or hypertrophy (heart failure stage B)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are effective for the management of asymptomatic LV dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Beta blockers and angiotensin converting enzyme (ACE) inhibitors if there is a recent or remote history of myocardial infarction (MI), regardless of left ventricular ejection fraction (LVEF).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; An angiotensin II receptor blocker (ARB) to post-MI patients who do not tolerate an ACE inhibitor and have a low LVEF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Beta blockers and ACE inhibitors in patients without a history of MI who have a reduced LVEF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Treatment of an acute MI according to current guidelines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Coronary revascularization according to current guidelines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Valve replacement or repair for hemodynamically significant valvular stenosis or regurgitation according to current guidelines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approaches for the management of asymptomatic LV dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; ACE inhibitors or ARBs in patients with hypertension and LV hypertrophy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; ARBs in patients with a low LVEF who are intolerant of ACE inhibitors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Placement of an ICD in patients with ischemic cardiomyopathy who are at least 40 days post-MI, have an LVEF of &le;30 percent, are NYHA functional class I on chronic optimal medical therapy, and have a reasonable expectation of survival with a good functional status for more than one year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of the following approach for the management of asymptomatic LV dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Placement of an ICD in patients with nonischemic cardiomyopathy who have an LVEF, are in New York Heart Association functional class I with chronic optimal medical therapy, and have a reasonable expectation of survival with good functional status for more than one year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following approaches are not useful or may be harmful for the management of asymptomatic LV dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Digitalis in patients with a low LVEF and sinus rhythm, since the risk of harm is not balanced by any known benefit.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Use of nutritional supplements to treat structural heart disease or prevent symptomatic heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Calcium channel blockers with negative inotropic activity may be harmful in post-MI patients who have a low LVEF.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41212=[""].join("\n");
var outline_f40_15_41212=null;
var title_f40_15_41213="Types of heart failure";
var content_f40_15_41213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Types of heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 313px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Michael Zile.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41213=[""].join("\n");
var outline_f40_15_41213=null;
var title_f40_15_41214="T and DHT in 5-alpha-reductase 2 deficiency";
var content_f40_15_41214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Testosterone and DHT in 5-alpha-reductase 2 deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effects of human chorionic gonadotropin (hCG) and testosterone administration on serum testosterone (T) and dihydrotestosterone (DHT) concentrations and their ratio in subjects with steroid 5-alpha-reductase 2 deficiency. Serum hormones were measured in the basal state, 96 hours after the administration of hCG, and 48 hours after the administration of mixed testosterone esters. Patient values are the red circles, the green areas represent the results (&plusmn;1 SD) in eight normals, and the blue areas the results in seven hypogonadal men on testosterone replacement. Serum DHT is lower and the T/DHT ratio higher in the patients with 5-alpha-reductase 2 deficiency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Mendonca BB, Inacio M, Costa EM, et al. Male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency. Medicine (Baltimore)&nbsp;1996; 75:64.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41214=[""].join("\n");
var outline_f40_15_41214=null;
var title_f40_15_41215="MS pulsed wave Doppler echo";
var content_f40_15_41215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulsed wave Doppler echocardiogram in mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 248px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD4AYMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAoqaC2nuN3kQyy7euxS2PyqGgAooqxeWlzYzeTe281vLtD7JUKNgjIOD2IINAFeip7Kzub+6jtbG3mubmQ4SKFC7txngDk0XNnc2scD3NvNCk6eZE0iFRIucblz1GQeR6UAQUUUUAFFT2tnc3YmNrbzTiCMzS+Whby0GMs2OijI5PHNLeWlzYzeTe281vLtD7JUKNgjIOD2IINAFeiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA9o+BfijTPDPgP4gS6jq91p1xI+mPAthcJHeTBJ3LiIMRu4IDYzhSc10/hvXfAniyfXvEGp6Voa6tfas0k9hqN1FARaGNQpjeQqu4tuLFfn3dsV4t4X8Faz4nsXutGiinRL23sXTfhkedtsZI7KTxuroNP+D3irULG5urZLJhHJcRwp5+WuzASJTFgYIBUgEkZwcZoA73R9M8Bp8MdSjurnw3cXR0u/mt5DPDHdRXKs5hj5bzZGPy4ICqQAADnJi+MsnhPVvDWoX+h6jpN34gjXTkujLOhcQC2Vdtt82GIcfPj5h04A55DVfhXN/xLpdLvYIbBtDsNVvrzUpliigkuQQqAgZ5YYAwehyay4/hdr8cuprq0um6PFp94NPkm1G6WKN7gruEaNzk7cNnpgg5oA9O+AF14Z0m38Kaj9q8NW1+l/c/2xc6pcxxXMKbMQeRvYfKcnJUdetZvhy38J3E/hV7i/wBBLweGmea3vZYnWS589v3ZMjeXFJt5+bt0XJBGDafCJr+K6canb6W1toFrrBF7PGyzGU4yGBASP3O4jIBzmuW1D4d69YaNcarcpbLp8FjbagZxKCrxXDFYgvqxKsMdtp9KAPcrfT/hmvifXxEPCsFrK9u8d093BcRQL5CmRVhd1yu8nmIl85GBgVkxan4R1jR/hrDrEvhqTS7JLi2nDSGORJx53kiWPdvWB22MxIxkjJAOK8n8A/DnWfHUUx0KawM8blBbzSlZHO3PGFIA7AsQCeKLX4c6vLpFlfXF1pdi18GaztLu7Ec9wqttLInpkEDJBOOM0AemC88M6adfEN1oNpq114KuoL5NOuE+yPdmePZHEQSrOUAJVCRxx3qW/j8IS3+ttocvha71wW+mi1/ti7Q2nleQPP2M7bDIHwCGOQM7ea87n+FGvW2pX9peXmiW405C99O2oRtFafOI1EpXJVmYjCkZ9qmt/g74ob+1Te/2fp8Wm3P2SWa6ucI0mwSDDKDhdjK25sLhhz1oA4XWgg1m/EYtQguJNotSTDjcceWTyU9M84xVKuz1j4dazo/hC18Q6lLYQW11BHcwW7TfvpI5CAjKMbTkHO0NuAySBg1xlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUypEbdmLuJs4VAgKkfXPH5Um7DjFy2IaKsC3zj58ZPpXTfD/wAOWmv6xdWt95nkRQLJ5wu4rSKHM8Ue+aWQMFjAkP3VZi20Ac5o5kI5GirmsS21xq17Np9n9hs5J3eC18wyeRGWJVN55baMDJ5OM1V29OetMBtFFLigDrfh34/1nwDd6hcaGLZmvbfyJFuELqpDBlkUAjDqRkHkDPQ1q+FPiJ4ig0O08M2mmWusJC8ps45IpnmiL5Zwoidd4zlsMGGc1c+Ec/huy8P+Ir3XrTRLzUIrvTks4dTbOY3ldZ2VNw3ALtJ6gcE16Vp//Cun8V6WyDw1p9vY+KLuzWS3vBH5th9mLJLI5kJZTIcB847DHSgDyeL4q6x5SW13p2j3un/2ZaaXJZXMLtFMlsSYXbDht4JPIIByeMcUn/C1dZupNTOu2Gka5Bf339pNb6hbs0cU4UJuQIykfKFXaSQQoyDXpfhHUPDGt+GPhPY68/hj+zrKa7g1OO5uVjmgJaRkyrOCEfhmbGN2ORnFUvg/J4M1hJ7/AMRWnhGxSW/itZNNmZYfKt/LAMyvPIzEE5yE+bdySBigDiv+FleILZ7a+vdF02WwudFTQ1huLaUW9zbQsBkEOCWDLglWAzxgVD4j+IH9o/CPwx4MtjdE2E0s95JMqhWO5vKRCCSVUO+d2OSMdK0fifLpcngTwLp2lX1rMbFtTRoophI0SteMY92DkZXBGeo5rd1K28At4P0LULZtIg1TXJLC1uYWBf8AsvynYXM7RhtwV8JxxkFsGldAct8NfiV4j8M2ltpGhaTY6o0V42oW6SwSySLJswxAjddw2rn5gcYJGKow/ErUP7Osba90jRNQmsAy2V3dW7tNbIzl9qkOAQCTjcCVzwRXutt/wg+keMfC1/Y3nhq0u7a51G3nuLO7t1SSA2cgjdxG21dzHAzk84JJ4rzSOPwN/wAKlTW5E0//AISP7J/Y76erDzfN87d9sCZznysjdjG7ii6A5KH4j6ouv+I9SubHTLyHxA2/UNPuInNtId/mLgBw42sMj5vzrZ0r41+JtN1XVNUig019Tv5vOa5aORWj/drGqBUkVGRVUBVdWA/E11HxgtPAo8JyjwnBomxJ4Wsbq0u4/tBiK4ZJItxlY9yZACCODjivDGiAVjuzj260XQHcXvxR1q58DSeFY7XT7bT5o4453hWTdKEIYEqzmNWJAJZEUk9a4KpjDiPeTxnB4pRASo55Pt7UcyAgopwGelJjr7UwEopQM0EYJBNACUUpGOtGPzoASiloxQAlFS+Vx16DNMK4IH9KVwG0VLJHsJG7PvikdNuOeT2xRdAR0VM0OOjZ/CkMfyg54PTii6AioqdYCeh7Z6U0RHy2fpg4+tF0BFRSkYFKBk4pgNopaSgAooooAKKKKACiiigAooooAKKKKACpoQpB3eoqGrEZh+ysCjmct8rBhtA9xjnv3/8ArqRUUnu7Di375Mcj19a7v4YXjaZNdXj6Rpeq2gA863v7GKfdjj5GdSUPzE5HBIGQ2MVwKfeQDnBzXq/wb06S+sdYfy2aLaVJA6H5f8a4sbWdCk6i6W/MIq7sc74/0SXULm/8V6VePqun3dy011I8arPaTSMWKzoowuWJw6jY3bB+UcSUPUdQea768GqeFNTn1TT5JICZRHhlDRyxnIZHU5DqehUgg5q7rXhez8SQyah4Utzb6gAz3WigljwTue2J5dfWM5Ze24dNadeM0mnuJo8wbG7jpQByKCpBAIoPXOOOK6BCdqVVJIAHNJjivRvgT4Ug8UeMpG1KzF3pWm2sl7cwNJ5QmwMRxbyQAWdlHX1pged4wwB9aReor0X48+EIPCHxAng02HydIvY0vLJd24LG45UHJztYMOp4A9a85HakgLa/KwJ4B5FSJFvBJOFQEg+vP/16gVtxjB6AYpWkLAKPXH1BrNpjJUHQHgAZYVAcBD65PGOtPhbc5LcZFR7tzEmmkIWAFjgZHTp9DXTadd+GLrT4bfVdHvra4QbDeaddZLn+80UgIJ9ldB9K5lAUORj8qIW429sk5H0pvugOvfwxpd+m3w/4m0+Zycrb6mDYS/iWJiH/AH9qnfeEte0lYn1HS7uG3bhLgR74T7rIuVb8DXOynMo46cV2nww+2S601rb3N1DbPGwmSGRlWRcdGAPI7YNZVqip03N9BrVnFSRlXxio5Rggjpiuo1fQZoJnXZIQJXXOB0CnH9K5+5tnjjLFTgHrjpTp1Yzs0wasVAD0ox2709RgE+n/ANekIODx3xW1xCBTz7CpI492GbgURqzsVRSWPAAHWt6HSXGkxzOrglyMY7bQf8/Ss6lRQ3Gc4eppycsuc4FEoxI2OBmkTrWnQRYdcOR6n/GkZQUyeCqkfzpzcSEZ9O1I3zOwIxxnFQAkeHfB4Uf5/pTHOckjA4ApUADcc8UrAGNPU0+oCbgIhj72cD8qVpAU2henAOabJjauOozmgLlTn2PSiwFpR8x28g5HH0rSv7FrfTFzGQ744I9QDVfw/ALrUIoyCS7KOPqM17FrHh1bnRldEclBg49e36V5+KxSoTjF9S0rnhVzF5MhRshh1BHSmRjLHPYZ6Vv+MdMex1i4XY2MK3I6ZANZMcB4PPK56e9d0KinBSXUlop9hzSU5hgL7im1qIKKKKACiiigAooooAKKKKACiiigAq1D5P2Z9yyedn5WDjbjjjGOe/f/AOvVqxG8QtmRkcylsqwcbQOOoxk9+/8A9eZFwdr6rbqaUhmTTE3TRyowUiMSriIZHRc53nucdCc5JOPo39nPTFPgG4nkUgXF67E/RVGP0r5hib5sYyDX1Z8Hrl7LwDpdt5QMcqmff3yzen0Ga+c4h5o4Xlj1Z0Sre1knrorau/8AX9dDK+I/heGdWt0ZznoAOpJOB+lcRd6BNbXEp3T20oZmikjO1lcENlSOhBr1HxJfW8n2y5Ry7iQBFx6bv8a2L3SbfWbVJ4ciZS7OnuRjv7141DHVMPCKlt+uhDimeBXllaeM2kTVPL0zxOkeUvnxHb6gcdJu0cmf+Wn3W/iwfmPnWsaZeaPfzWOp20ttdwsFkilXDKfpXs/izws8cskURLSGLY3PH3mz+VYerpEtjBo/jUSS2K4isdUhXfc2IwSAR/y1h/2CcjqpHIb6zCY6Feyb1ZjKNjl7L4ca9deErbxJ/wAS6HS7lJpIGuL+GJ5RExV9qMwZiCMYA7j1FXPhdpl9qM0trb3d5DZXTolxDC5VJtrbl3jOGweRnOK6rWvFt5Z/Dnw54G0GeCd7MX9tf3K28M8N0k0gdDBIwLr8rnPCMCcHkcd18NPDUOh+HLKV2ka6aYllxwOcVnmuOWHo2i9XoOEbs8T+JTag+sG1vLm6mtbJ/JtkmkZliUgHCgkhQcZwK4nGcV7l8bLCFhLPbq3m+aHfuBjcK8Ox0+tb5bX9vQjIUlZkxG3H0pFycHsMGnoyGLkZbnFOJGxlA/zxXWSRkYxj8aFUHcOhNNT1POeKkUYdc4BHWnsBHnkg+tERK8470gG5j6//AFqehwxUDHP5daYDRgKTxnmvVfgDafadZvpQpby0jUj/AHiR/SvK9pZSR2yT7V7R+zmUhutZU8yZtyo9gXz/ADFebm8uXCTa/rVFw+JHYeIPDsay2NwqO8bvvc9h8p9PpXkniPRGg0+9ZonVkc4/F1P8s19AfaILi2gs2DB2kjiGVIOR1/Un8q57xboy3lvcxqMPOoJH93A/+xr5zBY6VKSU/wCtTWUbnzZNZyRzNEVONwAOOvWqjAhOnGfT617fceDZFuI8o24zIVPbB3nn8AK811jw1eWr20axMxnXeBg5xX02Hx9Os7XMXFo1Phz4fOq3fmyRyGMRM4K9yD/9Y16ZceG4/wCycIsjPGrfL6nP9K6j4eeGINF8NxpK7mYqDyMfIc5P5nFLJMqS2mRw7fMB9Bn8s/57fN4nMZV6z5NkaqNlqfLut2rW164ZWUFjjI+lUFru/izYNaarDJs2xzZZevoAev0rhF619bhqntaMZ9zFqzLcpBu8A/LwAR9KYTuctjHamrgbW6EdvypA+B0/GtLCF2bWcqM44/WkI+cL6HHSgNiNgOvNIASM8Z69aYBkYye4ocfL8vOABTUBZSePlFSYBDj/AD2p7Ad78FtDGseLwjM4FvGZhtGc4r6ItYYH0K78ob/LaKXHPrjH04rx/wDZo8pfEuo3UhxshSIDryxOP5V7BFJHp2mwJISyXJkVjjOAGJBH+f8A6/xWd1JSxTh2t/mzoprQ8k+KGgrtmniDsXCAH228/kTiuY1Pwz9iuLcESKnkK2SO+M4r2jxpZxXOmNBHnzUjiUDtnqc/gazPEmh/2nc2S22dqBo39z0Fa4XMJRhGLemv5ITjqfOmv2DWE0CENteIOCR61lV6H8WrJrRdFaSNo3eOUEEEfdYDvXnlfVYSr7Wkp/1uYtWYUUUV0CCiiigAooooAKKKKACiiigAqxDMyx+VhNjHJJjUsOnRsZH51XqZZnW3aMCMqxySY1Ldv4sZH50mrlwla+tvQkgUeeFOMMeCa+qPCha00XQIIVxai0hD5GW3Ff8A65r5UtyfMQEd/wDP86+o9Av5orCxjX7saQKG28fKcenvXz2fxbhBepVMimSLyJWfPHmvICefvHHFdDpmtpBeRNCW8hy4cFe+8Y4+hrmPHamz1G5aBSRMFH97hlOP1FOsrhnghdlxwuARjouf5/59fBlSVSmpPZl3szcl08atM10gR1MjhucHDYx+pNcr428Jm/gtkaIPiXkqeiqoHp6k10nhW5WCyILLmV0Xr/CWYf1q5pt00xu0uB8jRZQdPmzITUQq1KE24/ZHZNHmPhrwaqnTnmhKoXlkUs2M5Ix1H+yK9N8O31vJpGHBDNOwQbQO+f8ACrstjHPpdqUUkxx7V59ea52wiaExSRc+TJjp3biqrYh4tNze3/BBLlOY+JKeZaaorqS7bETI7mIE/jurwC6jMM7IwwQa+nPGcdvJpst26sZmKSEA8ZYfT0FfOnim3Ntqzo3oDn14r6LI6t4chlUWpmx4DKTngU4EbH45Yj8qaRhV46ilGAremBjNe4zMYchgvYGnyEkhh1pMbvm6HGaUDsfTNMBI2IcHuepo3Yye5z2pgbG1vSnkbmbPrk0AEJK5GPvDHT/PpXsv7PZRdTv2kzt8y3GR9T/9evGj0GOCAa9n/Z8gWU6yQCSiwspA6Nk/4/57eZnFvqk/l+aLp/EeoXEZFzFdwrkJK03TgfMcfzH5VBqk+JrgjlCcKSOxPGK2WT7JYfZ3I8tkJ9OmK57xHN+9S3gGYRbBhnqWHPX/AD/h8bS9+RuzpdListVgmdkDPCsJ+UYw2wjj8Sa5s+F7e71/fdQqIbUvF1x0z049xVvwoXs5J8EAuIs5HBYKx/p0qLUb+4uLeKd2UfaHeTgY56EfqP8APQipwqNQen/ADdHQyzQSyNa2pxsiESgDGPmXHP1Irj4pN15DEcGSG8YMMfwYXge/FXtDlxezs3yqMMPfY4P86yrC2E2r3d4CPlmjbHqSaulTUOZMTZwXxxgL2WnXRjKgPIgIXHXBrx9MFgD0719FfGqzMnhy4gZSTaHfkdvkXOfyr50H86+tyWpz4VLsY1NyaTA6fdycU3jYM9Qf8aVxhQCeKYACwyOK9VEC4BHHp/WnPlePbGOtIoBDDHOKDkn9P50AInQ04nDketNXlD7Ur8kH15FHUD1T4Czi2vdSc7s5hxgE926/nXsVxOZbOwgmDCZLd5B8uBuKkjtzzivGvgpJ5EmoqRyXh59B82T0r2PUboTWunytj/V4b6Dp9K+NzZXxbdv6sbw+EqarcM1jdXk3BCJs4wMrhT+FO8MatHcm2Sbb5jMjr8nOd27n8Ks6lbw3nh+4iYkokSlcH+HeG/oOawdDt0i1C0u9rkKHLd8Nt47exriiozpST3X+RWtzjf2ifKksvCk8KhS6XStgY5Dp/jXi1etfHORpNN8LliMbbkgDt8yD+leS19flC5cJFev/AKUzCfxBRRRXpEhRRRQAUUUUAFFFFABRRRQAVMkzi3eEBCrHJJjUt/31jIqGrVvLL5EkQldYTligY7SeO35VMi4O19behasrJmNpI+3ZM5VQDk5G38uo/wA9fpWzuoILGCxnQqrRhHJP3xjJx6cCvnHQy1xd6ZaqhJ+1DB9SxQY/T9a+itdtvK8jYhMsC/MB1J8s5/n/AJ7/ADucvmlCMvM2fJf3NrL77K/43JdeQai9vLghUtYww/6aKeB/49+tSRWsd1cSLcOEEGxE7ZbOD/Kn6ink2ks7/IpkX5exDDGPzAqSeNTBE0IBkM6NKw753Eg14Kl7qSAxdPtjHPYwkB9lsWOOMBSxz+tdC8csObhxuiCKqADGGOQQT64BqG3sPMlsvLO15LKTLDjIO5sdPQj/AD1u35Z7O32nEbSQzEY68NuH45qalTmkv66jsWNFubuZl89CkKkbCV684UfXg/565jXttaPeBYnZdySKAevyn29Sfy/PZsVL24UZWQzGRF/3M8fhzWNqFsitfBo/lNruhY/xMGOMe/8AjWMOVydwKms6ei277A32W4SNYj1O4K2R+BJr5++IEMqaqBJGwECCJj79f619H3SzT6bpeyLzIYSDJjpkg8n8SRXlHxK0Pzra7nijDSsv2jIPONw46ehFe1lGIVOraXX/AIYia0PIXYGPpg9qQkGMAdc0oAYZxjAxSbScAcn2r64wF35UAdqbnPPXtS4+XPrSouVHHXpRoAzJ2YxUgyQCOAaY2SAO/Bpy5VMgcdR+dDAAF2Nnr2/Wvav2d5Gtf7RkT5o+PMUDk4BIx6civFSNr8dM17R8FoWttKupgxUTfNx7bgB07815ecWeFkn1sXDc9R8Vs8kcn2YbbVhJGCRnqq/4ms+/UogeUiQRQhE28YwD1/76P5Vbu5ZZ9MeAxk4m4YjoCuAB/wB8/wCezYvJv7eaYbRCWKYHAyMAivkIe7FJ9Dcwob+Zvsnl7RcyzRu5K8AE4JA9h/KtW6tpE0+3j25SKRk4/vEA/wA6r6XaQ/2nFuUF1mztPZN2QP5V0d+Vn0+4toIdt01zvAAwRgDOPyq6tRKSUUJIzI7ZWlghkjblCd/b5gP68/54g0fTXnu72ONC0onSTI6BTuI/QVbsZjdalZqina/yg44yqjj/AMdP+elrT7e7sb7UWjDeazhcDsqrx+GDWcpuKavrb9RnOeN7aSbwbrjXEZFy/mB8cDGzjj8q+XmUq5UjBBwa+t/iSI5/DtwLRwrSFPMReCQQMjp6DH4/l8w+KLNbTWXEaBYpAJFA6c19Fw/VvTkn1Mqi1MmQ5GBxgc0gPQ/570rKQ3Ixk0mOBj8P1r6IyEKlRuHSnggk44/+tSOTjYeo7UmcN+VG4CpjaevTFK2SFGc7P5UwZApV4OT3zQB658EvLK3ZmYbJsRH6nIUfqa9Skg80iCIF4vKYBh0O07QfzBH4iuB+BFpBcaPcu8QZ0vIRux6AmvQLeQRWdnKSFVVdGbsxJ3Z/Mmvi8ylfFTt0/wAjeGw21MFwktkinelmGYZ/unNUvD91K9zaLCm5GLPIcfc2ZH/sxrZ0y0jglubgrzcW0mxzzlccEe3P+e+ZpNhcWylkBRpPMC46c5JA4+lcalFqS/rqVY8u+O6wpF4fSE54nOfUHy8f1ryWvWPjsNi6BEy4dEmB9f8Alnj9K8nr7HKv90h8/wA2YT3CiiivRJCiiigAooooAKKKKACiiigAq3D9rNjJ5fn/AGTd8+3OzPHXtnp+lVKv6bafaMlmQIMjl13Z9lzk9aibSV2aUr3dr7Pb+tu5q+CYml8T6QiIXP2tCAPUMMV9P6xDGbstMAAysu4/89NpGPrjFfOXwqj8zx9ocZUFftsYOf8AeBr6R1m4tEmuDKUeDznkzkEqQBnA+hr5TPJN4iEV2/UqnsRyxx3mnLH5QmdFh3Lt67d5Lfyqrap5s8pj+a3M+w+gIXP58mo9H1i3tzavIUdbpdisW/2mX+n60miuEiliM67muC+1iBjOFBH514/LKN1/X9aGhoRwtFdWUgYhI7SWDaP7wXaO3XFX0tVnsra1wPtCRI2O5b5hj+Vcx/bcE94jpOwjWby9g6HI5P5jFaiapFFLbXD3G0j5gy4O7a3IP4E1NSlNW7gmix9qFnLA0jjcgc7cfxNnP6k1m3zXDXNjHKjbGt1yD/wLj68Z/GodUmijzezShokuVQqf4lY4JPvT9R1K1E+m6hNMRD5jQvCBnAywUY65wR/nrcYNWaW/5hc6HS3t20+O1dVV32YGMZByw/nWJq/h/wC0v9mntuZ4ZVAPYbSQPwOPWm+HtTtIr+NLqUSOJlQA/wAIAUD/ANmrqjdxXWoWExZPLk80RknqMLz/ADrCTnQndeo9z4tv7WWzmkgljMc0bYZT1BqrgqR7Y/lXufxY8ARtu1DTUQSShrlwvcEYA/MV4lLE0W4S9mVfevvsFjIYqmpx+ZzSi0yNgQVC/hSHK7OffFSKwLDg5B603AA569jXXckZnd0644pE5bB6ZxT2G35lPJ5+lJGmXQdycGmArA7gvPSvevg7p5TwheT3LYVz+6JP3QCckce9eH6hb/ZL8xPkFRnOPavprwPp9tYfC/RDI+JLqF52B6bQhJGfc7fyrws8rctCKX2mv8zSmtS9dTi2sy8mAjCJ8np905P5mm6VZE3c9tbndB5GVRT1lJBJ6dcA1h3V8kyWKGdZIJIykgOOwwCP0ro/Dl7aKIZxIqkSZLIc5GfLbP6mvm6kZQhdGt7lCRPs+sjZgN5qJnvzj+gP5VuWQkltJ7ojZNGWUMByWYdf1/SsfxJcWa6tAbFsq7Bt/TLfNWto97bzWF1IZFERlAVVIIyBwazqXcFKw0VDA+nXySupjSDao9mcjB+v3vz/AC0vtbHV7qERsGmUeUcfe52kj8MVh67rUdxpct0qKVdF25PJdJMZ9uCfyqCy1+3v7u0njfY9vbRSuf8AeAyB68qaPYznHma8vy/ULl1LQahpiOP9IRE82b3GR149B+leMfF/w3JYXkVzFblE2qMDoBjPTHv+ley+G9XtIoLm2QoV8sxsAfb5Rj8K6LWvClj4it5H1COJkxvjGQf4QoH510YfHPA1+aa90TjzLQ+K5QSVBGG60sajAz2avTPjJ8P4fBl1aTWsxktrpmVc4yNoXqB7lvyrzRUxgk8dcV9rhsTTxNJVab0ZztWdmLGA82SMDBpjACTkcdqdhgcqOR/jTcY2k8nPetxDcfvMY47ZqV0xEhxg459uaYCC5YjH9a1Lyy2aNaXh5WfcMehDUpSs0mB7r8DLRB4dn8lQWkkSXj1UEf1rooLd5Yp4nQ+VAjtt9yOP5VifB4jS/CEUrviWZf3a9sZHU108eoWr3eoltsI2mJY15DEBgDXwuLlJ4io1rqdMdkQWl1MtrarJEzYgeJRt6+gH4H/PfQ02XbPqCXEeBZupTI9SwP17fpWE2rW1pBaRSvllZnBxnH8OPzNatvqFnDaRSSyiSW+dTIzj+Et/TIrnqU3bbf8AzGmeXftMW0cN1oEsQAEiTAgDGCBF/QivEq9d/aA1SPUJNDjjl8xoRPuOc5yUAP8A47j8K8ir7PJ4yjgoKW+v5swn8QUUUV6ZAUUUUAFFFFABRRRQAUUUUAFWLdZETz0aMBDjBdd3b+HOT+VV6t2lq08bsrQjHA3zIhz9CamTSWppTg5uyTb8jqfhbIi+PdLmkcJHHK0zsSBjaCw/UCtTVvHt1PJciCcmNnmddyckMRiuP063vLS4EkM1sj427hcx5weD0b61G1jNh/nts5/5+I//AIquCph6VSr7SbT0S/P/ADNfq1dK3I/uZsjxnfi3toftDYt5FZDjnG5ief8AgVX4fH+orI7ibDALs+TjKnPPNcg2nzA/ftf/AAKj/wDiqBp03d7X/wACY/8A4qtHhsM90g+rYj+R/czdTxhfx3BZJ/k3bvu98k5/Wr03ju/a0jhE/Ee7advJ3EE8/nXKf2dNjO+1/wDAmP8A+KoOnzf37XH/AF9Rf/FU3h8O3qkH1bEfyP7mddeePry6hEUk2ULCQgJ/FVafxvfz3eZZgbcSeYE2cA49Pxrmf7Pm/v2v/gVH/wDFUv8AZ02cb7X/AMCY/wD4qksNhlskH1bEfyP7mdJaeN9QjvTO043Mcn5enJ6fnXQW3xRvvslrC8+GtwyxsI+m4c5Pr0rzxNOmLDL2uM/8/Mf/AMVSf2dN2e1/8Co//iqmeEws90vwD6tiP5H9zPadd+I+n3llbIkzM32PyWBj43DcT1+teKXExlcsemQTgd/8mp/sM+3JltyQOP8ASY//AIqm/YJecva8/wDTzH/8VSwuGo4VNQe4PDV5fYf3Mht48qzdcdKjbDOR26irqWc8e4LJa88f8fMf/wAVTRp0xCkvbcdf9Jj/APiq6+eN73F9Vr/yP7mUzwqZ6daVGKEEdQatHTpehe2wD0+0x/8AxVONhLuXa9twP+fmP/4qj2ke4fVK/wDI/uY/XbqO+1EzQZ2lFUcY5Ar0uPxyYvBem6WZyssFmUXavTJOBn6AV5hHp8wY5e2/8CY/8amFpdYz5lvjoP8ASY//AIquSvQo1lGMn8I1hq6+w/uZqR+Lr1GiBnby1VhjGcZHGPxxVvSPHmo2Np5PnApluqZIy2ev51yx06bP37X/AMCY/wD4qj+zpsfftf8AwJj/APiq0lh8PJWaQfVsR/I/uZ10vjy8aGPM2ZIwoRimT3B5+ho0v4gahaWU0TXDfM+4ALnt/wDqrkf7Onx9+1/8CY//AIqg6dMB9+1zn/n5j/8Aiqn6rhrWsvwD6tiP5H9zOlm8d6nLpyWvmptWMj/V/wARbJqtZeMdRtQQkygFEQkJzhTmsL+zpv79r/4FR/8AxVA06b+/a/8AgTH/APFVaoYdK1l+AfVsR/I/uZ0Wi+NdQsrh5JZywcqW+XPQ16lofxijKLBeXDBRhBiI5+/n1rwv+z5/79r/AOBUf/xVSR2FwpBElsOe11H/APFVzYnL8LiPit+A1h8QtoP7mel/GDxpaeKbaFEkMktvIQuE2jBJz/SvKQSOpOKvPZTsctJbnLZJNzH/APFU37BIGI32uOR/x8x//FVvhaVLDUlSg9EJ4au3fkf3MgDKMY6luc+lMlIyCBx9KsvYTZJD22P+vmP/AOKpx0+Vgcva7v8Ar5j/APiq6OeC1uL6rX/kf3Mo4yC3HXmtKW+MmgwWbHmOUsPl7HHf61AdOnBID23P/TzH/wDFU5tPmwDvtsY/5+Y+v/fVKUoStdh9Vr/yP7md9p3jKTS/DGm2okVXVXbhM45Urn8M1jv481EXyzLP8u7LDZweT2/Guc+y3L7Q8trtChR/pMfGP+BVB/Z0wH37X/wJj/8Aiq5YYTDptu12P6tiP5H9zOjuvGl7PAqmRd4dmyU7Ek/zxVubx1eSWtlDHOd0S4YlP9oH+lcj/Z039+1/8Co//iqF0+bP37X/AMCY/wD4qreGw/ZfgH1bEfyP7mO1XVLrU3ja7kLmNdq/zqhU9xbvAF3mI7s42Sq/T/dJqCuuCilaOxhOMoPlkrMKKKKokKKKKACiiigAooooAKKKKACrEMSPEWM0asD/AKs7tx/TH5ntVertkkJQs7uJs4VQg2ke5z/T/wCtMnZFwV76ff8A0tSIMQwOR96oz0JYck5qzEowSRkhgf1FRkCTcwGF3EgUkyCFss3uaXy2ABIGOvWtrQYbeeRjPtLKrFMn+LjFeha54d0600zToWjiW4uVKo2eW+YAf1rlrYyNKSg1uUo3PID1560V3HiTQbaxtPOjjAU5yc5x8p/riuKdcKp6571vRrRqrmiJqxHSilxx6Vr+FLKK/wBct7ecAxtnOf8AdJq5zUIuT6CMccEVdnsJINNtLxmXy7h5EA9Cm3P/AKEK0o7W2mnUfKEFyFJ9io/wNdVq9nat4CsduxpBfzrFg9ARFXNUxXLKKtu/0Y0jg/s8gKowHzEdxT1064JX5OHJ25YcjHNez6Homm3XhiK9uYojLGwbJPPAGf8A0Gt6PSdNns7WaGGEtCVjUDvuVgf5CvOqZuoNrl8i+Q+fv7JuZYxIqDaTgHcKjSznTCFR8wz1HbmvrXSPDOj/AGPTYPs0GyWNTg9GIPT9Kw73wnpFvf2kjRQGMWs0ZJP8ZBP59q5o8QQk3FxH7M+Yri1khUFgAG9wagRcYJNes+PxpH2BI7RIDMnULnKnC4/lXlkwKKqjk9PrXtYXEOvDmasQ1ZjcBYiT1GKcCML9aJUZlbsc5/OpBHuhfby28YHtzW7YiiqljgdacUcJuI+X1zXVeBNJTUtcggaNXLRyjbnqQhP9K6ObRrKXSPlijV3AYDnqGYY/z61z1cZGnPkt2Go3PNktZmXcqjH1Hv8A4UyWJ4wC4ADcj3r6E0bw1YGxgD20eGManPOFCsT/AOhj/PXifibo9pbaNYNbRqJkDBiOvGSc1zUc1jVq+zSG4WVzyylAzn2qeaNVZADwwBrofC9jay6fqFzcxqywrjk9C3A/rXo1KqhHmZNjD0zT5NQe5WIgeRBJcNn+6gyarRByw2dfrXT+AyI9Xuo8cTafeRH8YHx/Kuj8D6Pp13I8Mqxb0i80kk54bOK562K9i5cy0Vv1Glc4FLK4kB2pkocn5gMUjWEodSFBBGfvCvoC1sdJtJJWEMOyZ4VAOcNuzk9fY1Lpnh3TLq3WT7PEQ6blB/hO45+nBBrzXnKjduOhXsz5+XTp3gjZYw2/cfvDoDj+lLdaVc2zxJKArugcDcDwenSveLjS9N0W4iBWLyliZVySQT5hJ/rW3rljoF/ZWeoTwW8czKkKEjG4YB9+n9al51Zq0dGHsz5gnjeIqXHJFRnP4da6rxs1p/aDxWioEXIG3tXNKreUGx7n8CBXt0qnPBSasQyPGFHPp3qPBJq1Im1OfvA88/StLwtpf9qalHCehYDOaqVRQi5MRhkYqVIXYEgcAZ610vijRl090GwKfIBb2YBQf1NepeB/B1jqWnQnyIzK9kzYBxuZQDn864sRmNOjTVR7MpRbdjwPtSVr+ILaK2uJEhAAW4lj/AEY/nWRXfCXPFSRIUUUVQBRRRQAUUUUAFFFFABRRRQAVctQnkO3mSCZT8qhBtI4754/KqdWLdgqtn0qZbFRaW6uThSsJbGCWx+GM0yBcQTZ/PNOEhdUU9A3/wBaoxJshdR3OM1Goiewl+zzK24gKRn39q9O8SavFdp4SvAwWM7QF6AEMM9/WvJN2FZTycg5rZlv5pNP0aNpGIglcKM9OVrmxGHVScZdr/kxp2Nvx/dywTmzErGPLEAHtXFFyVA9K1PE95Jd6q5lPzJ8v496yK2w1PkppCe4oPPX8q2fCF2llr9rNMVEY3bs9PumsWnxOUcEHGM1rUgpxcX1EXvtBWGVkYg+cpxn2P8AhWrd6jK/hTSU81uLu53D3Cw4P61zhc7SueCQT9f8mrkswOi2cXdLiZz+Kxf/ABNZzpJuL8/0Y7nbWPiO4j02yto5j5MiEOvbPQ967fTby5gsmJkIiWVdvPfBryjSRk2ynBAVm57Y3H+ldLea+8WnxFHZVZ42C++05z+IrycThlJ8sUWmeo6X4uEej2s7XAMkU6Iq/wBxeT6+4rkvEHjkywxfZ7vJVn3YHT5iMdfSvPm1q5itkUOQpYHbngkADP6VjXt0zbwuFBck4PrUUMppqfM0DmW9T1CSSW4LytIGckH2wcfpWQzs+3ccntzQ5LKxbnpj8qTOAoxk8817cIKKsiCxvzuVhklBjP4GnW7Yt5Wz8+4Ac9Rg5qNCSfMbJ2qF574p6uotsbfmJyfoM0mugHS/DO8MXjOwVeBJ5q/99RuPX3Famuai9jFYw7tkrIWx7bmOev8AnNcRoV82n6va3SMwaNsgjrVzxPqTXt9DIucCFVX265rkqYbnxCl0t+V/8xp6HqumeJ2tkMUsu9d+xc84+QD1+lcF408QtqlvGEk+Qk/jxg9/esKXV5xsUSMdrlsn+IkD/Cs2aUsiLnKrnHNTh8BGnPntqNyGvIWZcn7oxWlYXrQaNfxI+wSvHuH94DdWSTmnByI2TsxB/LP+NehKCkrEG54RlK6yG3Y/0e43H28p6j0jWLqyupJbed0doihwevOag8OMF1Ni3/PvcD84XrPiYhhj6VlKmpTlfsv1GeqQ+IDNa2yzTAArEFZuzKTk9fetW18UTW+nhUkZWUFQw6nr7+1eZSTN5MexiFByB6ZJp8mqTKIFDErgg89Tg/4150sDGXQrmOu1HxJPqBht55SzKfmc++739TWLqfi/UJ4bS1FzIsdudyAd/lAHf2rBa9ka5aUEgHBIBqlPKXdX9Bjr6V0U8HBPVCch1zcNPuZ2LPnkmkUHcEJwMEEevIqLG0kdRt3fjihXLEsTjHf8a7eXsIllYGYEfdbH48CrXhzUX0/UIpVkKBW3cewqgGAZQc7aijba2aHBSi4sR2vxHvBJqixxuCv2ZCwHq2Cf5CvV/hhrKCCwO8IVt3AHTdnA9a+ftWuJLi7LyuZG2qNx9ABXV+HfEUmnR2rxsw8qBlx6nIrycZgvaYaNNf1oaRlZ3OX1Oc3IMzHO+4lb89tZ1TOxNugzwGY4/Bahr2IqysZhRRRVAFFFFABRRRQAUUUUAFFFFABViPyjbMpjkM275WDgKB6EY+veq9WYJIFhKyJJ5u7IYP8AKB9MfXvUyLg7X1W3X+nr/VyZ5YgkZgjkEoIJZ3VlPf7u31x3P+C6oVfUb10IZTO5BB4I3dqgMigrtIwCe3btTQ6Ybnkj0qFGzuW6zlBwfl5bX/zIe9SiQ4iGeFOfpURxnigHp7GtDEmvJvtF1JKTncc1BRSjrQlZWASiiimAVKz5t0j/ALrs35gf4VFSjHGelAGhbu2MhjkBh19qvX8rGOGIkDaFxj8f8ay45Y1z82OfQ1Zu7uGVo2Rvuqoxj0GDXPKN5bDEkuMH2Tge2etVcgA+44/OnCSLyyCSWLA9O1N3x4YnOdvH1q0rCEYbXKe1IxBCkdQaHdTkqeSMUxSvAJOKpIB4BC98HpUsAPlkt908D61D5i5OD39Knknja0hjBwyli3HqaTuBUBwcilkYsQSc8Cm8UVoAuef1oJOMH1pKKAEooooAtadL5NwXzj91Iv5ow/rUEfLKB1zTQcH8KUHA460ra3AvpKWVecknB9OOlNkdHPHYZB/Coi8YQbW54J4PWoiy+XgEk+9ZqIFpmUKWz1Qn61VBK59P8ad5ikYJwMYpu5T1Pfk1SVgHFgceu2lfaCB/sf1qPcAeD9KUOD949/0p2AWUYYY6VEfapZHU/d9qj47elNADHJ5OTTkZiAATxk/y/wAKZTo2Ck59KGAh+6BTaWkpgFFFFABRRRQAUUUUAFFFFABRRRQAVesru2hhMVzp0FwGbJlMkiyKPRSG2g9wSp5PORxVGinGTi7omUVJWf8Al+Rrefon/QP1L/wPT/4zWTRRTlNy3/IUKahtf5tv8woooqSy5YpYvv8At9xcw4xs8m3WXPrnLrjt61a+y6PJ8sOqXKSHo1zZhIx9Sju35KecdOoyaKtTSVnFP7/8zKVOTd1Jr7v8jW/s/T4/mm1q2kjHVbaGV5D9A6op/Fhx69Kz7pYFnYWkkssPG15YwjHjnKhmA596hoolJPZW+/8AzHCEou7k3936JFua08vTbW8V9yTPJEVIwVdNpP1GHXnjnIxwCdjUNSm0610yzhWETwWilpTErHErNLtBPVSsiAgjswHys27nK1vFHy67c2/X7Lts9397ylEe72zszjtnHNaRlyxco6bL+vmjGdNTnGFTVav9F+Dt5h/bcz/Lc2mmzRH70f2OOLP/AAKMKw/Bh+XFMmudLlidv7NnhuGU48i6xEp7Hays2OmRv55xjtmUVHtZPfX11NFh6a+FW9G1+CL1lb2U8RW4vWtrgn5d8JaLHHLMpLA9eAh7epIL3Tbi0iE5CzWjNtW5hO+NieQM/wALYGdrYYDqBVGrljqV9p+/7BeXNrvxv8mVk3Y6ZweepoTg9JL7v6/yCUaid4O/k/8ANf8ABJxYx2dvbXOqRz7Z2JS3U+W7x7c+ZuYHCkkYO0hsPyMcv/tGwj+WHRbZ4x0a5mleQ/UoyL+SjjHXqcyWR5pXlmdnkdizOxyWJ5JJ7mmUe0t8K09Ew9jzazbv5Nr8mbMt3okrBzpV3ExA3JBfAJnAyVDRswBOTgsetV7qXS2gYWtnexzcbXlu0dRzzlRGCeM9xWdRQ6sn2+5f5BGhGNrN/e/8wooorM2JrVYGnUXckkUPO54ow7DjjCkqDz71ppp+lBZJZtaXysZSOK1dpiSRgFW2oDgknDkccZ61jUVcZKO8U/v/AMzOcJSekmvS36plu+jsU2fYLi5mznd59usWPTGHbPf0p9taR3OnXcqFlntVErg/deMsqcdwwZh6ggnpt+ajWt4b+a9uY25jeyudyno22F2GR7MqsPcA9qqFpztbcipzU6ble9tf8/w0JdKm+w6He3XlxO800VttlXKyxYZpFx7FYSSMMuVwRnlk3iPUZ5nluTaXEzsWaSeyhkck/wC0yE47AdAAAMAYptz/AMirp3/X7c/+gQVk1UqkoJRi7aL/AD/Uzp0adRyqTim23+Gn6Gt9v06fm+0vEg5L2U/k7yepZWDqPYKFA546Yqf6DJff8vNtZH/dnkXj/gAPP0wD3xzUorN1G9/yNo0lG/K397/J6Gt/Y0lzzo8n9pdzFBE/nRqehZMfgSpYA8Z5Ga9lYrNby3NzOttborBHZSTLIFyI1A6npk9FBGTyAakUjwypLC7JIjBldTgqRyCD2NWL/Ur7UNn2+8ubrZnb58rPtz1xk8dBVc0N7a/h/mTy1U+Xm079f8n+HzLEN9YwRIi6TBO20b3uZpCS3fbsZAF9AQT15PaUahpUsTJc6KsbZBV7O6eM9DkHzPMBByOgHT3rHopKrJdvuX+Q3h4vq/8AwJ/5mnNNo5icQ2OoLIVO1mvUYA9iR5QyPbIrMooqZScty4QUNvzb/MKKKKksKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDe8OWEerQz2I2xztcWz+cVBKRlzEwHvumjOOAdp54FZmrXf9oareXmzy/tEzzbM527mJxnv1qbQruax1A3FqGMywzBSj7CuYmG4H1XOfwov7SKFLjyt+62mEDlmBDk7uQMDb9zpz168c3OrHkjDr1/T82iaODqynOt9np621X3RT/4O+dRWnJb2RsHMK3Yu441kk80qEwSoyuBk/eGOnHPtWZWUZcx0VqDotJtO6voFFFFUYhRRRQAUUUUAFFW47UiO5MwKvHCsqgEc7mTGfwbNFrFD9nlnuBI6o6oERgpywY5yQf7vTHep51a5usPPmUXpe7+69/yZUoqe8h+z3c8G7d5bsm7GM4OM1BTTuroynFwk4y3QVp+G5I49btVmdY4JibeV2OAkcgMbtnoCFYnJ445zWZRVwlyyUuxlUhzwcO5s+II3t7fSLa4RoriG0KyxONroTPKwDA8g7WU89iD3rGrR17VJdZ1N764H7+RI1c8fMyoqluAMZK5x2zWdVVWnN8u3T5EYeMo01z77v1erCiipBGxhaUD5FYKTnuckfyNZm6TeiI6KuTW8cWrvbYleJZzHhOXYBsce9P1GK0WGGaw+0eU7Mh84jOQFPQDp8w7/ljmOdXS7nQ8NJRnJte67PvvbQoUUUVZzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFWtln/Zu/wA+4/tDzceT5K+V5ePveZvzuzxt2Yxzu7VVopNX6gFOJGwDaMgk7ucn2/z602imFwpzsGOQoUYAwM+nXn86bRQF+gU52DHIUKMAYGfTrz+dNooC/QcjBXVioYA5KnOD7HHNNoooC/Qlt5mgcugBJRk59GUqf0NOa6uG8rdPKfJ/1eXPyfT06Dp6VBRSsr3LVWajyp6f1/kTi5l8lYXd3hXJWNmO1Sc8gZ685qCiihJIUpuW7HAjYRtGSQd3OR7f59KbRRTJuFFFFADmIIUBQCBgkZ556n/Pam0UUA3cnmuJJWLE7cxrGQvAIUADP/fIP1oiuriEhoZ5YyF2Aq5GBnOPpnmoKKXKrWNPaz5ue7uOYhjkKF4AwM+nX8etCMFdWKhgDkqc4Pscc02imRfW4U5GCnJUMMEYOfTrx+dNooEnbUKcjBTkqGGCMHPp14/Om0UAnbUKlWZltpIQBsd1cnvlQwH/AKEaiooauOMnF3RIZZGaRi7lpPvknluc8+vIzSzzzXDh7iWSVgMBnYscenNRUUrIfPK1rhTmIIUBQCBgkZ556n/Pam0UybhTnYMchQowBgZ9OvP502igL9ApzsGOQoUYAwM+nXn86bRQF+gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulsed wave Doppler in a patient with mitral stenosis shows reduced diastolic flow after the E point (ie, reduced E-F slope), indicating reduced excursion of the mitral valve leaflet. The peak velocity is increased to over 2 m/sec, translating into a transvalvular gradient of 16 mmHg. There is also an increase in the amplitude of the A wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Thomas Binder, et al. Interactive Echocardiography, A Clinical Atlas, Futura, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_15_41215=[""].join("\n");
var outline_f40_15_41215=null;
